

Annual Report

2023–2024



Central Council for Research in Unani Medicine
Ministry of Ayush, Government of India

Annual Report

2023–2024



Central Council for Research in Unani Medicine
Ministry of Ayush, Government of India



Published by
CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE
Ministry of Ayush, Government of India
61-65, Institutional Area, Janakpuri, New Delhi – 110 058
Telephone: +91-11-28521981, 28525982
Website: <https://ccrum.res.in>
E-mail: unani-medicine@ccrum.res.in
unanimedicine@gmail.com

Printed at
Hi-Tech Graphics
F-28/3, Okhla Industrial Area, Phase-II, New Delhi-110 020



CONTENTS

1. OVERVIEW	5
1.1. Objectives	5
1.2. Programme-wise Achievements	5
2. MANAGEMENT	9
2.1. Governing Body	9
2.2. Executive Committee	9
2.3. Standing Finance Committee	10
2.4. Scientific Advisory Committee	10
2.4.1. Research Sub-Committees	11
2.4.1.1. Preclinical Research Sub-committee	11
2.4.1.2. Clinical Research Sub-committee	11
2.4.1.3. Fundamental Research Sub-committee	11
2.4.1.4. Literary Research Sub-committee	12
2.4.1.5. Drug Standardization Sub-committee	12
2.4.1.6. Survey and Cultivation of Medicinal Plants Sub-committee	12
2.5. Institutional Ethics Committee	13
2.5.1. Central Ethics Committee	13
2.5.2. Institutional Ethics Committee	13
2.6. Organisational Set-Up	20
2.7. Budget (Actual Expenditure)	26
3. TECHNICAL REPORT	28
3.1. Intramural Research	28
3.1.1. Centre-wise Activities	28
3.1.2. Programme-wise Activities	32
3.1.2.1. Survey and Cultivation of Medicinal Plants Programme	32
3.1.2.2. Drug Standardization Research Programme	34
3.1.2.3. Clinical Research Programme	39
Preclinical Studies	39
Clinical Studies	41
Randomised Controlled Trials	44
Validation of Unani Pharmacopoeial Drugs	44
Validation of Regimenal Therapies	55
Validation of Fundamentals	56
Research-oriented Healthcare	59
3.1.2.4. Literary Research	60
3.2. Studies under IMR Policy	61
3.3. Collaborative Research	63
3.4. Publications	69
3.4.1. Books, Monographs, Reports, etc.	69





3.4.2. Research Papers	70
3.5. Extension of Healthcare Services	78
3.5.1. School Health Programme	78
3.5.2. Unani Medical Centres in Allopathic Hospitals	79
3.5.3. Health Melas / Camps	79
3.5.4. Activities under Gender Component Plan for Women	79
3.5.5. Activities in the North-Eastern Region	79
3.5.6. Ayush Wellness Centre - President Estate	80
3.5.7. Unani Speciality Clinic at AIIA, New Delhi	80
3.5.8. Mobile Healthcare Programme under Scheduled Caste Sub-Plan	80
3.5.9. Mobile Healthcare Programme under Tribal Sub Plan	80
3.6. Linking Education with Research	81
3.7. Pharmacovigilance Programme	81
3.8. Development of Benchmarks for <i>Hijāma</i> (Cupping Therapy)	82
3.9. Development of STGs for Musculoskeletal Disorders	83
3.10. Setting Benchmarks: Contribution to BIS Standards for Unani Medicine	83
3.11. Strategic MoUs for Advancing Research and Development	84
4. INFORMATION, EDUCATION & COMMUNICATION	87
4.1. Library Services	87
4.2. Organization of Conferences, Seminars, Workshops, etc.	87
4.2.1. Unani Day 2024 and National Conference on Unani Medicine	87
4.2.2. Inauguration of Pharmacy Block & ' <i>Ilāj bi'l-Tadbīr</i> (Regimenal Therapy) Unit	89
4.2.3. National Workshop on Finalization of SOPs for <i>Hijāma</i>	90
4.2.4. National Seminar on Pharmacovigilance of ASU&H Drugs	90
4.2.5. NABL Awareness Workshop	91
4.2.6. National Seminar on Pharmacovigilance of ASU&H Drugs	92
4.2.7. Awareness Programme on Pharmacovigilance of ASU&H Drugs	92
4.2.8. Hands-on Training Programme for Administrative Staff	93
4.2.9. Vigilance Awareness Webinar	93
4.2.10. Orientation Programme on CCRUM's Vision and Activities	93
4.2.11. Other Events	93
4.3. Participation in Training and Capacity Building Programmes	97
4.4. Participation in Arogya Fairs/ Expos	99
4.5. Participation in Promotion of Official Language	101
4.6. Appointments	101
4.7. Promotions	102
4.8. Retirements	103
4.9. Deaths	104
5. FINANCIAL STATEMENT	105
5.1. Audit Report	105
5.2. Audited Statement of Accounts	109
5.3. Notes on Accounts	180



1. OVERVIEW

1.1. Objectives

The Central Council for Research in Unani Medicine (CCRUM) is an autonomous organization under the Ministry of Ayush, Government of India. It was established on March 30, 1978 under the Societies Registration Act, 1860 and started functioning from January 10, 1979. The main objectives of the CCRUM are as follows:

- To formulate aims and patterns of research on scientific lines in Unani Medicine
- To undertake any research or other related programmes in Unani Medicine including undergraduate, postgraduate and post-doctoral educational programmes in Unani Medicine
- To prosecute and assist in research, propagation of knowledge and experimental measures generally in connection with the causation, mode of spread, treatment and prevention of diseases
- To initiate, aid, develop and coordinate scientific research in different fundamental and applied aspects of Unani Medicine and to promote and assist institutions of research for the study of diseases, their prevention, causation, treatment, management and other remedial measures
- To provide technical and financial support for research for the furtherance of objectives of the Central Council
- To exchange information with other institutions, associations and societies interested in the objectives similar to those of the Central Council and specially in observation and study of diseases across the globe, East Asia and in India, in particular
- To prepare, print, publish and exhibit any papers, posters, pamphlets, periodicals, standard treatment protocols and books for furtherance of the objectives of the Central Council and to contribute to development of such literature.

1.2. Programme-wise Achievements

The year 2023–2024 marked a period of significant progress for the CCRUM, demonstrating notable achievements across its diverse research initiatives. Strategic milestones included the establishment of MoUs with 16 leading institutions to advance research and development in Unani Medicine. Another critical accomplishment was CCRUM's contribution to the Bureau of Indian Standards (BIS) for the publication of seven essential standards that strengthen regulatory and quality assurance frameworks for Unani practices. A landmark achievement was CCRUM's contribution to Standard Treatment Guidelines (STGs) for musculoskeletal disorders in Unani Medicine. Developed by the Ayush Vertical of the Directorate General of Health Services, Ministry of Health & Family Welfare, these guidelines, led primarily by CCRUM experts, establish Unani Medicine's efficacy in managing conditions like osteoarthritis, rheumatoid arthritis, and spondylosis, reinforcing its role in public health. Additionally, the CCRUM developed comprehensive SOPs for *Hijāma* (cupping therapy), a core Unani regimen known for pain relief, detoxification, and humoral balance. These SOPs, developed in collaboration with domain experts, provide structured protocols for each stage—pre-cupping, cupping, and post-cupping—ensuring adherence to sterilisation and infection control standards for safe, consistent practice.





Throughout the reporting period, the CCRUM excelled in its core research domains, namely the Survey and Cultivation of Medicinal Plants, Drug Standardization Research, Clinical Research, and Literary Research. These fundamental areas formed the backbone of the organization's pursuit of advancements in Unani Medicine. Additionally, the council extended its reach into supplementary domains such as information, education, and communication. The CCRUM also continued the expansion of healthcare services facilitated by a well-established network of 23 centres across the country. These centres played a pivotal role in disseminating Unani healthcare, effectively reaching diverse communities, and contributing to the overall well-being of the population.

Under the **Survey and Cultivation of Medicinal Plants Programme**, ethno-pharmacological surveys were conducted in different forest divisions/areas. As a result of these surveys, 2079 botanical specimens were collected and 429 plant species were identified. Later, herbarium sheets of 759 specimens including new and previous collections containing their basic details were prepared and 413 index cards were updated. A total of 338 herbarium sheets were digitized as well. The survey teams collected 4,269 saplings of important medicinal species for plantation and 292 kg of raw drugs. The surveyors recorded 212 folk medicinal claims from the tribal inhabitants and other rural folks of the study areas. Experimental and large-scale cultivation of some important medicinal species was also undertaken which yielded 51 kg of raw drugs. A total of 485 common species of medicinal plants used in Unani Medicine were maintained in the nurseries of the CCRUM centres.

Under the **Drug Standardization Research Programme**, SOPs for manufacture of 27 Unani formulations and their pharmacopoeial standards were developed. Besides, pharmacopoeial standards for 10 single drugs were developed. The drug testing laboratory at the RRIUM, Chennai analysed 12 ASU drug samples received from different organizations. Besides, 59 drug samples were analysed for quality control purposes and phyto-constituents were isolated from 02 Unani single drugs at the Chemical Research Unit located at RRIUM, Srinagar.

Under the **Clinical Research Programme**, preclinical safety evaluation studies, clinical studies on validation of safety and efficacy of classical/pharmacopoeial formulations, regimen therapies and fundamentals of Unani Medicine continued. Besides, research under intramural research (IMR) policy and collaborative research also continued.

Preclinical safety and pharmacological studies were undertaken on 06 Unani drugs at RRIUM, Srinagar and NRIUMSD, Hyderabad.

In clinical research, 03 randomised controlled trials (RCTs) were conducted. Besides, 49 studies for clinical validation of Unani pharmacopoeial formulations in different diseases were conducted, 20 studies were initiated, and 20 new studies were allotted. Various regimen therapy procedures were performed on 21,276 patients of different diseases. *Hijāma bilā-Sharṭ* (dry cupping) was performed on 4,067 patients, *Hijāma bi'l-Sharṭ* (wet cupping) on 1,495, *Hijāma bi'l-Nār* (fire cupping) on 411, *Hijāma Muzliqa* (moving cupping) on 3,928, *Ḥammām al-Bukhār* (steam bath) on 727, *Dalk Mu'tadil* (moderate massage) on 1,249, *Ḥammām Yābis* (sauna) on 38, *Naṭūl* (fomentation) on 218, *Inkibāb* (vaporization) on 3,450, *Mundij-Mushil* therapy on 233, *Ta'īq* (leeching) on 359, *Takmīd* (fomentation) on 806, *Faṣḍ* (venesection) on 09, and other therapies (*Amal-i-Kayy* or cauterization, cleaning & dressing, and mechanical massage) on 120 patients.



Under the validation of the fundamentals of Unani Medicine, 03 genetic studies were completed and 09 were in progress. Clinical assessment of *Mizāj* (temperament) of 411 patients was done and susceptibility of acquiring diseases in relation to the temperament of the patients was studied. Besides, 05 projects were undertaken and 07 projects initiated under the IMR policy at various institutes of the CCRUM.

The CCRUM also undertakes research in collaboration with other prestigious institutes. During the reporting period, 41 collaborative studies continued/were initiated at different collaborating institutions.

Literary Research Programme of the CCRUM published two organ-specific Unani compendia: *Adwiya Kulwiyya* on kidney drugs and *Adwiya Qalbiyya* on cardiac drugs in English and Urdu, respectively. A special issue of *Jahān-e-Tibb* on epidemics was also released, exploring Unani perspectives on prevention, treatment, and post-pandemic care.

The CCRUM standardised *Hijāma* (Cupping Therapy) through SOPs covering all procedural stages for safe and consistent practice. In global integration efforts, the CCRUM expanded Unani's SNOMED CT nomenclature and contributed to ICD-11 for dual coding of Unani conditions. Updates to NUMC Version 1.0 added 198 codes for the NAMASTE Portal, advancing Unani Medicine's global health alignment.

With a view to disseminating the research findings, 113 research papers were published in national and international scientific journals. During the reporting period, 07 books were also brought out. Besides, the publication of the quarterly English journal *Hippocratic Journal of Unani Medicine*, quarterly Urdu journal *Jahan-e-Tib*, Annual Report, and IEC material continued.

Research-oriented healthcare services continued at GOPDs and special OPDs of clinical centres of the CCRUM. During the reporting period, a total of 8,88,663 beneficiaries comprising 7,06,810 in GOPDs, 55,267 in Geriatric OPDs, 16,012 in RCH / MCH OPDs, 55,142 in NCD's OPDs and 55,432 in OPDs for post-trial treatment access (PTA) were treated at different centres. In-patient department (IPD) services continued at seven peripheral institutes of the council and a total of 14,402 beneficiaries were treated.

Under the **Mobile Clinical Research Programme**, 20 rural pockets/urban slums covering over 1.79 lakh population were adopted and a total of 34,129 patients were treated with Unani pharmacopoeial formulations in 475 mobile visits made to these pockets during the reporting period. Under the **School Health Programme**, a total of 4,267 school children were covered and their health check-up was conducted. Of them, 2,593 children were found suffering from different ailments and 2,285 of them were treated in 121 visits made to their schools.

The **Unani Medical Centres** functioning under the scheme of co-location of Ayush centres in Dr. Ram Manohar Lohia Hospital, Deen Dayal Upadhyay Hospital and VMMC & Safdarjung Hospital, New Delhi treated 32,158; 25,598 and 21,111 patients, respectively. Besides, 54 health camps were organized on different occasions and 5,114 patients were treated in these camps.

At **Ayush Wellness Clinic** established in President Estate, 3,679 patients were treated in Unani OPD and 1,790 in Regimenal Therapy Section.

Under the **Gender Component Plan for Women**, 4,71,486 female patients were treated in different OPDs. Clinical studies on the diseases specific to women, such as *Sayalān al-Raḥim* (leucorrhoea), *Sū' al-Qinya* (anaemia), *Ihtibās al-Ṭamth* (amenorrhoea) and *Kathrat al-Ṭamth* (menorrhagia) also continued.





Under the **Activities in North Eastern Region**, 96,800 patients were treated for their common and chronic ailments at RRIUM, Silchar, and CRU, Imphal.

Under the **Special Component Plan – Scheduled Caste Sub-Plan (SCSP) and Tribal Sub-Plan (TSP)**, 13,25,686 total population including 7,91,909 SC population were covered under SCSP, whereas 60,100 total population including 47,059 ST population were covered under TSP. A total of 141,265 and 44,931 individuals benefited from SCSP and TSP, respectively.

The academic activities under the **postgraduate programme** in Unani Medicine successfully continued. A total of 33 new scholars in addition to continuing MD (Unani) students were actively engaged in academic, research and training activities at NRIUMSD, Hyderabad, and RRIUM, Srinagar.

Under the **Pharmacovigilance Programme**, 57 ADRs were reported and a dozen of activities and events were organized for creating awareness.

During the period under report, the CCRUM celebrated Unani Day and organized a National Conference on 'Unani Medicine for One Earth, One Health' at the A P Shinde Symposium Hall, NASC, Pusa, New Delhi, on February 12, 2024. The conference emphasized India's growing role as a global leader in Traditional Medicine and the importance of evidence-based research in Ayush. Apart from this, the CCRUM organized more than 80 conferences, seminars, workshops and other such events and provided its workforce to participate in more than 30 training and capacity-building programmes.

The CCRUM participated in 29 Arogya fairs/expos and similar events to propagate Unani Medicine and highlight its activities and achievements.

The council continued the promotion of the Official Language and organized Hindi Pakhwada at the headquarters and different centres. Quarterly workshops on Hindi language were also organized. The CCRUM attained success in the official language review of 05 of its institutes conducted by the third sub-committee of the Committee of Parliament on Official Language.

In summary, 2023–2024 was a year of accomplishments for the CCRUM, marking progress in research, education, and healthcare service delivery, solidifying its role in advancing Unani Medicine. The council aims to build on these achievements for sustained growth and greater impact in the coming years.

New Delhi
December, 2024

Dr. N. Zaheer Ahmed
Director General



2. MANAGEMENT

The management of the affairs of the CCRUM is entrusted to the Governing Body (GB), the Executive Committee (EC) and the Standing Finance Committee (SFC). The research activities are conducted with the recommendations of the Scientific Advisory Committee and ethical clearance of the Institutional Ethics Committee (IEC).

2.1. Governing Body

The constitution of the GB of the CCRUM as of March 31, 2024 was as given below:

President

Minister Incharge, Ministry of Ayush

Vice-President-I

Minister of State, Ministry of Ayush

Vice-President-II

Secretary, Ministry of Ayush

Official Members

- Financial Advisor, Ministry of Ayush
- Special Secretary / Additional Secretary / Joint Secretary (dealing with CCRUM), Ministry of Ayush
- Adviser (Unani), Ministry of Ayush
- Director, National Institute of Unani Medicine, Bengaluru

Non-Official Members

- Prof. Aftab Ahmad, Jamia Hamdard, New Delhi
- Prof. Mohammad Idris, Ayurvedic & Unani Tibbia College, New Delhi
- Prof. S. J. B. Bokhari, Government Nizamia Tibbi College, Hyderabad
- Prof. Irfan Ahmad, Unani Medical College, Prayagraj, Uttar Pradesh
- Dr. Mohd. Zafar Hasan, Private Practitioner, Bhopal
- Prof. Sunil Kohli, Hamdard Institute of Medical Sciences & Research, New Delhi
- Dr. Swaran Jeet Singh Flora, Former Director, National Institute of Pharmaceutical Education and Research, Raebareli
- Dr. Rajeev Kumar Sharma, Former Director, Pharmacopoeial Laboratory for Indian Medicine, Ghaziabad
- Dr. Kommu Nagaiah, Senior Principal Scientist, Indian Institute of Chemical Technology, Hyderabad

Member Secretary

- Director General, CCRUM

2.2. Executive Committee

The constitution of the EC at the end of the reporting period was as given below:

Chairperson

Secretary, Ministry of Ayush, Government of India





Official Members

- Financial Advisor, Ministry of Ayush, Government of India
- Special Secretary/Additional Secretary/Joint Secretary (dealing with CCRUM), Ministry of Ayush, Government of India
- Adviser (Unani), Ministry of Ayush, Government of India
- Director, National Institute of Unani Medicine, Bengaluru

Non-Official Members

- Prof. Aftab Ahmad, Jamia Hamdard, New Delhi
- Prof. S. J. B. Bokhari, Government Nizamia Tibbi College, Hyderabad
- Prof. Irfan Ahmad, Unani Medical College, Prayagraj, Uttar Pradesh
- Dr. Swaran Jeet Singh Flora, Former Director, National Institute of Pharmaceutical Education and Research, Raebareli
- Dr. Kommu Nagaiah, Indian Institute of Chemical Technology, Hyderabad

Member Secretary

- Director General, CCRUM

2.3. Standing Finance Committee

The composition of the SFC at the end of the reporting period was as follows:

- | | | |
|--|---|------------------|
| • Special Secretary/Additional Secretary/Joint Secretary (dealing with CCRUM), Ministry of Ayush, Government of India | : | Chairperson |
| • Financial Advisor or his nominee not below the rank of Deputy Secretary, Integrated Finance Division, Ministry of Ayush, Government of India | : | Member |
| • Adviser (Unani), Ministry of Ayush, Government of India | : | Member |
| • Prof. Aftab Ahmad, Jamia Hamdard, New Delhi | : | Member |
| • Dr. Swaran Jeet Singh Flora, Former Director, National Institute of Pharmaceutical Education and Research, Raebareli | : | Member |
| • Director General, CCRUM | : | Member-Secretary |

2.4. Scientific Advisory Committee

The following was the composition of the SAC as on March 31, 2024:

- | | | |
|---|---|-------------|
| • Prof. Asim Ali Khan, Former Director General, CCRUM, New Delhi | : | Chairperson |
| • Prof. Abdul Wadud, Director, NIUM, Bengaluru | : | Member |
| • Prof. Md. Idris, A&U Tibbia College, New Delhi | : | Member |
| • Prof. Asia Sultana, Ajmal Khan Tibbiya College, AMU, Aligarh | : | Member |
| • Prof. Syed Imamuddin Ahmed, Former Principal, Government Unani Medical College, Chennai | : | Member |
| • Prof. D. S. Arya, Department of Pharmacology, AIIMS, New Delhi | : | Member |
| • Dr. Jugal Kishore, VMMC & Safdarjung Hospital, New Delhi | : | Member |



- Dr. Veena Gupta, Senior Scientist, ICAR-National Bureau of Plant Genetic Resources, New Delhi : Member
- Dr. K. Nagaiah, Chief Scientist, Centre for Natural Product and Traditional Knowledge, CSIR-IICT, Hyderabad : Member
- Director General, CCRUM : Member Secretary

2.4.1. Research Sub-Committees

The SAC is assisted by the following six research sub-committees, namely Preclinical Research Sub-committee, Clinical Research Sub-committee, Fundamental Research Sub-committee, Literary Research Sub-committee, Drug Standardization Sub-committee, and Survey and Cultivation of Medicinal Plants Sub-committee.

2.4.1.1. Preclinical Research Sub-committee

- Prof. Md. Idris, A&U Tibbia College, New Delhi : Chairperson
- Prof. Ghulamuddin Sofi, National Institute of Unani Medicine, Bengaluru : Member
- Dr. Hina Tabassum, Scientist-E, ICMR, New Delhi : Member
- Dr. H. N. Yadav, Department of Pharmacology, AIIMS, New Delhi : Member
- Prof. (Dr.) Abul Kalam Najmi, Department of Pharmacology, Jamia Hamdard, New Delhi : Member
- Prof. Mohd. Aftab Ahmad, Jamia Hamdard, New Delhi : Member
- DDG/AD (U), CCRUM Headquarters : Member
- Programme Officer : Member Secretary

2.4.1.2. Clinical Research Sub-committee

- Prof. Aleemuddin Quamri, National Institute of Unani Medicine, Bengaluru : Chairperson
- Dr. R. M. Pandey, Department of Biostatistics, AIIMS, New Delhi : Member
- Dr. Tanica Lyngdoh, Scientist-E, Indian Council of Medical Research, New Delhi : Member
- Dr. Rohit Kumar, VMMC & Safdarjung Hospital, New Delhi : Member
- Dr. Syed Shariq Naeem, JN Medical College, AMU, Aligarh : Member
- Prof. Arshiya Sultana, National Institute of Unani Medicine, Bengaluru : Member
- DDG/AD (U), CCRUM Headquarters : Member
- Programme Officer : Member Secretary

2.4.1.3. Fundamental Research Sub-committee

- Dr. Kumar Swamy Thangaraj, Former Director, Centre for DNA Fingerprinting and Diagnostics, Hyderabad : Chairperson
- Prof. K. M. Y. Amin, Ajmal Khan Tibbiya College, AMU, Aligarh : Member
- Dr. B. Vijaylakshmi, Institute of Genetics, Hyderabad : Member



- Dr. Aloka Nanda, Consultant, NRIUMSD, Hyderabad : Member
- Prof. Syed Ziaur Rahman, JN Medical College, AMU, Aligarh : Member
- Prof. Ashhar Qadeer, Ajmal Khan Tibbiya College, AMU, Aligarh : Member
- DDG/AD (U), CCRUM Headquarters : Member
- Programme Officer : Member Secretary

2.4.1.4. Literary Research Sub-committee

- Hakim Wasim Ahmad, Former Deputy Director, CRIUM, Lucknow : Chairperson
- Prof. (Dr.) Neshat Quaiser, Department of Sociology, Jamia Millia Islamia, New Delhi : Member
- Dr. M. Raziul Islam, Eminent Scholar of Unani Medicine, New Delhi : Member
- Prof. Abdul Haseeb Ansari, National Institute of Unani Medicine, Bengaluru : Member
- Dr. Wasim Ahmad, National Institute of Unani Medicine, Bengaluru : Member
- Dr. Mohammad Akram, Department of Arabic, University of Delhi, New Delhi : Member
- DDG/AD (U), CCRUM Headquarters : Member
- Programme Officer : Member Secretary

2.4.1.5. Drug Standardization Sub-committee

- Prof. Dr. Rajendran Aanaimuthu, Proprietor, Life Care Phyto Labs, Chennai : Chairperson
- Prof. Aftab Ahmad, Jamia Hamdard, New Delhi : Member
- Dr. Shariq Shamsi, National Institute of Unani Medicine, Bengaluru : Member
- Dr. A. Jayanthi, Pharmacopoeia Commission of Indian Medicine and Homoeopathy, Ghaziabad : Member
- Dr. Mohd. Mujeeb, Department of Pharmacognosy & Phytochemistry, Jamia Hamdard, New Delhi : Member
- Dr. Santosh Joshi, Hamdard Laboratories India, Ghaziabad : Member
- DDG/AD (U), CCRUM Headquarters : Member
- Programme Officer : Member Secretary

2.4.1.6. Survey and Cultivation of Medicinal Plants Sub-committee

- Dr. A. Ameer Jahan, Advisory Committee Chairman, Tamil Nadu State Medicinal Plants Board, Chennai : Chairperson
- Prof. Tajuddin, Ajmal Khan Tibbiya College, AMU, Aligarh : Member
- Dr. Athar Ali Khan, Department of Botany, AMU, Aligarh : Member



- Dr. Vinay Kumar Singh, Former Assistant Director (Botany), : Member
CCRUM, New Delhi
- Dr. Shahidul Khair, Former Research Officer (Botany), : Member
CCRUM, New Delhi
- Prof. Mohd. Mujeeb, Department of Pharmacognosy & : Member
Phytochemistry, Jamia Hamdard, New Delhi
- DDG/AD (U), CCRUM Headquarters : Member
- Programme Officer : Member Secretary

2.5. Institutional Ethics Committee

It is mandatory that all the proposals on biomedical research involving human participants are approved by a duly constituted ethics committee to protect their welfare and rights. At the end of the reporting period, there were 18 Institutional Ethics Committees (IEC) functioning at various institutes/units of the CCRUM. These committees review and approve research proposals involving human participants. They also examine compliance with regulatory requirements, applicable guidelines and laws. Besides, the CCRUM has a Central Ethics Committee (CEC) at its headquarters to examine the multi-centric clinical trials or human clinical trials which may have to be carried out in certain specific conditions like COVID-19 pandemic or any other clinical trials referred to it by the CCRUM headquarters for examination and approval. The composition of the CEC as well as IEC as on March 31, 2024 was as follows:

2.5.1. Central Ethics Committee

- Prof. Sunil Kohli, Hamdard Institute of Medical Sciences and : Chairperson
Research, New Delhi
- Dr. Jugal Kishore, Department of Community Medicine, : Member
VMMC and Safdarjung Hospital, New Delhi
- Dr. Yasmeen Shamsi, School of Unani Medical Education & : Member
Research, Jamia Hamdard, New Delhi
- Prof. Aftab Ahmad, School of Unani Medical Education & : Member
Research, Jamia Hamdard, New Delhi
- Shri Shive Rattan Sharma, Senior Consultant (Legal), : Member
CCRUM, New Delhi
- Dr. Mohammad Akram, Department of Arabic, University of : Member
Delhi, New Delhi
- Prof. Shahina Tabassum, Zakir Husain Delhi College, : Member
University of Delhi, New Delhi
- Assistant Director (Unani), CCRUM Headquarters : Member Secretary

2.5.2. Institutional Ethics Committee

National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad

- Dr. K. Nagaiah, Chief Scientist, CSIR-Indian Institute of : Chairperson
Chemical Technology, Hyderabad
- Prof. Chennakesavulu Dara, ESIC Medical College & : Member
Hospital, Hyderabad



- Prof. Maqbool Hussain, Government Nizamia Tibbi College, Hyderabad : Member
- Dr. M Mohammed Idris, Senior Principal Scientist, CSIR-CCMB, Hyderabad : Member
- Shri Abdul Fatah Khan, Advocate, Hyderabad : Member
- Shri Nasirul Haq, Former Administrative Officer, Telangana Electrical Department : Member
- Hafez Mohammed Ajaz Ahmed, Hyderabad : Member
- Dr. Qamar Uddin, Research Officer (Unani) Scientist-IV, NRIUMSD, Hyderabad : Member Secretary

Central Research Institute of Unani Medicine (CRIUM), Lucknow

- Dr. Kauser Usman, Department of Medicine, King George's Medical University, Lucknow : Chairperson
- Dr. Tarique Mahmood Ansari, Faculty of Pharmacy, Integral University, Lucknow : Member
- Prof. Abdul Haleem, Principal, Eram Unani Medical College, Lucknow : Member
- Sh. Jamal Saeed Siddiqui, Advocate, Civil Court, Lucknow : Member
- Sh. Maqsood Ahmad Khan, Ashrafiya Education Society, Lucknow : Member
- Prof. Shabbir Ahmad Nadwi, Former Head, Department of Arabic, University of Lucknow : Member
- Sh. Abdul Jabbar, Khurram Nagar, Lucknow : Member
- Dr. Mahboobus Salam, Research Officer (Unani), CRIUM, Lucknow : Member Secretary
- Dr. Najmus Sehar, Research Officer (Unani), CRIUM, Lucknow : Alternate Member Secretary

Regional Research Institute of Unani Medicine (RRIUM), Chennai

- Hakim Syed Imamuddin Ahmed, Former Principal, Government Unani Medical College, Chennai : Chairperson
- Dr. Noman Anwar, Research Officer (Unani), RRIUM, Chennai : Member Secretary
- Dr. P. Elango, Bharat Medical College & Hospital, Chennai : Member
- Dr. R. Ilavarasan, Assistant Director Incharge, CSM Drug Research Institute of Ayurveda, Chennai : Member
- Dr. V. Md. Habibullah, Head, Department of Jarahat, Government Unani Medical College, Chennai : Member
- Dr. Syed Hissar, Scientist C, ICMR-NIRT, Chennai : Member
- Dr. K. Amjath Khan, Advocate, Madras High Court, Chennai : Member
- Dr. C. Ponnuraja, Scientist D, NIRT, Chennai : Member
- Dr. M. Habibullah Jamali, The New College, Chennai : Member





- Shri Abdul Samad, Institute of Management, The New : Member
College, Chennai
- Dr. Athar Parvez Ansari, Research Officer (Unani) Scientist-II, : Alternate Member
RRIUM, Chennai Secretary
- Mrs. R. Naseema Begum, Stenographer, RRIUM, Chennai : Member

Regional Research Institute of Unani Medicine (RRIUM), Srinagar

- Prof. Zulfikar Ali Bhat, Dean, School of Applied Science & : Chairperson
Technology, University of Kashmir, Srinagar
- Prof. M. Salim Khan, Head, Department of Social and : Member
Preventive Medicine, Government Medical College, Srinagar
- Dr. Zubair Ashai, Associate Professor, Government Medical : Member
College, Srinagar
- Dr. Showkat Hussain Yatoo, Administrator, Jammu & Kashmir : Member
Ayush Board
- Shri Sajad Buchh, Advocate, Srinagar : Member
- Dr. Saima Farhad, Assistant Professor, University of Kashmir, : Member
Srinagar
- M. Ishtiyahq Ahmad Nadwi, Hazratbal, Srinagar : Member
- Shri Gh. Mohd. Bhat, Hazratbal, Srinagar : Member
- Dr. Arsheed Iqbal, Research Officer (Unani) Scientist-IV, : Member Secretary
RRIUM, Srinagar

Regional Research Institute of Unani Medicine (RRIUM), Aligarh

- Prof. K. M. Y. Amin, Ajmal Khan Tibbiya College, Aligarh : Chairperson
Muslim University, Aligarh
- Dr. Misbahuddin Azhar, Research Officer (Unani) Scientist-IV, : Member Secretary
RRIUM, Aligarh
- Dr. Fakhre Alam, Research Officer (Unani) Scientist-IV, : Alternate Member
RRIUM, Aligarh Secretary
- Prof. Tanzeel Ahmad, Ajmal Khan Tibbiya College, Aligarh : Member
Muslim University, Aligarh
- Dr. M. Mahboobur Rahman, Aligarh Muslim University, Aligarh : Member
- Shri Savir Khan, Maktaba Jamia Ltd., Aligarh : Member

Regional Research Institute of Unani Medicine (RRIUM), New Delhi

- Prof. Prem Kapoor, Department of Medicine, Hamdard : Chairperson
Institute of Medical Sciences & Research, New Delhi
- Prof. Surrender Singh, Department of Pharmacology, AIIMS, : Member
New Delhi
- Prof. Muhammad Hussain, Department of Biotechnology, : Member
Jamia Millia Islamia, New Delhi
- Dr. Habeebul Rahiman V. M., Department of Social Work, : Member
Jamia Millia Islamia, New Delhi



- Shri Mobashshir Sarwar, Advocate, Delhi High Court, New Delhi : Member
- Dr. Arif Zaidi, Former Dean, School of Unani Medical Education and Research, Jamia Hamdard, New Delhi : Member
- Prof. Muhammad Akram, School of Unani Medical Education and Research, Jamia Hamdard, New Delhi : Member
- Dr. Sheikh Aquil, Department of Urdu, Satyavati College, New Delhi : Member
- Dr. Priyanka Verma, Research Officer (Biochemistry), RRIUM, New Delhi : Member Secretary

Regional Research Institute of Unani Medicine (RRIUM), Mumbai

- Dr. Ranjit Mankeshwar, Head, Department of PSM, Grant Govt. Medical College & Sir J. J. Group of Hospitals, Mumbai : Chairperson
- Dr. Sadiq Bapumiya Patel, Clinical Pharmacologist, Mumbai : Member
- Dr. Partitosh Baghel, Consultant Physician, Fortis, Mumbai : Member
- Dr. Qazi Rashid Anwar, Unani Physician, MIJ Tibbia, S. L. Rahija Hospital, Mumbai : Member
- Shri Faridul Haq Khan, Advocate, Mumbai : Member
- Shri Farid Alam Qureshi, Social Worker, Mumbai : Member
- Shri Abbas Ali Riyasat, Teacher, Mumbai : Member
- Dr. Nikhat Shaikh, Research Officer (Unani) Scientist-III, RRIUM, Mumbai : Alternate Member Secretary
- Dr. Masroor Qureshi, Research Officer (Unani) Scientist-IV, RRIUM, Mumbai : Member Secretary

Regional Research Institute of Unani Medicine (RRIUM), Kolkata

- Dr. Santanu Munshi, Professor & Head, Clinical & Experimental Pharmacology, School of Tropical Medicine, Kolkata : Chairperson
- Prof. Md. Tajuddin, The Calcutta Unani Medical College & Hospital, Kolkata : Member
- Prof. Parimal Karmakar, Jadavpur University, Kolkata : Member
- Md. Imtiyaz, Secretary, Sankalp Today (NGO), Kolkata : Member
- Smt. Sima Perween, Advocate, Kolkata : Member
- Shri Haider Ali, President, Howrah Health Awareness Mission, Kolkata : Member
- Syed Md. Mubashshir Nasim, President, Quranic Education, Howrah : Member
- Shri Anirban Goswami, Investigator (Statistics), RRIUM, Kolkata : Member Secretary



Regional Research Institute of Unani Medicine (RRIUM), Patna

- Prof. S. K. Sinha, Patna Medical College, Patna : Chairperson
- Prof. Abdul Aziz, Nalanda Medical College, Patna : Member
- Prof. Shahnawaz Akhtar, Government Tibbi College & Hospital, Patna : Member
- Shri Nadim Akhtar, Advocate, Patna High Court, Patna : Member
- Dr. Haroon Rasheed, State Project Officer, ADARSH, Patna : Member
- Dr. Syed Shah Shamimuddin Munemi, Department of Arabic, Oriental College, Patna : Member
- Shri Md. Fahim, Patna : Member
- Dr. Rajesh, Research Officer (Unani), RRIUM, Patna : Member Secretary

Regional Research Institute of Unani Medicine (RRIUM), Bhadrak

- Prof. Debashish Hota, Head, Department of Pharmacology, AIIMS, Bhubaneswar : Chairperson
- Dr. Jhasaketan Mohanty, Former Sr. Medicine Specialist, District Headquarters Hospital, Bhadrak : Member
- Dr. Sayed Mozammil Ali, Medical Officer (Unani), Government Unani Dispensary, Balasore : Member
- Shri S. K. Noor Muzaffar Alam, Advocate, Bhadrak : Member
- Shri S. M. Farooque, Secretary, Fellowship (NGO), Bhadrak : Member
- Shri Basant Kumar Nayak, Bhadrak : Member
- Dr. Abdur Rasheed, Research Officer (Unani), RRIUM, Bhadrak : Member Secretary

Regional Research Institute of Unani Medicine (RRIUM), Silchar

- Dr. Dolly Roy, Chairperson / Associate Professor of Pharmacology, Silchar Medical College and Hospital, Silchar : Chairperson
- Dr. Riturag Thakuria, Assistant Professor, Department of Medicine, Silchar Medical College and Hospital, Silchar : Member
- Dr. Wahiduzzaman, Former Deputy Director, RRIUM, Patna : Member
- Shri Ramizur Rahman Barlaskar, Advocate, Silchar Bar Association, Silchar : Member
- Shri Lutfur Rahman Laskar, Secretary, Bank Sangha (NGO), Neairgram, Cachar : Member
- Maulana Ikramuddin Mazumder, Assistant Teacher, Ghoniwala Hafizia Madrasa, Silchar : Member
- Shri Saleh Ahmed Mazumder, Silchar : Member
- Dr. Akthar Hussain Jamali, Research Officer Incharge, RRIUM, Silchar : Member Secretary



Regional Research Centre (RRC), Prayagraj

- Dr. Khurshid Parveen, Professor, MLN Medical College, Prayagraj : Chairperson
- Dr. Zubair Ahmad Khan, Ex-Deputy Director, CCRUM, New Delhi : Member
- Prof. Irfan Ahmad, State Unani Medical College, Prayagraj : Member
- Prof. Najeeb Hanzla Ammar, State Unani Medical College, Prayagraj : Member
- Shri Vinay Singh, Advocate, High Court of Judicature, Prayagraj : Member
- Shri Anwar Azam Islahi, Prayagraj : Member
- Shri Janey Alam, Prayagraj : Member
- Hakim Mohd Ehsan Ansari, Research Officer (Unani) Scientist-IV, RRC, Prayagraj : Member Secretary

Clinical Research Unit (CRU), Meerut

- Dr. Surbhi Gupta, Head, Department of Pharmacology, Subharti Medical College, Meerut : Chairperson
- Dr. Sabahatullah, Physician, Amroha : Member
- Dr. Mohd Asif Khan, Consultant Physician, Meerut : Member
- Dr. Mushtaq Hussain, Allama Iqbal Unani Medical College, Muzaffarnagar : Member
- Mohd. Aslam, Advocate, Collectorate of Meerut : Member
- Mohd. Akhlaq, Imam, Chhoti Masjid Sotiganj, Meerut : Member
- Mohd. Parvaz, Social Worker, Meerut : Member
- Shri Sarfaraz Ahmad, Social Worker, Meerut : Member
- Dr. Shagufta Parveen, Research Officer (Unani), CRU, Meerut : Member Secretary

Clinical Research Unit (CRU), Burhanpur

- Dr. Ranjendra Sighal, Director, Icon Hospital, Burhanpur : Chairperson
- Dr. Syed Mohd Abbas Zaidi, Assistant Professor, HSZH Government Unani Medical College, Bhopal : Member
- Dr. Mazhar Subhan Ansari, Assistant Professor (Ilmul Advia), Saifia Hamidia Unani Tibbiya College, Burhanpur : Member
- Maulana Shaikh Javed Qasmi, Burhanpur : Member
- Shri Waseem Khan, Advocate, Burhanpur : Member
- Shri Rizwan Abbas, Rotarian, Social Worker, Director Red Cross Society, Burhanpur : Member
- Shri Mohammad Ismail Khan, Burhanpur : Member
- Dr. Fahmi Husna Seemab, Pathologist, District Hospital, Burhanpur : Member
- Dr. Haider Ali Ansari, Research Associate (Unani), CRU, Burhanpur : Member Secretary



**Clinical Research Unit (CRU), Kurnool**

- Dr. Habeebullah, Dr. Abdul Haq Unani Meical College, : Chairperson
Kurnool
- Dr. M. Ramesh, Research Officer (Unani) Scientist-III, Clinical : Member Secretary
Research Unit, Kurnool
- Dr. Abdur Rahim Qazi, Rtd. CMO (Unani), CGHS, : Member
Government of India
- Dr. G. Bhanu Prakash, Assistant Professor, Kurnool Medical : Member
College, Kurnool
- Shri A. S. Omar Javeed, Advocate, Kurnool : Member
- Shri Syed Zakir Ahmed Rasheedi, Social Worker & Arabic : Member
Lecturer, Dr. Abdul Haq Unani Medical College, Kurnool
- Shri Syed Abid Hussain, Retired Admin & Accounts Officer, : Member
Dr. Abdul Haq Unani Medical College, Kurnool

Clinical Research Unit (CRU), Bengaluru

- Prof. Abdul Nasir Ansari, National Institute of Unani Medicine, : Chairperson
Bengaluru
- Prof. Ghulamuddin Sofi, National Institute of Unani Medicine, : Member
Bengaluru
- Dr. Madhu Kumar, Consultant, Bengaluru : Member
- Dr. Fayaz Ahmed Shariff, Govt. Unani Medical College, : Member
Bengaluru
- Shri Naveen Kumar M, City Civil Court, Labour Court & High : Member
Court of Karnataka, Bengaluru
- Shri Agha, Social Worker, Bengaluru : Member
- M. Iqbal Khasmi, Vijayanagar, Bengaluru : Member
- Dr. Syed Sadullah Hadi, Research Officer (Unani) Scientist- : Member Secretary
IV, CRU, Bengaluru

Clinical Research Unit (CRU), Kerala

- Dr. Iftikharuddin Khan, Markaz Unani Medical College, : Chairperson
Kozhikode, Kerala
- Dr. N. P. Hamsa, Medical Superintendent, Lakshmi Hospital, : Member
Kerala
- Dr. Shakkeer Ali K. A., Medical Officer (Unani), Government : Member
Unani Dispensary, Kasargod, Kerala
- Adv. C.P. Muhammed, Aluva, Kerala : Member
- Shri Abdul Salam, Secretary, Safa Charitable Trust, Edathala : Member
- Shri Layaq Ali, Gram Panchayat, Edathala, Kerala : Member
- Shri Jamal Tannari Moulvi, Faculty, Al-Kausariya Arabic : Member
College, Edathala, Kerala
- Dr. M. A. Waheed, Research Officer (Unani), CRU, Kerala : Member Secretary



Clinical Research Unit (CRU), Bhopal

- Dr. Hameed Uz Zafar Ghori, Department of Radiation : Chairperson
Oncology, Gandhi Medical College, Bhopal
- Dr. Anil Sewer, Associate Professor, Gandhi Medical College, : Member
Bhopal
- Dr. Mirza Gufran Baig, Unani Medical Officer, State Unani : Member
Dispensary, Ginnori, Bhopal
- Sh. Hussain Ali Saifi, Advocate Independent Litigator, District : Member
Court, Bhopal
- Shri Mohd. Yusuf Khan, Theologist-cum-Social Worker, : Member
Bhopal
- Shri Mohammad Yasir, New Okaf Colony, Bhopal : Member
- Dr. Afshan Qaiser, Research Officer Incharge, CRU, Bhopal : Member Secretary

2.6. Organisational Set-Up

The CCRUM is headquartered in New Delhi and has a network of 23 centres functioning in different parts of the country. These centres are as follows:

Centre	Number
National Research Institute of Unani Medicine for Skin Disorders	01
Central Research Institute of Unani Medicine	01
Regional Research Institute of Unani Medicine	09
Regional Research Centre	01
Clinical Research Unit	07
Hakim Ajmal Khan Institute for Literary & Historical Research in Unani Medicine	01
Drug Standardization Research Institute	01
Drug Standardization Research Unit	01
Unani Wing at Ayush Wellness Centre, Rashtrapati Bhavan, New Delhi	01

The CCRUM centres are located in different States. The following is the State-wise institutional network.

Andhra Pradesh

- Clinical Research Unit (CRU), Kurnool

Assam

- Regional Research Institute of Unani Medicine, Silchar

Bihar

- Regional Research Institute of Unani Medicine (RRIUM), Patna

Delhi

- Regional Research Institute of Unani Medicine (RRIUM), New Delhi
- Hakim Ajmal Khan Institute for Literary & Historical Research in Unani Medicine (HAKILHRUM), New Delhi
- Drug Standardization Research Unit (DSRU), New Delhi





- Unani Medical Centre (Extension Centre of RRIUM, New Delhi), Dr. Ram Manohar Lohia Hospital, New Delhi
- Unani Speciality Centre (Extension Centre of RRIUM, New Delhi), Deen Dayal Upadhyay Hospital, New Delhi
- Unani Medical Centre (Extension Centre of RRIUM, New Delhi), VMMC & Safdarjung Hospital, New Delhi
- Unani Wing at Ayush Wellness Centre, Rashtrapati Bhavan, New Delhi

Jammu & Kashmir

- Regional Research Institute of Unani Medicine (RRIUM), Srinagar

Karnataka

- Clinical Research Unit (CRU), Bengaluru

Kerala

- Clinical Research Unit (CRU), Edathala (Alwaye) with an extension centre at Pattiam, Kannur

Madhya Pradesh

- Clinical Research Unit (CRU), Bhopal
- Clinical Research Unit (CRU), Burhanpur

Maharashtra

- Regional Research Institute of Unani Medicine (RRIUM), Mumbai

Manipur

- Clinical Research Unit (CRU), Imphal

Odisha

- Regional Research Institute of Unani Medicine (RRIUM), Bhadrak

Tamil Nadu

- Regional Research Institute of Unani Medicine (RRIUM), Chennai

Telangana

- National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad

Uttar Pradesh

- Central Research Institute of Unani Medicine (CRIUM), Lucknow
- Regional Research Institute of Unani Medicine (RRIUM), Aligarh
- Drug Standardization Research Institute (DSRI), Ghaziabad
- Regional Research Centre (RRC), Prayagraj
- Clinical Research Unit (CRU), Meerut


West Bengal

- Regional Research Institute of Unani Medicine (RRIUM), Kolkata






Management of CCRUM



Organizational Set-up of CCRUM




*With three extension centres in New Delhi


**With one extension centre in Pattiam

***With two extension centres in Mumbai and Goa





Organizational Structure at CCRUM



2.7. Budget (Actual Expenditure)

The centre-wise actual expenditure of the Council during 2023-24 was as follows:

S. No.	Name of State and Centre	Amount
1.	Andhra Pradesh	
	(i) CRU, Kurnool	1,16,64,848.00
2.	Assam (NER)	
	(i) RRIUM, Silchar	6,72,50,102.00
3.	Bihar	
	(i) RRIUM, Patna	4,37,90,395.00
4.	Jammu & Kashmir	
	(i) RRIUM, Srinagar	12,97,47,630.00
5.	Karnataka	
	(i) CRU, Bengaluru	1,57,83,800.00
6.	Kerala	
	(i) CRU, Alwaye	88,62,113.00
7.	Madhya Pradesh	
	(i) CRU, Burhanpur	97,64,506.00
	(ii) CRU, Bhopal	1,35,54,657.00
8.	Maharashtra	
	(i) RRIUM, Mumbai	10,43,84,538.00
9.	Manipur (NER)	
	(i) Clinical Research Unit, Imphal	11,90,769.00
10.	New Delhi	
	(i) HAKILHRUM, New Delhi	2,97,42,927.00
	(ii) RRIUM, New Delhi	12,98,76,978.00
	(iii) Headquarters, New Delhi	18,56,69,373.00
	(iv) DSRU, New Delhi	1,51,06,683.00
11.	Odisha	
	(i) RRIUM, Bhadrak	5,12,99,758.00
12.	Tamil Nadu	
	(i) RRIUM, Chennai	10,46,84,507.00
13.	Telangana	
	(i) NRIUMSD, Hyderabad	24,19,22,172.00
14.	Uttar Pradesh	





S. No.	Name of State and Centre	Amount
	(i) DSRI, Ghaziabad	4,34,67,226.00
	(ii) CRIUM, Lucknow	10,51,37,139.00
	(iii) RRC, Prayagraj	2,13,38,375.00
	(iv) RRIUM, Aligarh	7,51,85,058.00
	(v) CRU, Meerut	2,31,53,210.00
15.	West Bengal	
	(i) RRIUM, Kolkata / Howrah	2,05,95,441.00
16.	Other Charges	
	(i) AHMIS	-
	(ii) Contribution to NPS	3,90,92,371.00
	(iii) CGHS Contribution	8,14,604.00
	(iv) Pension Fund Transfer	28,14,96,741.00
	(v) IEC	12,920.00
	(vi) Swachhata Action Plan	35,66,352.00
	(vii) Hindi Pakhwada	5,51,048.00
	(viii) Collaborative Research Projects	3,37,52,302.00
	(ix) Hindi Workshop	1,92,515.00
	(x) Arogya Mela	39,46,042.00
	(xi) NABL Fees	12,980.00
	(xii) Training Programme	1,40,000.00
	(xiii) Seminar/Workshop	10,59,278.00
	(xiv) Capital Works	-
	(xv) Pharmacovigilance	4,50,000.00
	(xvi) Unani Day Expenses	44,87,494.00
	Grand Total S. No. 1 to 16	1,82,27,46,852.00





3. TECHNICAL REPORT

3.1. Intramural Research

3.1.1. Centre-wise Activities

CENTRE	ACTIVITIES
National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad	<ul style="list-style-type: none"> • Survey and Cultivation of Medicinal Plants Programme • Drug Standardization Research Programme • Clinical Research Programme <ul style="list-style-type: none"> ◦ Validation of Unani Pharmacopoeial Drugs ◦ Pharmacological Research Programme ◦ Validation of Regimenal Therapies ◦ Validation of Fundamentals • Research-oriented Healthcare <ul style="list-style-type: none"> ◦ General Outpatient Department (GOPD) Programme ◦ In-patients Department (IPD) Programme • Mobile Healthcare Programme under Scheduled Caste Sub-Plan
Central Research Institute of Unani Medicine (CRIUM), Lucknow	<ul style="list-style-type: none"> • Clinical Research Programme <ul style="list-style-type: none"> ◦ Validation of Unani Pharmacopoeial Drugs ◦ Validation of Regimenal Therapies • Research-oriented Healthcare <ul style="list-style-type: none"> ◦ General Outpatient Department (GOPD) Programme ◦ In-patients Department (IPD) Programme ◦ Mobile Clinical Research Programme • Mobile Healthcare Programme under Scheduled Caste Sub-Plan
Regional Research Institute of Unani Medicine (RRIUM), Chennai	<ul style="list-style-type: none"> • Survey and Cultivation of Medicinal Plants Programme • Drug Standardization Research Programme • Clinical Research Programme <ul style="list-style-type: none"> ◦ Validation of Unani Pharmacopoeial Drugs ◦ Validation of Regimenal Therapies • Research-oriented Healthcare <ul style="list-style-type: none"> ◦ General Outpatient Department (GOPD) Programme ◦ In-patients Department (IPD) Programme ◦ Mobile Clinical Research Programme • Mobile Healthcare Programme under Scheduled Caste Sub-Plan
Regional Research Institute of Unani Medicine (RRIUM), Bhadrak	<ul style="list-style-type: none"> • Survey and Cultivation of Medicinal Plants Programme • Clinical Research Programme





CENTRE	ACTIVITIES
	<ul style="list-style-type: none"> ○ Validation of Unani Pharmacopoeial Drugs ○ Validation of Regimenal Therapies • Research-oriented Healthcare <ul style="list-style-type: none"> ○ General Outpatient Department (GOPD) Programme ○ In-patients Department (IPD) Programme ○ Mobile Clinical Research Programme • School Health Programme • Mobile Healthcare Programme under Tribal Sub Plan
Regional Research Institute of Unani Medicine (RRIUM), Patna	<ul style="list-style-type: none"> • Clinical Research Programme <ul style="list-style-type: none"> ○ Validation of Unani Pharmacopoeial Drugs ○ Validation of Regimenal Therapies • Research-oriented Healthcare <ul style="list-style-type: none"> ○ General Outpatient Department (GOPD) Programme ○ In-patients Department (IPD) Programme ○ Mobile Clinical Research Programme • School Health Programme • Mobile Healthcare Programme under Scheduled Caste Sub-Plan
Regional Research Institute of Unani Medicine (RRIUM), Aligarh	<ul style="list-style-type: none"> • Survey and Cultivation of Medicinal Plants Programme • Drug Standardization Research Programme • Clinical Research Programme <ul style="list-style-type: none"> ○ Validation of Unani Pharmacopoeial Drugs • Research-oriented Healthcare <ul style="list-style-type: none"> ○ General Outpatient Department (GOPD) Programme ○ In-patients Department (IPD) Programme ○ Mobile Clinical Research Programme • Mobile Healthcare Programme under Scheduled Caste Sub-Plan
Regional Research Institute of Unani Medicine (RRIUM), Mumbai	<ul style="list-style-type: none"> • Clinical Research Programme <ul style="list-style-type: none"> ○ Validation of Unani Pharmacopoeial Drugs ○ Validation of Regimenal Therapies • Research-oriented Healthcare <ul style="list-style-type: none"> ○ General Outpatient Department (GOPD) Programme ○ In-patients Department (IPD) Programme ○ Mobile Clinical Research Programme • Mobile Healthcare Programme under Scheduled Caste Sub-Plan
Regional Research Institute of Unani Medicine (RRIUM), Srinagar	<ul style="list-style-type: none"> • Survey and Cultivation of Medicinal Plants Programme • Drug Standardization Research Programme





CENTRE	ACTIVITIES
	<ul style="list-style-type: none">• Clinical Research Programme<ul style="list-style-type: none">○ Validation of Unani Pharmacopoeial Drugs○ Pharmacological Research Programme○ Validation of Regimenal Therapies• Research-oriented Healthcare<ul style="list-style-type: none">○ General Outpatient Department (GOPD) Programme○ In-patients Department (IPD) Programme○ Mobile Clinical Research Programme• School Health Programme• Mobile Healthcare Programme under Tribal Sub Plan
Regional Research Institute of Unani Medicine (RRIUM), Kolkata	<ul style="list-style-type: none">• Clinical Research Programme<ul style="list-style-type: none">○ Validation of Unani Pharmacopoeial Drugs• Research-oriented Healthcare<ul style="list-style-type: none">○ General Outpatient Department (GOPD) Programme○ Mobile Clinical Research Programme• Mobile Healthcare Programme under Scheduled Caste Sub-Plan
Regional Research Institute of Unani Medicine (RRIUM), New Delhi	<ul style="list-style-type: none">• Clinical Research Programme<ul style="list-style-type: none">○ Validation of Unani Pharmacopoeial Drugs○ Validation of Regimenal Therapies• Research-oriented Healthcare<ul style="list-style-type: none">○ General Outpatient Department (GOPD) Programme○ In-patients Department (IPD) Programme○ Mobile Clinical Research Programme• Unani Speciality Clinics at Allopathic Hospitals• Mobile Healthcare Programme under Scheduled Caste Sub-Plan
Regional Research Institute of Unani Medicine (RRIUM), Silchar	<ul style="list-style-type: none">• Clinical Research Programme<ul style="list-style-type: none">○ Validation of Unani Pharmacopoeial Drugs• Research-oriented Healthcare<ul style="list-style-type: none">○ General Outpatient Department (GOPD) Programme
Regional Research Centre (RRC), Prayagraj	<ul style="list-style-type: none">• Clinical Research Programme<ul style="list-style-type: none">○ Validation of Unani Pharmacopoeial Drugs• Research-oriented Healthcare<ul style="list-style-type: none">○ General Outpatient Department (GOPD) Programme○ Mobile Clinical Research Programme• Mobile Healthcare Programme under Scheduled Caste Sub-Plan





CENTRE	ACTIVITIES
Clinical Research Unit (CRU), Bengaluru	<ul style="list-style-type: none"> • Clinical Research Programme <ul style="list-style-type: none"> ◦ Validation of Unani Pharmacopoeial Drugs • Research-oriented Healthcare <ul style="list-style-type: none"> ◦ General Outpatient Department (GOPD) Programme • Mobile Healthcare Programme under Scheduled Caste Sub-Plan
Clinical Research Unit (CRU), Meerut	<ul style="list-style-type: none"> • Clinical Research Programme <ul style="list-style-type: none"> ◦ Validation of Unani Pharmacopoeial Drugs • Research-oriented Healthcare <ul style="list-style-type: none"> ◦ General Outpatient Department (GOPD) Programme • Mobile Healthcare Programme under Scheduled Caste Sub-Plan
Clinical Research Unit (CRU), Bhopal	<ul style="list-style-type: none"> • Clinical Research Programme <ul style="list-style-type: none"> ◦ Validation of Unani Pharmacopoeial Drugs • Research-oriented Healthcare <ul style="list-style-type: none"> ◦ General Outpatient Department (GOPD) Programme • Mobile Healthcare Programme under Scheduled Caste Sub-Plan
Clinical Research Unit (CRU), Burhanpur	<ul style="list-style-type: none"> • Clinical Research Programme <ul style="list-style-type: none"> ◦ Validation of Unani Pharmacopoeial Drugs • Research-oriented Healthcare <ul style="list-style-type: none"> ◦ General Outpatient Department (GOPD) Programme • Mobile Healthcare Programme under Tribal Sub Plan
Clinical Research Unit (CRU), Edathala	<ul style="list-style-type: none"> • Clinical Research Programme <ul style="list-style-type: none"> ◦ Validation of Unani Pharmacopoeial Drugs • Research-oriented Healthcare <ul style="list-style-type: none"> ◦ General Outpatient Department (GOPD) Programme
Clinical Research Unit (CRU), Kurnool	<ul style="list-style-type: none"> • Clinical Research Programme <ul style="list-style-type: none"> ◦ Validation of Unani Pharmacopoeial Drugs • Research-oriented Healthcare <ul style="list-style-type: none"> ◦ General Outpatient Department (GOPD) Programme • Mobile Healthcare Programme under Tribal Sub Plan
Clinical Research Unit (CRU), Imphal	<ul style="list-style-type: none"> • Research-oriented Healthcare <ul style="list-style-type: none"> ◦ General Outpatient Department (GOPD) Programme
Hakim Ajmal Khan Institute for Literary & Historical Research	<ul style="list-style-type: none"> • Literary Research Programme • Research-oriented Healthcare



CENTRE	ACTIVITIES
in Unani Medicine (HAKILHRUM), New Delhi	<ul style="list-style-type: none"> General Outpatient Department (GOPD) Programme
Drug Standardization Research Institute (DSRI), Ghaziabad	<ul style="list-style-type: none"> Drug Standardization Research Programme
Drug Standardization Research Unit (DSRU), New Delhi	<ul style="list-style-type: none"> Drug Standardization Research Programme

3.1.2. Programme-wise Activities

3.1.2.1. Survey and Cultivation of Medicinal Plants Programme

The CCRUM has a programme for extensive surveys of medicinal plants in different parts of the country, primarily with a view to collect and identify medicinal plants and record basic data on ethno-pharmacological uses of plants from the tribal and other rural folks of the study area. The broad objectives of the programme are:

- To survey, collect and identify medicinal plants in different forest zones of the country;
- To study distribution, availability, ethno-pharmacological uses and threats of medicinal plants;
- To carry out experimental and field-scale cultivation of medicinal plants;
- To maintain a herbarium of medicinal plants and raw drugs for demonstration purposes;
- To maintain a demonstrable herb garden;
- To document folk knowledge on medicinal uses of plants;
- To collect samples of genuine drugs from the forests for pharmacopoeial standardization; and
- To develop nurseries of medicinal plants for demonstration purposes with a view to popularize them among the masses.

This programme is carried out at the following research centres:

- National Research Institute of Unani Medicine for Skin Disorders, Hyderabad
- Regional Research Institute of Unani Medicine, Chennai
- Regional Research Institute of Unani Medicine, Srinagar
- Regional Research Institute of Unani Medicine, Bhadrak
- Regional Research Institute of Unani Medicine, Aligarh

Ethnopharmacological Survey

Under this programme, the Council undertook ethno-pharmacological surveys in different Forest Divisions/areas during the period under report. These include Tirupattur Forest Division, Tirupattur & Cauvery North Wildlife Sanctuary Forest Division, Tamil Nadu; Hyderabad Forest Divisions & Asifabad Forest Division, Telangana; Tirupati Forest Division & Chittoor Forest Division Andhra Pradesh; Sindh Valley Forest Division and Tangmarg Forest Division, Shopian Forest Division & Kupwara / Kamraj Forest Division, Union Territory of Jammu and Kashmir. As a result of the survey tours conducted, 2079 botanical



specimens were collected by the surveyors. During the period under report 429 plant species were identified.

Herbarium

The plant specimens collected from the study areas, including previous collections, were mounted on herbarium sheets. During the reporting period, 759 such herbarium sheets were prepared and information pertaining to the botanical name, family, local name, Unani name (wherever available), date of collection, brief morphological features and medicinal / other uses of the plants were recorded on each herbarium sheet. Besides, 413 index cards were updated.

The survey team members collected 4269 saplings of important medicinal species for plantation in the Herbal Garden and nursery attached to the Institutes.

The survey teams also collected 292 kg of raw drugs and sent them to the pharmacy section of NRIUMSD, Hyderabad and RRIUM, Chennai for the preparation of Unani formulations.

Digitization and Documentation of Herbarium Specimens

Under this activity, 338 herbarium sheets were digitized by the Council's research centres at Chennai and Hyderabad.

Folk Claims

The surveyors enquired from the local communities about the traditional uses of plants after obtaining oral informed consent. The information was systematized taxonomically and efforts were made to develop a database for comparative analysis of the information recorded. As a result, 212 folk medicinal claims were recorded from the tribal inhabitants and other rural folks of the study areas. The Council publishes the information in the form of books providing details comprising botanical name and family, synonym, local name, Unani name, habit and habitat, wild or cultivated, medicinal efficacy claimed and name of the tribe, locality, collection number, part(s) used, mode of application, and biodynamic notes.

Experimental and Field-Scale Cultivation of Medicinal Plants

Under this activity, the Council cultivates some important medicinal plants used in Unani medicines. These include *Atrilāl* (*Ammi majus* L.), *Afsantīn* (*Artemisia absinthium* L.), *Bābchī* (*Psoralea corylifolia* L.), *Gulnār Fārsī* (*Punica granatum* L. abortive var.), *Gurmārbūtī* (*Gymnema sylvestre* (Retz.) R Br. ex Sm.), *Gul Bābūna* (*Matricaria chamomilla* L.), *Gilo* (*Tinospora cordifolia* (Willd.) Miers), *Janglī Piyāz* (*Drimia indica* (Roxb.) Jessop), *Khūlanjān* (*Alpinia galanga* (L.) Willd.), *Nāgdon* (*Artemisia nilagirica* (C.B. Clarke) Pamp), *Dirmānā Turkī* (*Artemisia maritima* L.), *Ajwāyin Khurāsāni* (*Hyoscyamus niger* L.), *Sudāb* (*Ruta graveolens* L.), *Brahmī* (*Bacopa monnieri* (L.) Wettst. etc. As a result of the field-scale cultivation, 51kg of raw drugs were obtained and supplied to the pharmacy section of NRIUMSD, Hyderabad and RRIUM, Chennai from RRIUM, Aligarh and Srinagar for the preparation of Unani formulations.

Herbal Garden and Nursery of Medicinal Plants

With a view to popularize medicinal plants among the masses, the Council maintained about 485 plant species in Herbal Garden at NRIUMSD, Hyderabad and RRIUM's Aligarh, Chennai and Srinagar. Some of the important and interesting species grown under this activity include: *Āmla* (*Phyllanthus emblica* L.), *Anār* (*Punica granatum* L.), *Ashok* (*Saraca asoca*



(Roxb.) Willd.), *Atrilāl* (*Ammi majus* L.), *Afsantīn* (*Artemisia absinthium* L.), *Arūsā* (*Justicia adhatoda* L.), *Aspaghol* (*Plantago ovata* Forssk.), *Aṣl al-Sūs* (*Glycyrrhiza glabra* L.), *Asrol* (*Rauvolfia serpentina* (L.) Benth. ex Kurz.), *Bed Mushk* (*Salix caprea* L.) *Bijāsar* (*Pterocarpus marsupium* Roxb.), *Belgirī* (*Aegle marmelos* (L.) Correa.), *Bābchī* (*Psoralea corylifolia* L.), *Banafshā* (*Viola odorata* L.), *Bhāngrā* (*Eclipta prostrata* (L.) L.), *Brinjāsif* (*Achillea millefolium* L.), *Fūfal* (*Areca catechu* (L.f.) Willd.), *Ga'uzabān* (*Borago officinalis* L.), *Ghīkwār* (*Aloe vera* (L.) Burm.f.), *Gulnār Fārsī* (*Punica granatum* L. abortive var.), *Gurmārbūtī* (*Gymnema sylvestre* (Retz.) R. Br. ex Sm.), *Hīnā* (*Lawsonia inermis* L.), *Irsā* (*Iris ensata* Thunb), *Jadwār* (*Delphinium denudatum* Wall. ex Hook.f. & Thoms.), *Keorā* (*Pandanus tectorius* Soland. ex Parkinson.), *Kājū* (*Anacardium occidentale* L.), *Khālanjān* (*Alpinia galanga* Willd.), *Konch* (*Mucuna pruriens* L.), *Mako* (*Solanum americanum* Mill.), *Marorphālī* (*Helicteres isora* L.), *Muqil* (*Commiphora mukul* (Hook. ex Stocks) Engl.), *Pālas* (*Butea monosperma* (Lam.) Taub.), *Qinnāb* (*Cannabis sativa* L.), *Qurṭūm* (*Carthamus tinctorius* L.), *Qust* (*Saussurea costus* (Falc.) Lipsch.), *Rāsan* (*Inula racemosa* C.B. Clarke), *Rivandchīnī* (*Rheum emodi* Wall ex Meissn), *Sadābahār* (*Catharanthus roseus* (L.) G. Don), *Ṣandal Surkh* (*Pterocarpus santalinus* L.f.), *Satāwar* (*Asparagus racemosus* Willd.), *Sudāb* (*Ruta graveolens* L.), *Raiḥān* (*Ocimum tenuiflorum* L.), *Tagar* (*Valeriana jatamansi* Jones), *Tok Balūch* (*Ginkgo biloba* L.), *Turbud* (*Ipomoea turpethum* R. Br.), *ʿUd Ṣalīb* (*Paeonia emodi* Wallich ex Royel), *Waj* (*Acorus calamus* L.), *Zehraj / Māhī Zehraj* (*Verbascum thapsus* L.), etc.

3.1.2.2. Drug Standardization Research Programme

The Drug Standardization Research Programme is mainly concerned with evolving pharmacopoeial standards for single and compound drugs of Unani Medicine included in various volumes of *National Formulary of Unani Medicine (NFUM)* and *Essential Drugs List* for their incorporation in *Unani Pharmacopoeia of India (UPI)*. The work on compound formulations includes development of standard operating procedures (SOPs) for their manufacture followed by the development of their pharmacopoeial standards. Besides, standardization of investigational drugs for clinical trials at the CCRUM and estimation of heavy metals, microbial load, aflatoxins, and pesticidal residues in the drugs and chemical investigations of Unani medicinal plants are also carried out under this programme. The standardization work is carried out in accordance with the format approved by the Scientific Advisory Board, Pharmacopoeia Commission for Indian Medicine & Homoeopathy, Government of India through the following research centres:

- Drug Standardization Research Institute (DSRI), Ghaziabad
- National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad
- Regional Research Institute of Unani Medicine (RRIUM), Chennai
- Regional Research Institute of Unani Medicine (RRIUM), Srinagar
- Regional Research Institute of Unani Medicine (RRIUM), Aligarh
- Drug Standardization Research Unit (DSRU), New Delhi



During the reporting period, the following works were carried out:

Development of SOPs for Method of Preparation of Unani Formulations and their Pharmacopoeial Standards

Under this programme, SOPs for the method of preparation and pharmacopoeial standards of the following 27 Unani formulations were developed:

S. N.	Formulation	S. N.	Formulation
1	<i>Kushta Bayḍa-i-Murgh</i>	15	<i>Khamīra Uṣṭūkhūdūs</i>
2	<i>Kushta Busud</i>	16	<i>Khamīra Yashab</i>
3	<i>Kuḥl Chiknī Dawā'</i>	17	<i>Itṛīfal Ghudadī</i>
4	<i>Kuḥl Ṣadaf</i>	18	<i>Ma'jūn 'Aqrab</i>
5	<i>Shiyāf Abyaḍ</i>	19	<i>Ma'jūn Adharāqī</i>
6	<i>Kushta Fawlād</i>	20	<i>Ma'jūn Falaksayr</i>
7	<i>Kushta Gaudantī</i>	21	<i>Ma'jūn Band Kushād</i>
8	<i>La'ūq Abhal</i>	22	<i>Ma'jūn Fanjnosh</i>
9	<i>La'ūq Ḥulba</i>	23	<i>Ma'jūn Fotnajī</i>
10	<i>La'ūq Dīq al-Nafas</i>	24	<i>Ma'jūn Ḥajar al-Yahūd</i>
11	<i>La'ūq Bihīdāna</i>	25	<i>Ma'jūn Ḥaml 'Ambarī 'Alwī Khānī</i>
12	<i>Jawārish Falāfilī</i>	26	<i>Kushta Marwārid</i>
13	<i>Khamīra Ga'uzabān 'Ambarī Jawāhirwāla</i>	27	<i>Kushta Ṣadaf</i>
14	<i>Khamīra Zahr Mohra</i>		

Development of Pharmacopoeial Standards of Single Drugs

Under the programme, pharmacopoeial standards of the following 10 single drugs were developed:

S. N.	Drug	Scientific Name	Part Studied
1.	<i>Kanghī</i>	<i>Abutilon indicum</i> Mill.	Leaf
2.	<i>Ḥabb al-Qilqil</i>	<i>Cardiospermum halicacabum</i> L.	Fruit
3.	<i>Ḥabb al-Sumna</i>	<i>Buchanania angustifolia</i> Roxb.	Seed
4.	<i>Panwār</i>	<i>Cleome icosandra</i> L.	Seed
5.	<i>Kāshim (Chātim)</i>	<i>Alstonia scholaris</i> R. Br.	Root
6.	<i>Karafs</i>	<i>Apium graveolens</i> L.	Leaf
7.	<i>Asārūn</i>	<i>Berberis aristata</i> DC.	Root Bark Extract
8.	<i>Halyūn</i>	<i>Blepharis edulis</i> Pers.	Seed
9.	<i>Kīkar (Mughīlān)</i>	<i>Acacia arabica</i> L.	Resin
10.	<i>Kath Safayd</i>	<i>Acacia leucophloea</i> Willd.	Resin



Analysis of DTL Samples

The drug testing laboratory (DTL) at the RRIUM, Chennai analysed the following 12 ASU drug samples received from different organizations:

S. No.	Sample	Source	Parameters Analysed
1.	NMVM	National Institute of Siddha, Chennai	Microbial Load
2.	MVM		
3.	CMKC		
4.	CMKIH		Aflatoxin
5.	Narkanranthai Legium (NL)		Antibacterial Study
6.	CMK		
7.	TW	Islamiah College, Chennai	Thin Layer Chromatography
8.	<i>Dimād Muḥallil</i>	Luqman Unani Medical College, Vijayapura	HPTLC Studies
9.	<i>Ma'jūn Khabath al-Ḥadīd</i>	NIUM, Bangalore	Physico-chemical and HPTLC studies
10.	<i>Lavandula angustifolia</i> Moench		Heavy metals and HPTLC Studies
11.	VT Rasayan	All India Institute of Ayurveda, New Delhi	Microbial Load and Aflatoxins
12.	Coded: MD	Annai Violet Arts & Science College, Chennai	HPTLC Studies

Quality Control Work on Drug Samples

The following drug samples were analyzed for quality control purposes:

S. N.	Sample	Source	Parameters Analysed
1	<i>Rowghan Hindī</i>	RRIUM, Aligarh	Heavy metals
	<i>Rowghan Khiḍāb</i>		
2	Sample I to X	RRIUM, Srinagar	Heavy metals, Microbial load, Aflatoxin
3	<i>Ma'jūn Jalālī</i>	RRIUM, Aligarh	Microbial load, Aflatoxin, Heavy metals
	<i>Ma'jūn Ispand Sokhtānī</i>		



S. N.	Sample	Source	Parameters Analysed
4	Sample I to IX	RRIUM, Srinagar	Microbial load, Aflatoxins, Heavy metals
5	<i>Safūf Na 'na', Safūf Hāḍim Kalān, Safūf Surkh, Safūf Lājward, Safūf Kishnīz, Asārūn, Halyūn, Kāshim, Karafs</i> (9)	DSRU, New Delhi	Heavy metals
6	<i>MHY, MAZ, MBK, MFH, MFJ, Busud, Lājward, Hajar al-Yahūd, Hāshā, Pudīna Kohī, Bisehrī Būtī</i> (10)	DSRU, New Delhi	Heavy metals
7	<i>Khamīra Abresham Sāda</i>	Department of Pharmacy, RRIUM, Chennai	Quality control studies
8	<i>'Araq Bādiyān</i>		
9	<i>Jawārish Zar 'ūnī Sāda</i>		
10	<i>Sharbat 'Unnāb</i>		
11	<i>Habb Asgand</i>		
12	<i>Ma 'jūn Chobchīnī</i>		
13	<i>'Araq Kāsnī</i>		
14	<i>Sharbat 'Unnāb</i>		
15	<i>Jawārish Anārayn</i>		
16	<i>Ma 'jūn Chobchīnī</i>		
17	<i>'Araq Kāsnī</i>		
18	<i>Itīrfal Ustūkhūdūs</i>		
19	<i>Habb Sūranjān</i>		
20	<i>Khamīra Ga 'uzabān Sāda</i>		
21	<i>'Unnāb</i>		
22	<i>Chobchīnī, Khuṣya al-Tha 'lab, Khūlanjān, Gul Ga 'uzabān, Behman Safayd, Behman Surkh, Shaqāqul Miṣrī, Abresham, Mughāth, Jadwār</i> (10)		
23	<i>Sharbat 'Unnāb</i>		
24	<i>Ma 'jūn Chobchīnī</i>		
25	<i>Bīkh Kāsnī, Bīkh Bādiyān, Tukhm Kāsnī, Tukhm Khayārza, Tukhm Khiyār, Tukhm Kharbūzah, Tukhm Khārkhasak Khurd</i> (7)		
26	<i>Sharbat Buzūrī Mu 'tadil</i>		
27	<i>'Araq Mako</i>		
28	<i>Hajar al-Yahūd, Kāknaj, Asārūn, Maghz Tukhm-i-Kharbūzah, Tukhm Gazar, Tukhm Karafs, Maghz Tukhm-i-Qurṭum, Anīsūn, Maghz Tukhm-i-Tarbūz, Maghz Tukhm-i-Kadū, Maghz Tukhm-i-Khiyarza</i> (12)		
29	<i>Habb Sūranjān</i>		
30	<i>Sharbat Buzūrī Mu 'tadil</i>		
31	<i>Post Halela Kābulī, Post Halela Zard, Halela Siyāh, Post Halela Balela, Kishnīz Khushk, Āmla</i> (6)		
32	<i>Itīrfal Kishnīzī</i>		



S. N.	Sample	Source	Parameters Analysed
33	<i>Ma'jūn Ḥajar al-Yahūd</i>		
34	<i>Sharbat 'Unnāb</i>		
35	<i>Ḥabb Sūranjān</i>		
36	<i>Tukhm Jawz Māthal, Rīwand Chīnī, Zanjabīl, Ṣamagh 'Arabī (4)</i>		
37	<i>Ma'jūn Dabīd al-Ward</i>		
38	<i>Ḥabb Shifā'</i>		
39	<i>Chobchīnī, Khuṣya al-Tha'lab, Khūlanjān, Gul Ga'uzabān, Behman Safayd, Behman Surkh, Shaqāqul Miṣrī, Abresham, Jadwār (9)</i>		
40	<i>'Araq Mako</i>		
41	<i>Ṭabāshīr, Satt Gilo, Maghz Khasta-i-Jāmun, Gurmār Būtī, Kushta Bayḍa-i-Murg, Kushta Zamarrud, Lu'āb Aspaghol (8)</i>		
42	<i>Ma'jūn Chobchīnī</i>		
43	<i>Post Halela Kābulī, Uṣṭūkhūdūs, Post Balela, Halela Siyāh, Kishmish, Āmla, Aftīmūn, Bisfā'ij (8)</i>		
44	<i>Bīkh Kāsnī, Bīkh Bādiyān, Tukhm Kāsnī, Tukhm Khayārza, Tukhm Kiyār, Tukhm Kharbūza, Tukhm Khārkhasak Khurd (7)</i>		
45	<i>Aftīmūn, Gārīqūn, Turbud Safayd, Uṣṭūkhūdūs, Bisfā'ij, Bādiyān (6)</i>		
46	<i>Qurṣ Dhayābītus Khāṣ</i>		
47	<i>Mako Khushk & Bādiyān</i>		
48	<i>Anjīr, Tukhm Khaṭmī, Aṣl al-Sūs, Irsā, Tukhm Karafs, Parsiā'oshān, Zūfā Khushk, Mawīz Munaqqa (8)</i>		
49	<i>Sharbat Buzūrī Mu'tadil</i>		
50	<i>Itīrfal Uṣṭūkhūdūs</i>		
51	<i>Sharbat Zūfā Murakkab</i>		
52	<i>Ḥabb Aftīmūn</i>		
53	<i>Alsī, Rub al-Sūs, Filfil Siyāh, Gond Kīkar, Maghz Bādām Shīrīn, Maghz Akhrot (6)</i>		
54	<i>'Araq Mako</i>		
55	<i>Naushādar, Namak Siyāh, Namak-i-Sang, Tankār Bīryān, Narkachūr, Halela Siyāh, Post Halela Kabulī, Bā'obarang, Filfil Siyāh, Zanjabīl (10)</i>		
56	<i>'Araq Bādiyān</i>		
57	<i>Ga'uzabān, Kishnīz, Ṣandal Safayd, Tukhm Rayḥān, Tukhm Bālango, Bāndranjboyā (6)</i>		
58	<i>Gul Bābūna, Rowghan Kunjad (2)</i>		
59	<i>Jawārish Shāhī</i>		



Isolation of Phytoconstituents from Unani Single Drugs

Two Unani single drugs were taken up for isolation of phytoconstituents at RRIUM, Srinagar. The details of the isolated compounds are given below:

S. N.	Drug	Scientific Name	Part Studied	Phytoconstituents Isolated
1.	<i>Anannās</i>	<i>Ananas comosus</i> Merr. syn. <i>Ananas sativus</i> Schult.	Leaf	Ascorbic Acid, Quercetin, Flavones-3-Ol, Flavones, Ferulic Acid
2.	<i>Darmana Turkī</i>	<i>Artemesia meritima</i> L.	Whole plant	Gallic Acid, Catechin, Vanillic Acid, Caffeic Acid, Epicatechin, Ferulic Acid

3.1.2.3. Clinical Research Programme

Preclinical Studies

During the reporting period, preclinical safety and toxicity studies were conducted on several Unani formulations at the Regional Research Institute of Unani Medicine (RRIUM), Srinagar, and the National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad. The studies adhered to the OECD guidelines for acute and repeated dose toxicity evaluations. Summarized below are the details of each study.

Preclinical Studies conducted at RRIUM, Srinagar

Habb Khardal (HK): *Habb Khardal* is a traditional polyherbal formulation with expectorant and anti-inflammatory properties, used in the treatment of hoarseness, pharyngitis, laryngitis, chronic catarrh, and phlegmatic cough.

- **Acute Oral Toxicity:** Conducted as per OECD-425 guidelines, a single dose of 2000 mg/kg body weight was administered to Wistar rats. No mortality or significant toxicological symptoms were observed.
- **Repeated Dose Oral Toxicity (28-day):** A repeated dose study was performed with 1000 mg/kg body weight. Preliminary findings based on hematology, biochemistry, body weight, and feed intake suggest that *Habb Khardal* is safe for its intended use. Histopathological assessments were ongoing.

La'ūq Unşul (LU): *La'ūq Unşul* is a traditional Unani expectorant formulation used for treating chronic cough.

- **Acute Oral Toxicity:** A single dose of 2000 mg/kg body weight was administered, following OECD-425 guidelines. No toxicity or gross pathological abnormalities were observed.
- **Repeated Dose Oral Toxicity (28-day):** The study involved repeated administration of 1000 mg/kg body weight in Wistar rats. No significant differences were observed in body weight, feed intake, behavior, or biochemical parameters. The formulation demonstrated a favorable safety profile. The final safety confirmation awaits histopathological evaluation.



Preclinical Studies conducted at NRIUMSD, Hyderabad

Ma'jūn Muṣaffī A'ḏam (MMA): *Ma'jūn Muṣaffī A'ḏam* is a blood-purifying formulation indicated for treating acne, boils, syphilis, arthralgia, and arthritis.

- **Acute Oral Toxicity:** Conducted as per OECD-425 guidelines, a single dose of 5000 mg/kg body weight was administered to Sprague Dawley (SD) rats. No mortality or toxicological symptoms were observed, and the LD50 was determined to be greater than 5000 mg/kg.
- **Repeated Dose Oral Toxicity (28-day):** The study was conducted as per OECD-407 guidelines with doses of 1200, 1800, and 2400 mg/kg body weight per day, corresponding to 1X, 1.5X, and 2X the therapeutic dose. No toxicological alterations were observed in survival, behavior, body weight, or organ weight. Histopathological assessment was ongoing, but initial findings indicate MMA is safe for its intended use.

Mufarriḥ Shaikh al-Ra'īs (MSUR): *Mufarriḥ Shaikh al-Ra'īs* is a cardi tonic formulation used to treat heart weakness and palpitation.

- **Acute Oral Toxicity:** A single dose of 2000 mg/kg body weight was administered, as per OECD-425 guidelines. No significant adverse effects were observed, and the LD50 was greater than 2000 mg/kg.
- **Repeated Dose Oral Toxicity (28-day):** Doses of 500, 1000, and 2000 mg/kg body weight were administered daily for 28 days. Rats were monitored for clinical signs, body weight, and feed intake. No significant toxicological effects were observed, and histopathological results are pending.

Safūf Makhāna (SM): *Safūf Makhāna* is an aphrodisiac formulation, used to treat conditions such as nocturnal emissions, spermatorrhoea, premature ejaculation, and leucorrhoea.

- **Acute Oral Toxicity:** A single dose of 2000 mg/kg body weight was administered, following OECD-425 guidelines. The LD50 was determined to be greater than 2000 mg/kg in SD rats.
- **Repeated Dose Oral Toxicity (28-day):** The formulation was administered at doses of 600, 1200, and 1800 mg/kg body weight per day for 28 days. No toxicological alterations were observed in body weight, feed intake, survival, or biochemical parameters. The final safety assessment is pending histopathological evaluation.

Ḥabb Gul-i-Āk (HGA): *Ḥabb Gul-i-Āk* is traditionally used as a sedative and anti-inflammatory, particularly for treating arthritis and joint pain.

- **Acute Oral Toxicity:** Conducted as per OECD-425 guidelines, a single dose of 2000 mg/kg body weight was administered to SD rats. No significant toxicological symptoms or mortality were observed, with the LD50 greater than 2000 mg/kg.
- **Repeated Dose Oral Toxicity (90-day):** The study was conducted with doses of 25, 125, and 250 mg/kg body weight per day for 90 days, corresponding to approximately 1X, 5X, and 10X the therapeutic dose. No significant toxicological effects were observed in terms of survival, body weight, behavior, or organ weight. Histopathological evaluation is in progress.

The preclinical safety and toxicity studies of the Unani formulations conducted during the 2023–2024 reporting period demonstrated no significant adverse effects across acute and repeated dose studies. The formulations studied were well-tolerated in animal models. Histopathological evaluations are pending to confirm the final safety profiles.



Clinical Studies

The Clinical Research Programme of the CCRUM deals with the methods of diagnosis and treatment of diseases and aims at the critical appraisal of the theory of pathogenesis, symptomatology, clinical methods of diagnosis, principles and methods of treatment, and the drug and diet therapies peculiar to Unani Medicine. Under this programme, clinical studies on different diseases were undertaken with a view to develop safe and effective Unani treatments. Besides, clinical validation of the safety and efficacy of Unani pharmacopoeial formulations and validation of Unani pharmacopoeial fast-acting drugs in different diseases was conducted. The programme continued at the following centres:

- National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad
- Central Research Institute of Unani Medicine (CRIUM), Lucknow
- Regional Research Institute of Unani Medicine (RRIUM), Chennai
- Regional Research Institute of Unani Medicine (RRIUM), Bhadrak
- Regional Research Institute of Unani Medicine (RRIUM), Patna
- Regional Research Institute of Unani Medicine (RRIUM), Aligarh
- Regional Research Institute of Unani Medicine (RRIUM), Mumbai
- Regional Research Institute of Unani Medicine (RRIUM), Srinagar
- Regional Research Institute of Unani Medicine (RRIUM), Kolkata
- Regional Research Institute of Unani Medicine (RRIUM), New Delhi
- Regional Research Institute of Unani Medicine (RRIUM), Silchar
- Regional Research Centre (RRC), Prayagraj
- Clinical Research Unit (CRU), Bengaluru
- Clinical Research Unit (CRU), Meerut
- Clinical Research Unit (CRU), Bhopal
- Clinical Research Unit (CRU), Burhanpur
- Clinical Research Unit (CRU), Edathala
- Clinical Research Unit (CRU), Kurnool

CENTRE-WISE ALLOCATION OF DISEASES FOR CLINICAL STUDIES ON SAFETY AND EFFICACY OF UNANI DRUGS

Centre	Diseases
National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad	<i>Haṣāt al-Kulya</i> (nephrolithiasis), <i>Kathrat al-Ṭamth</i> (heavy menstrual bleeding), <i>Ḍīq al-Nafas</i> (bronchial asthma), <i>Ḍu'f al-Mi'da</i> (functional dyspepsia), <i>Iḥtibās al-Ṭamth</i> (amenorrhoea), <i>Mālankhūliyā</i> (mixed anxiety depressive disorder), <i>Sū' al-Qinya</i> (anaemia), <i>Ḥummā</i> (fever), <i>Kathrat al-Bawl</i> (overactive bladder), <i>Amrāḍ-i-Jild</i> (skin eruptions), <i>Dhayābīṭus Sukkarī</i> (diabetes mellitus), <i>Qūbā</i> (dermatophytosis), <i>Bawāsīr 'Amyā'</i> (non-bleeding piles), <i>Fālij</i> (hemiplegia), <i>Su'āl Muzmin</i> (chronic cough)
Central Research Institute of Unani Medicine (CRIUM), Lucknow	<i>Sū' al-Qinya</i> (anaemia), <i>Sayalān al-Raḥīm</i> (leucorrhoea), <i>Ḍīq al-Nafas</i> (bronchial asthma), <i>Ḍu'f al-Dimāgh</i> (cerebrasthenia), <i>Ḥummā</i> (fever), <i>Iḥtibās al-Ṭamth</i> (amenorrhoea), <i>Kathrat al-Ṭamth</i> (heavy menstrual



Centre	Diseases
	bleeding), <i>Sū' al-Haḍm</i> (dyspepsia), <i>Waja' al-Mafāṣil</i> (rheumatoid arthritis), <i>Ḍu'f al-Mi'da</i> (functional dyspepsia), <i>Ḥaṣāt al-Kulya</i> (nephrolithiasis), <i>Mālankhūliyā</i> (mixed anxiety depressive disorder)
Regional Research Institute of Unani Medicine (RRIUM), Chennai	<i>Ḥaṣāt al-Kulya</i> (nephrolithiasis), <i>Ḥummā</i> (fever), <i>Qūbā</i> (dermatophytosis), <i>Mālankhūliyā</i> (mixed anxiety depressive disorder), <i>Ḍīq al-Nafas</i> (bronchial asthma), <i>Ḍu'f al-Dimāgh</i> (cerebrasthenia), <i>Sahar</i> (insomnia), <i>Waja' al-Mafāṣil</i> (rheumatoid arthritis), <i>Fālij</i> (hemiplegia) and <i>Sayalān al-Raḥim</i> (leucorrhoea), <i>Qarḥa 'Asīr al-Indimāl</i> (non-healing ulcers), <i>Waja' al-Qaṭan</i> (lumbar pain / lumbago)
Regional Research Institute of Unani Medicine (RRIUM), Bhadrak	<i>Buthūr al-Jild</i> (skin eruptions), <i>Waja' al-Mafāṣil</i> (rheumatoid arthritis), <i>Sur'at al-Inzāl</i> (premature ejaculation), <i>Khafaqān</i> (palpitation), <i>Jarab</i> (scabies), <i>Ḍīq al-Nafas</i> (bronchial asthma), <i>Ḍu'f al-Mi'da</i> (functional dyspepsia), <i>Bahaq Abyaḍ / Aswad</i> (pityriasis alba/nigra), <i>Mālankhūliyā</i> (mixed anxiety depressive disorder)
Regional Research Institute of Unani Medicine (RRIUM), Patna	<i>Sū' al-Qinya</i> (anaemia), <i>Nazla Muzmin</i> (chronic rhinosinusitis), <i>Qūbā</i> (dermatophytosis), <i>Niqris</i> (gout), <i>Waja' al-Mafāṣil</i> (rheumatoid arthritis), <i>Ḍu'f al-Mi'da</i> (functional dyspepsia), <i>Ḍu'f al-Dimāgh</i> (cerebrasthenia), <i>Bawāsīr Dāmiya</i> (bleeding piles), <i>Sahar</i> (insomnia), <i>Ḍīq al-Nafas</i> (bronchial asthma), <i>Taqṭīr al-Bawl</i> (post-micturition dribble)
Regional Research Institute of Unani Medicine (RRIUM), Aligarh	<i>Ḍu'f al-Ishtihā'</i> (anorexia), <i>Ḍīq al-Nafas</i> (bronchial asthma), <i>Ḍu'f al-Mi'da</i> (functional dyspepsia), <i>Ḥummā Ajāmiyya</i> (malaria), <i>Sayalān al-Raḥim</i> (leucorrhoea), <i>Ḍu'f al-Dimāgh</i> (cerebrasthenia), <i>Qulā'</i> (stomatitis), <i>Niqris</i> (gout), <i>Ḥumūḍat al-Mi'da</i> (hyperacidity), <i>Jildī Qurūḥ</i> (cutaneous ulcers), <i>Waram al-Ḥanjara</i> (laryngitis), <i>Sū' al-Haḍm</i> (functional dyspepsia), <i>Su'āl Muzmin</i> (chronic cough), <i>Shaqīqa</i> (migraine)
Regional Research Institute of Unani Medicine (RRIUM), Mumbai	<i>Ḍīq al-Nafas</i> (bronchial asthma), <i>Ḥaṣāt al-Kulya</i> (nephrolithiasis), <i>Sū' al-Qinya</i> (anaemia), <i>Iḥtibās al-Ṭamth</i> (amenorrhoea), <i>Niqris</i> (gout), <i>Qūbā</i> (dermatophytosis), <i>Khafaqān</i> (palpitation), <i>Mālankhūliyā</i> (mixed anxiety depressive disorder), <i>Sayalān al-Raḥim</i> (leucorrhoea), <i>Nisyān</i> (amnesia), <i>Salas al-Bawl</i> (stress urinary incontinence), <i>Qurūḥ</i> (healing ulcers), <i>Waram-i-Kabid Bārid</i> (non-alcoholic fatty liver disease), <i>Waja' al-Mafāṣil</i> (rheumatoid arthritis)
Regional Research Institute of Unani Medicine (RRIUM), Srinagar	<i>Ḍīq al-Nafas</i> (bronchial asthma), <i>Ḍu'f al-Mi'da</i> (functional dyspepsia), <i>Ḥummā</i> (fever), <i>Sayalān al-Raḥim</i> (leucorrhoea), <i>Mālankhūliya</i> (mixed anxiety depressive



Centre	Diseases
	disorder), <i>Dhayābītus Sukkarī</i> (diabetes mellitus), <i>Ḍaghṭ al-Dam Qawī</i> (hypertension), <i>Kathrat al-Ṭamth</i> (heavy menstrual bleeding), <i>Iḥtibās al-Ṭamth</i> (amenorrhoea), <i>Niqris</i> (gout), <i>Taqṭīr al-Bawl</i> (post-micturition dribble), <i>Dā' al-Tha'lab</i> (diffuse alopecia), <i>Qarḥa 'Asīr al-Indimāl</i> (non-healing ulcers), <i>Iḥtibās al-Ṭamth</i> (amenorrhoea), <i>Buthūr</i> (skin eruptions)
Regional Research Institute of Unani Medicine (RRIUM), Kolkata	<i>Nazla Muzmin</i> (chronic rhinosinusitis), <i>Ḍu'f al-Ishtihā'</i> (anorexia), <i>Sū' al-Qinya</i> (anaemia), <i>Su'āl Muzmin</i> (chronic cough)
Regional Research Institute of Unani Medicine (RRIUM), New Delhi	<i>Sayalān al-Raḥīm</i> (leucorrhoea), <i>Buthūr al-Jild</i> (skin eruptions), <i>Kathrat al-Ṭamth</i> (heavy menstrual bleeding), <i>Sū' al-Qinya</i> (anaemia), <i>Khafaqān</i> (palpitation), <i>Sū' al-Haḍm</i> (dyspepsia), <i>Dhayābītus Sukkarī</i> (diabetes mellitus), <i>'Irq al-Nasā</i> (sciatica), <i>Nisyān</i> (amnesia), <i>Ḍu'f al-A'sāb</i> (neurasthenia), <i>Ḍīq al-Nafas</i> (bronchial asthma), <i>Waram-al-Ḥalq</i> (pharyngitis)
Regional Research Institute of Unani Medicine (RRIUM), Silchar	<i>Buthūr al-Jild</i> (skin eruptions), <i>Waja' al-Asnān</i> (toothache), <i>Sū' al-Qinya</i> (anaemia), <i>Sahar</i> (insomnia), <i>Bahaq Abyaḍ / Aswad</i> (pityriasis alba/nigra), <i>Ḍu'f al-Ishtihā'</i> (anorexia)
Regional Research Centre (RRC), Prayagraj	<i>Nazla Ḥārr</i> (common cold), <i>Niqris</i> (gout), <i>Sū' al-Qinya</i> (anaemia), <i>Waja' al-Mafāṣil</i> (rheumatoid arthritis), <i>Su'āl Yābis</i> (dry cough), <i>Sahar</i> (insomnia), <i>Ḍīq al-Nafas</i> (bronchial asthma), <i>Bawāsīr 'Amyā'</i> (non-bleeding piles)
Clinical Research Unit (CRU), Bengaluru	<i>Fālīj</i> (hemiplegia), <i>Buthūr</i> (skin eruptions), <i>Dā' al-Tha'lab</i> (diffuse alopecia)
Clinical Research Unit (CRU), Meerut	<i>Ḍu'f al-Ishtihā'</i> (anorexia), <i>Bawāsīr Dāmiya</i> (bleeding piles), <i>Waram al-Ḥanjara</i> (laryngitis), <i>Khafaqān</i> (palpitation), <i>Waja' al-Qaṭan</i> (lumbar pain / lumbago)
Clinical Research Unit (CRU), Bhopal	<i>Ḍu'f al-Ishtihā'</i> (anorexia), <i>Sayalān al-Raḥīm</i> (leucorrhoea), <i>Mālankhūliya</i> (mixed anxiety depressive disorder)
Clinical Research Unit (CRU), Burhanpur	<i>Sū' al-Haḍm</i> (functional dyspepsia), <i>Buthūr</i> (skin eruptions), <i>Ḍu'f al-Mi'da</i> (functional dyspepsia)
Clinical Research Unit (CRU), Kerala	<i>Nazla</i> (common cold), <i>Sahar</i> (insomnia), <i>Sur'at al-Inzāl</i> (premature ejaculation), <i>Waram-i-Ḥalq</i> (pharyngitis)
Clinical Research Unit (CRU), Kurnool	<i>Amrāḍ-i-Jild</i> (skin eruptions), <i>Dā' al-Tha'lab</i> (diffuse alopecia), <i>Shaḡīqa</i> (migraine)



Randomised Controlled Trials

The following studies under the randomised controlled trials were conducted/initiated during the reporting period:

A single blind, randomised, parallel group study to compare the efficacy and safety of Unani formulation *Qurş Mafāşil* with Paracetamol in patients of *Taḥajjur al-Mafāşil* (osteoarthritis)

A randomised controlled clinical study of a Unani formulation *Qurş Mafāşil* with Paracetamol in the patients of *Taḥajjur al-Mafāşil* (osteoarthritis) was carried out at NRIUMSD, Hyderabad and CRIUM, Lucknow. The patients were divided into two groups. The test group received *Qurş Mafāşil* in a dose of two tablets (500 mg each) whereas the control group received Paracetamol one tablet (500 mg) once a day for eight weeks.

During the reporting period, 51 patients were registered in the study. Out of 23 cases who completed the study, 03 were relieved and 20 were partially relieved. There were 09 dropouts and 19 cases were under study. The test drug was found well-tolerated and no adverse effect was observed.

A single blind, randomized, parallel group study to compare the efficacy and safety of Unani formulation *Safūf Dama Haldī Wālā* with Salbutamol in patients with *Ḍīq al-Nafas* (bronchial asthma)

A randomised controlled clinical study of a Unani formulation *Safūf Dama Haldī wālā* with Salbutamol in the patients of *Ḍīq al-Nafas* (bronchial asthma) was carried out at NRIUMSD, Hyderabad. The patients were divided into two groups. The test group received *Safūf Dama Haldī wālā* in powder form in a dose of 5 g once daily whereas the control group received Salbutamol 2 mg once a day for 51 days.

During the reporting period, 09 patients were registered, of which 04 completed the study. Of the completed cases, 03 were relieved and 01 patient was not relieved. There were 04 dropouts and 01 case was under study. The test and control drugs were found well-tolerated and no adverse effect was observed.

A single blind, randomised, parallel group study to compare the efficacy and safety of Unani formulation *Cap. Shaqīqa* with Divalproate in the patients of *Shaqīqa* (migraine)

A randomised controlled clinical study of a coded Unani formulation *Cap. Shaqīqa* with Divalproate in the patients of *Shaqīqa* (migraine) was carried out at RRIUM, Chennai. The patients were divided into two groups. The test group received *Cap. Shaqīqa* in the dose of two capsules (500 mg each) twice a day, whereas the control group received Divalproate 250 mg (body weight <30 kg) or 850 mg (body weight >80 kg) once a day for 12 weeks.

During the reporting period, 48 patients were registered in the study. Out of them, 28 cases completed the study. Of the completed cases, 19 cases were relieved, 05 partially relieved and 04 were not relieved. There were 08 dropouts and 12 cases were under study. The test drug was found well-tolerated and no adverse effect was observed.

Validation of Unani Pharmacopoeial Drugs

Clinical validation of a Unani pharmacopoeial formulation *Safūf Chobchīnī* in *Niqris* (gout)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Safūf Chobchīnī* in patients with *Niqris* (gout) at RRIUMs, Mumbai, Patna, and RRC, Prayagraj.



Patients were administered 5 g of *Safūf Chobchīnī* twice daily for six weeks. Out of the 166 patients who completed the study, 108 (65.06%) experienced relief, 39 (23.49%) were partially relieved, and 19 (11.44%) showed no relief. The test drug was well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *Habb Muṣaffī-i-Khūn* in *Buthūr al-Jild* (skin eruptions)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Habb Muṣaffī-i-Khūn* in patients with *Buthūr al-Jild* (skin eruptions) at RRIUMs, New Delhi and Bhadrak, and RRC, Silchar. Patients were administered one pill (250 mg) of *Habb Muṣaffī-i-Khūn* twice daily for two weeks. Of the 132 patients who completed the study, 42 (31.81%) were relieved, 59 (44.6%) were partially relieved, and 31 (23.48%) showed no relief. The test drug was well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *Ma'jūn Najāḥ* in *Mālankhūliyā* (mixed anxiety depressive disorder)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Ma'jūn Najāḥ* in patients with *Mālankhūliyā* (mixed anxiety depressive disorder) at NRIUMSD, Hyderabad; and RRIUMs, Srinagar, Chennai, and Mumbai. Patients were administered 5 g of *Ma'jūn Najāḥ* twice daily for six weeks. Out of the 129 patients who completed the study, 91 (70.54%) were relieved, 31 (24.03%) were partially relieved, and 7 (5.42%) showed no relief. The test drug was well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *Qurṣ Anjibār* in *Kathrat al-Ṭamth* (heavy menstrual bleeding)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Qurṣ Anjibār* in patients with *Kathrat al-Ṭamth* (heavy menstrual bleeding) at NRIUMSD, Hyderabad; CRIUM, Lucknow; and RRIUM, New Delhi. Patients were administered two tablets (500 mg) of *Qurṣ Anjibār* thrice daily for 12 weeks. Out of the 25 patients who completed the study, 7 (21.21%) were relieved, 15 (45.45%) were partially relieved, and 3 (9.09%) showed no relief. The test drug was well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *Ma'jūn Ḥajar al-Yahūd* in *Ḥaṣāt al-Kulya* (nephrolithiasis)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Ma'jūn Ḥajar al-Yahūd* in patients with *Ḥaṣāt al-Kulya* (nephrolithiasis) at NRIUMSD, Hyderabad; and RRIUMs, Mumbai and Chennai. Patients were administered 5 g of *Ma'jūn Ḥajar al-Yahūd* twice daily for eight weeks. Of the 14 patients who completed the study, 6 (42.85%) were relieved, 5 (35.71%) were partially relieved, and 3 (21.42%) showed no relief. The test drug was well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *Ma'jūn Suhāg Sonth* in *Sayalān al-Raḥīm* (excessive abnormal vaginal discharge)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Ma'jūn Suhāg Sonth* in patients with *Sayalān al-Raḥīm* (excessive abnormal vaginal discharge) at CRIUM, Lucknow; RRIUM, Srinagar; and CRU, Meerut. Patients were administered 5 g of *Ma'jūn Suhāg Sonth* twice daily for four weeks. Out of the 32 patients who completed the



study, 11 (34.37%) were relieved, 17 (53.12%) were partially relieved, and 4 (12.5%) showed no relief. The test drug was well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *Habb Khabath al-Hadīd* in *Sū' al-Qinya* (anaemia)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Habb Khabath al-Hadīd* in patients with *Sū' al-Qinya* (anaemia) at CRIUM, Lucknow; and RRIUMs, New Delhi and Mumbai. Patients were administered one pill of *Habb Khabath al-Hadīd* twice daily for 12 weeks. Out of the 3 patients studied, 1 completed the study and showed partial relief. The test drug was well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *Habb Hindī Dīqī* in *Dīq al-Nafas* (bronchial asthma)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Habb Hindī Dīqī* in patients with *Dīq al-Nafas* (bronchial asthma) at RRIUMs, Srinagar, Aligarh, and Patna. Patients were administered one pill (125 mg) of *Habb Hindī Dīqī* twice daily for four weeks. Of the 68 patients who completed the study, 38 (55.88%) were relieved, 18 (26.47%) were partially relieved, and 12 (17.64%) showed no relief. The test drug was well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *Ma'jūn Sangdāna Murgh* in *Ḍu'f al-Mi'da* (functional dyspepsia)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Ma'jūn Sangdāna Murgh* in patients with *Ḍu'f al-Mi'da* (functional dyspepsia) at NRIUMSD, Hyderabad; and RRIUMs, Srinagar and Aligarh. Patients were administered 5 g of *Ma'jūn Sangdāna Murgh* twice daily for six weeks. Out of the 41 patients who completed the study, 23 (56.09%) were relieved, 16 (39.02%) were partially relieved, and 2 (4.87%) showed no relief. The test drug was well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *Jawārish Pūdīna Wilāyatī* in *Sū' al-Haḍm* (dyspepsia)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Jawārish Pūdīna Wilāyatī* in patients with *Sū' al-Haḍm* (dyspepsia) at CRIUM, Lucknow; RRIUM, New Delhi; and CRU, Meerut. Patients were administered 5 g of *Jawārish Pūdīna Wilāyatī* twice daily for six weeks. Out of the 33 patients who completed the study, 20 (60.60%) were relieved, 12 (36.36%) were partially relieved, and 1 (3.03%) showed no relief. The test drug was well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *La'ūq Dīq al-Nafas* in *Dīq al-Nafas* (bronchial asthma)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *La'ūq Dīq al-Nafas* in patients with *Dīq al-Nafas* (bronchial asthma) at NRIUMSD, Hyderabad; and RRIUMs, Chennai and Bhadrak. Patients were administered 5 g of *La'ūq Dīq al-Nafas* twice daily for four weeks. Out of the 76 patients who completed the study, 40 (52.63%) were relieved, 1 (1.31%) was partially relieved, and 35 (46.05%) showed no relief. The test drug was well-tolerated, with no adverse effects reported.



Clinical validation of a Unani pharmacopoeial formulation *Sayalānī* in *Sayalān al-Raḥīm* (leucorrhoea)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Sayalānī* in patients with *Sayalān al-Raḥīm* (leucorrhoea) at RRIUMs, Mumbai, Aligarh, and CRU, Bhopal. Patients were administered two tablets of *Sayalānī* twice daily for four weeks. Out of the 11 patients who completed the study, 3 (27.27%) were relieved, 7 (63.64%) were partially relieved, and 1 (9.09%) showed no relief. The test drug was well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *Ḥabb 'Irq al-Nasā* in *Waja' al-Mafāṣil* (rheumatoid arthritis)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Ḥabb 'Irq al-Nasā* in patients with *Waja' al-Mafāṣil* (rheumatoid arthritis) at CRIUM, Lucknow; RRIUM, Patna; and RRC, Prayagraj. Patients were administered two tablets of *Ḥabb 'Irq al-Nasā* thrice daily for 12 weeks. Out of the 13 patients who completed the study, 11 (84.61%) were relieved, and 2 (15.38%) were partially relieved. The test drug was well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *Ma'jūn Khabath al-Ḥadīd* in *Sū' al-Qinya* (anaemia)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Ma'jūn Khabath al-Ḥadīd* in patients with *Sū' al-Qinya* (anaemia) at CRIUM, Lucknow; RRIUMs, Patna, Silchar, Kolkata; and RRC, Prayagraj. Patients were administered 5 g of *Ma'jūn Khabath al-Ḥadīd* twice daily for 12 weeks. Out of the 116 patients who completed the study, 48 (41.37%) were relieved, 61 (52.58%) were partially relieved, and 7 (6.03%) showed no relief. The test drug was well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *Khamīra Ga'uzabān Sāda* in *Khafaqān* (palpitation)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Khamīra Ga'uzabān Sāda* in patients with *Khafaqān* (palpitation) at RRIUMs, New Delhi, Mumbai, and Bhadrak. Patients were administered 5 g of *Khamīra Ga'uzabān Sāda* twice daily for four weeks. Out of the 70 patients who completed the study, 5 (7.14%) were relieved, 32 (45.71%) were partially relieved, and 33 (47.14%) showed no relief. The test drug was well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *Iṭrīfal Kabīr* in *Ḍu'f al-Dimāgh* (cerebrasthenia)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Iṭrīfal Kabīr* in patients with *Ḍu'f al-Dimāgh* (cerebrasthenia) at CRIUM, Lucknow; and RRIUMs, Chennai, Aligarh, and Patna. Patients were administered 5 g of *Iṭrīfal Kabīr* twice daily for six weeks. Out of the 92 patients who completed the study, 44 (47.82%) were relieved, 44 (47.82%) were partially relieved, and 4 (4.34%) showed no relief. The test drug was well-tolerated, with no adverse effects reported.



Clinical validation of a Unani pharmacopoeial formulation *Habb Qulā'* in *Qulā'* (stomatitis)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Habb Qulā'* in patients with *Qulā'* (stomatitis) at RRIUM, Aligarh and CRU, Kurnool. Patients were administered one tablet (250 mg) of *Habb Qulā'* twice daily for 10 days. Out of the 30 patients who completed the study, 27 (90%) were relieved, and 3 (10%) were partially relieved. The test drug was well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *Qurş Zirishk* in *Sū' al-Qinya* (anaemia)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Qurş Zirishk* in patients with *Sū' al-Qinya* (anaemia) at NRIUMSD, Hyderabad. Patients were administered one tablet (850 mg) of *Qurş Zirishk* thrice daily for 84 days. Out of the 38 patients who completed the study, 37 (97.36%) were relieved, and 1 (2.63%) was partially relieved. The test drug was well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *Rawghan Nafa'-i-Waram-i-Niqris* and *Ma'jūn Yahyā bin Khālīd* in *Niqris* (gout)

A study was conducted to clinically validate the Unani pharmacopoeial formulations *Rawghan Nafa'-i-Waram-i-Niqris* and *Ma'jūn Yahyā bin Khālīd* in patients with *Niqris* (gout) at RRIUM, Aligarh. Patients were administered 5 g of *Ma'jūn-i-Yahyā bin Khālīd* twice daily and *Rawghan Nafa'-i-Waram-i-Niqris* was applied locally on the affected area for 84 days. Out of the 4 patients who completed the study, none were relieved. The test drugs were well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *Kushta Bayḍa-i-Murgh* in *Sayalān al-Raḥīm* (leucorrhoea)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Kushta Bayḍa-i-Murgh* in patients with *Sayalān al-Raḥīm* (leucorrhoea) at RRIUM, New Delhi and CRU, Bhopal. Patients were administered one tablet (50 mg) of *Kushta Bayḍa-i-Murgh* twice daily for 28 days. Out of the 105 patients who completed the study, 43 (40.95%) were relieved, 60 (57.14%) were partially relieved, and 2 (1.9%) showed no relief. The test drug was well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *Qurş Dawā' al-Shifā'* in *Ḍaght al-Dam Qawī* (hypertension)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Qurş Dawā' al-Shifā'* in patients with *Ḍaght al-Dam Qawī* (hypertension) at RRIUM, Srinagar. Patients were administered two tablets of *Qurş Dawā' al-Shifā'* once daily for 84 days. Out of the 63 patients who completed the study, 47 (74.60%) were relieved, and 16 (25.39%) were partially relieved. The test drug was well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *Qurş 'Aṭash* in *Ḥumūḍat al-Mi'da* (hyperacidity)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Qurş 'Aṭash* in patients with *Ḥumūḍat al-Mi'da* (hyperacidity) at RRIUM, Aligarh. Patients were administered one tablet (850 mg) of *Qurş 'Aṭash* thrice daily for 42 days. Out of the 26



patients who completed the study, 8 (30.76%) were relieved, and 18 (69.23%) were partially relieved. The test drug was well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *Ma'jūn Adharāqī* and *Rawghan Surkh* in *Waja' al-Mafāṣil* (rheumatoid arthritis)

A study was conducted to clinically validate the Unani pharmacopoeial formulations *Ma'jūn Adharāqī* and *Rawghan Surkh* in patients with *Waja' al-Mafāṣil* (rheumatoid arthritis) at RRIUM, Chennai. Patients were administered 3 g of *Ma'jūn Adharāqī* twice daily, and *Rawghan Surkh* was applied locally on the affected area for 84 days. Out of the 43 patients who completed the study, 2 (4.65%) were relieved, 39 (90.69%) were partially relieved, and 2 (4.65%) showed no relief. The test drugs were well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *Ḥabb 'Irq al-Nasā* in *'Irq al-Nasā* (sciatica)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Ḥabb 'Irq al-Nasā* in patients with *'Irq al-Nasā* (sciatica) at RRIUM, New Delhi. Patients were administered two tablets (800 mg each) of *Ḥabb 'Irq al-Nasā* thrice daily for 84 days. Out of the 32 patients who completed the study, 24 (75%) were relieved, 6 (18.75%) were partially relieved, and 2 (6.25%) showed no relief. The test drug was well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *Ḥabb Banafsha* in *Ḍīq al-Nafas Ri'wī* (bronchial asthma)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Ḥabb Banafsha* in patients with *Ḍīq al-Nafas Ri'wī* (bronchial asthma) at CRIUM, Lucknow and CRU, Meerut. Patients were administered two tablets (200 mg each) of *Ḥabb Banafsha* twice daily for 84 days. Out of the 4 patients who completed the study, all 4 (100%) were partially relieved. The test drug was well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *Kundurī* in *Salasal-Bawl* (stress urinary incontinence)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Kundurī* in patients with *Salasal-Bawl* (stress urinary incontinence) at RRIUM, Mumbai and CRU, Meerut. Patients were administered 6 g of *Kundurī* twice daily for 84 days. Out of the 81 patients who completed the study, 41 (50.61%) were relieved, 27 (33.33%) were partially relieved, and 13 (16.04%) showed no relief. The test drug was well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *Ma'jūn Zanjabīl* in *Kathrat al-Ṭamth* (menorrhagia)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Ma'jūn Zanjabīl* in patients with *Kathrat al-Ṭamth* (menorrhagia) at RRIUM, Srinagar. Patients were administered 5 g of *Ma'jūn Zanjabīl* twice daily for 84 days. Out of the 46 patients who completed the study, 36 (78.26%) were relieved, and 10 (21.73%) were partially relieved. The test drug was well-tolerated, with no adverse effects reported.



Clinical validation of a Unani pharmacopoeial formulation *Jawārish Dārchīnī Qawī* in *Ḍuʿf al-Mīʿda* (dyspepsia)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Jawārish Dārchīnī Qawī* in patients with *Ḍuʿf al-Mīʿda* (dyspepsia) at CRIUM, Lucknow and RRIUM, Patna. Patients were administered 5 g of *Jawārish Dārchīnī Qawī* twice daily for 14 days. Out of the 56 patients who completed the study, 24 (42.85%) were relieved, 30 (53.57%) were partially relieved, and 2 (3.57%) showed no relief. The test drug was well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *Rawghan Banafsha* in *Sahar* (insomnia)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Rawghan Banafsha* in patients with *Sahar* (insomnia) at RRIUM, Silchar; RRIUM, Chennai; and RRC, Prayagraj. *Rawghan-i-Banafsha* was applied locally on the scalp for 14 days. Out of the 72 patients who completed the study, 36 (50%) were relieved, 32 (44.44%) were partially relieved, and 4 (5.55%) showed no relief. The test drug was well-tolerated, with no adverse effects reported.

Clinical validation of Unani pharmacopoeial formulations *Iṭrīfal Mundī* and *Marham Raskapūr* in *Jarab* (scabies)

A study was conducted to clinically validate the Unani pharmacopoeial formulations *Iṭrīfal Mundī* and *Marham Raskapūr* in patients with *Jarab* (scabies) at RRIUM, Bhadrak. Patients were administered 10 g of *Iṭrīfal Mundī* twice daily, and *Marham Raskapūr* was applied locally on the affected area for 14 days. Out of the 56 patients who completed the study, all 56 (100%) were partially relieved. The test drugs were well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation '*Araq Chirāʿita*' in *Amrāḍ al-Jild* (skin eruptions)

A study was conducted to clinically validate the Unani pharmacopoeial formulation '*Araq Chirāʿita*' in patients with *Amrāḍ al-Jild* (skin eruptions) at NRIUMSD, Hyderabad and CRU, Kurnool. Patients were administered 125 ml of '*Araq Chirāʿita*' once daily for 14 days. Out of the 30 patients who completed the study, 23 (76.66%) were relieved, and 7 (23.33%) were partially relieved. The test drug was well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *Ḥabb Kalaf* in *Bahaq Abyaḍ/Aswad* (Pityriasis alba/nigra)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Ḥabb Kalaf* in patients with *Bahaq Abyaḍ/Aswad* (Pityriasis alba/nigra) at RRIUM, Bhadrak, and Silchar. Patients were administered one pill (250 mg) of *Ḥabb Kalaf* twice a day, mixed with lemon juice and applied locally on the affected area. Out of the 101 patients who completed the study, all (100%) were partially relieved. The test drug was well-tolerated, with no adverse effects reported.





Clinical validation of a Unani pharmacopoeial formulation *Ma'jūn Tīwāj* in *Bawāsīr Dāmiya* (bleeding piles)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Ma'jūn Tīwāj* in patients with *Bawāsīr Dāmiya* (bleeding piles) at RRIUM, Patna, and CRU, Meerut. Patients were administered 5 g of *Ma'jūn Tīwāj* twice a day for 42 days. Out of the 109 patients who completed the study, 71 (65.13%) were relieved, 33 (30.27%) were partially relieved, and 5 (4.58%) showed no relief. The test drug was well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *Jawārish Zar'ūnī Sāda* in *Haṣāt al-Kulya* (nephrolithiasis)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Jawārish Zar'ūnī Sāda* in patients with *Haṣāt al-Kulya* (nephrolithiasis) at CRIUM, Lucknow. Patients were administered 5 g of *Jawārish Zar'ūnī Sāda* twice a day for 56 days. Out of the 17 patients who completed the study, 5 (29.41%) were relieved, 10 (58.82%) were partially relieved, and 2 (11.76%) showed no relief. The test drug was well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *Jawārish Qurṭum* in *Iḥtibās al-Ṭamth* (amenorrhoea)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Jawārish Qurṭum* in patients with *Iḥtibās al-Ṭamth* (amenorrhoea) at RRIUM, Srinagar. Patients were administered 5 g of *Jawārish Qurṭum* twice a day for 5 days each month for three months. Out of the 25 patients who completed the study, 14 (56%) were relieved, and 11 (44%) were partially relieved. The test drug was well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *Safūf Sūranjān Za'frānī* in *Niqris* (gout)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Safūf Sūranjān Za'frānī* in patients with *Niqris* (gout) at RRIUM, Srinagar. Patients were administered 2.5 g of *Safūf Sūranjān Za'frānī* twice daily for 42 days. Out of the 8 patients who completed the study, 5 (62.5%) were relieved, and 3 (37.5%) were partially relieved. The test drug was well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *Habb Khunāq* in *Waram al-Ḥanjara* (laryngitis)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Habb Khunāq* in patients with *Waram al-Ḥanjara* (laryngitis) at RRIUM, Aligarh, and CRU, Meerut. Patients were administered three pills (1 g each) of *Habb Khunāq* chewed thrice a day for 14 days. Out of the 67 patients who completed the study, 21 (31.34%) were relieved, 29 (43.28%) were partially relieved, and 17 (25.37%) showed no relief. The test drug was well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *La'ūq Fālij* and *Rowghan Mom* in *Fālij* (hemiplegia)

A study was conducted to clinically validate the Unani pharmacopoeial formulations *La'ūq Fālij* and *Rowghan Mom* in patients with *Fālij* (hemiplegia) at RRIUM, Chennai, and CRU, Bengaluru. Patients were administered 5 g of *La'ūq Fālij* twice a day and *Rowghan Mom* (10



ml) was applied locally twice a day for 12 weeks. Out of the 16 patients who completed the study, 3 (18.75%) were relieved, 11 (68.75%) were partially relieved, and 2 (12.5%) showed no relief. The test drugs were well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *Jawārish Kundur* in *Kathrat al-Bawl* (overactive bladder)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Jawārish Kundur* in patients with *Kathrat al-Bawl* (overactive bladder) at NRIUMSD, Hyderabad. Patients were administered 5 g of *Jawārish Kundur* twice daily for 12 weeks. All 34 patients who completed the study were relieved (100%). The test drug was well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *Iṭrīfal Aftīmūn* in *Malankhūliyā* (mixed anxiety depressive disorder)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Iṭrīfal Aftīmūn* in patients with *Malankhūliyā* (mixed anxiety depressive disorder) at CRIUM, Lucknow, and CRU, Bhopal. Patients were administered 5 g of *Iṭrīfal Aftīmūn* twice a day for six weeks. Out of the 26 patients who completed the study, 6 (23.07%) were relieved, 16 (61.53%) were partially relieved, and 4 (15.38%) showed no relief. The test drug was well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *Ma'jūn Balādur* in *Nisyān* (amnesia)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Ma'jūn Balādur* in patients with *Nisyān* (amnesia) at RRIUM, New Delhi. Patients were administered 5 g of *Ma'jūn Balādur* twice a day for 12 weeks. Out of the 6 patients who completed the study, 4 (66.66%) were relieved, and 2 (33.33%) were partially relieved. The test drug was well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *Ḥabb Kibrīt Ṣaghīr* in *Qūbā* (dermatophytosis)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Ḥabb Kibrīt Ṣaghīr* in patients with *Qūbā* (dermatophytosis) at NRIUMSD, Hyderabad. Patients were administered one pill (250 mg) of *Ḥabb Kibrīt Ṣaghīr* twice a day for 35 days. Out of the 18 patients who completed the study, 13 (72.22%) were relieved, 1 (5.55%) was partially relieved, and 4 (22.22%) showed no relief. The test drug was well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *Rowghan Kadū Shīrīn* in *Sahar* (insomnia)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Rowghan Kadū Shīrīn* in patients with *Sahar* (insomnia) at RRIUM, Patna, and CRU, Kerala. Patients were administered 2 ml of *Rowghan Kadū Shīrīn* at night for 14 days. Out of the 52 patients who completed the study, 46 (88.46%) were relieved, 5 (9.61%) were partially relieved, and 1 (1.92%) showed no relief. The test drug was well-tolerated, with no adverse effects reported.





Clinical validation of a Unani pharmacopoeial formulation *Tiryāq Raḥīm* in *Sayalān al-Raḥīm* (leucorrhoea)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Tiryāq Raḥīm* in patients with *Sayalān al-Raḥīm* (leucorrhoea) at RRIUM, Patna, and CRU, Kerala. Patients were administered 5 g of *Tiryāq Raḥīm* twice a day for 14 days. Out of the 117 patients who completed the study, 111 (94.87%) were relieved, and 6 (5.13%) were partially relieved. The test drug was well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *Ḥabb Pachlona* in *Sū' al-Haḍm* (functional dyspepsia)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Ḥabb Pachlona* in patients with *Sū' al-Haḍm* (functional dyspepsia) at RRIUM, Aligarh, and CRU, Burhanpur. Patients were administered one pill (500 mg) of *Ḥabb Pachlona* twice a day for 14 days. Out of the 50 patients who completed the study, 16 (32%) were relieved, 24 (48%) were partially relieved, and 10 (20%) showed no relief. The test drug was well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *Ḥabb Mafāṣil* and *Ḍimād Muḥallil* in *Waja' al-Mafāṣil* (rheumatoid arthritis)

A study was conducted to clinically validate the Unani pharmacopoeial formulations *Ḥabb Mafāṣil* and *Ḍimād Muḥallil* in patients with *Waja' al-Mafāṣil* (rheumatoid arthritis) at RRIUM, Bhadrak. Patients were administered two pills (800 mg each) of *Ḥabb Mafāṣil* thrice a day, and *Ḍimād Muḥallil* (10 g) was applied locally once a day for 12 weeks. Out of the 7 patients who completed the study, all (100%) were partially relieved. The test drugs were well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *La'ūq Ḍīq al-Nafas Balghamī* in *Ḍīq al-Nafas* (bronchial asthma)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *La'ūq Ḍīq al-Nafas Balghamī* in patients with *Ḍīq al-Nafas* (bronchial asthma) at RRIUM, Mumbai, and RRC, Prayagraj. Patients were administered 5 g of *La'ūq Ḍīq al-Nafas Balghamī* twice a day for 28 days. Out of the 8 patients who completed the study, 3 (37.5%) were relieved, 3 (37.5%) were partially relieved, and 2 (25%) showed no relief. The test drug was well-tolerated, with no adverse effects reported.

Clinical validation of a Unani pharmacopoeial formulation *Ma'jūn La'na* in *Ḍu'f al-A'sāb* (neurasthenia)

A study was conducted to clinically validate the Unani pharmacopoeial formulation *Ma'jūn La'na* in patients with *Ḍu'f al-A'sāb* (neurasthenia) at RRIUM, New Delhi. Patients were administered 5 g of *Ma'jūn La'na* twice daily for six weeks. Out of the 11 patients who completed the study, 5 (45.45%) were relieved, and 6 (54.54%) were partially relieved. The test drug was well-tolerated, with no adverse effects reported.

New studies initiated

The following studies under validation of Unani pharmacopoeial drugs were initiated during the reporting period:

- Clinical validation of *Ḥabb Āb-i-Gandāna* and *Marham Bawāsīr* in *Bawāsīr 'Amyā'* (non-bleeding piles)



- Clinical validation of *Habb Gul-i-Āk* and *Rowghan Hīnā* in *Waja' al-Mafāṣil* (rheumatoid arthritis)
- Clinical validation of *Iṭrīfal Zamānī* and *Rowghan Kāhū* in *Mālankhūliyā* (mixed anxiety depressive disorder)
- Clinical validation of *Habb Khardal* in *Waram-i-Halq* (pharyngitis)
- Clinical validation of *Ma'jūn Rāshidī* in *Taqṭīr al-Bawl* (post-micturition dribble)
- Clinical validation of *La'ūq Anjīr Qawī* and *Rowghan Haft Barg* in *Fālij* (hemiplegia)
- Clinical validation of *La'ūq Unṣul* in *Su'āl Muzmin* (chronic cough)
- Clinical validation of *Habb Kotwālī* and *Marham Khall Khumrī* in *Dā' al-Tha'lab* (alopecia)
- Clinical validation of *Habb Ṣadr* in *Ḍīq al-Nafas* (bronchial asthma)
- Clinical validation of *Habb Mujarrab* in *Shaqīqa* (migraine)
- Clinical validation of *Qurṣ Sumbul al-Ṭīb* in *Warm-i-Kabid* (steatohepatitis)
- Clinical validation of *Jawārish 'Ūd Mulaiyin* in *Ḍu'f al-Ishtihā'* (anorexia)
- Clinical validation of *Jawārish Muqawwī-i-Mi'da* in *Ḍu'f al-Mi'da* (functional dyspepsia)
- Clinical validation of *Ma'jūn Masīḥī* in *Waja' al-Qatan* (non-specific low backache)
- Clinical validation of *Ma'jūn Adharāqī* in *Ḍu'f al-A'ṣāb* (neurasthenia)
- Clinical validation of *Mufarriḥ Shaykh al-Ra'īs* in *Khafaqān* (palpitation)
- Clinical validation of *Habb Muṣaffī-i-Khūn* and *Marham Kāfūr* in *Qurūḥ* (non-healing ulcers)
- Clinical validation of *Iṭrīfal Khabath al-Ḥadīd* and *Habb Mudīr* in *Iḥtibās al-Ṭamth* (amenorrhoea)
- Clinical validation of *Safūf Makhānā* in *Sayalān al-Raḥim* (leucorrhoea)
- Clinical validation of *Ma'jūn Muṣaffī A'ṣām* in *Buthūr* (skin eruptions)

New studies allotted

In addition to the above, the following studies under validation of Unani pharmacopoeial drugs were allotted during the reporting period:

- Clinical validation of *Qurṣ Ṭabāshīr Mulaiyin* in *Khushūnat al-Halq* (dryness of throat)
- Clinical validation of *Kushta Ṣadaf* in *Sayalān al-Raḥim* (leucorrhoea)
- Clinical validation of *Ma'jūn Mughallīz* in *Sur'at al-Inzāl* (premature ejaculation)
- Clinical validation of *Habb Ikhtilāj* in *Mālankhūliyā* (mixed anxiety depressive disorder)
- Clinical validation of *Iṭrīfal Muqil Mulaiyin* in *Waja' al-Mafāṣil* (rheumatoid arthritis)
- Clinical validation of *Habb Bāqilā* in *Su'āl* (cough)
- Clinical validation of *Jawārish Jāved Hindī* in *Ḍu'f al-Mi'da* (functional dyspepsia)
- Clinical validation of *Sharbat Anār Shīrīn* in *Ghathayān* (nausea)
- Clinical validation of *Habb Kibrīt* in *Sū' al-Ḥaḍm* (dyspepsia)
- Clinical validation of *Habb Anjīr* in *Bawāsīr* (haemorrhoids)
- Clinical validation of *Habb Filfil* in *Ḍīq al-Nafas* (bronchial asthma)
- Clinical validation of *Qurṣ Gulnār* in *Ishāl Muzmin* (chronic diarrhoea)
- Clinical validation of *Habb Limūn* in *Niqris* (gout)





- Clinical validation of *La'ūq Nazlī* in *Nazla Hār* (common cold)
- Clinical validation of *Ma'jūn Brahmī* in *Ḍu'f al-Dimāgh wa Ḥāfiẓa* (cerebrasthenia)
- Clinical validation of *Sharbat Murakkab Muṣaffī-i-Khūn* in *Qūbā* (dermatophytosis)
- Clinical validation of *Qulā'ī* in *Qulā'* (stomatitis)
- Clinical validation of *Qurṣ Foh* in *Iḥtibās al-Ṭamth* (amenorrhoea)
- Clinical validation of *Ḥabb Sūzāk Ḥād* in *Ḥurqat al-Bawl* (burning micturition)
- Clinical validation of *Jawārish Tamar Hindī* in *Khafaqān* (palpitation)

Validation of Regimenal Therapies

Besides pharmacotherapy, Unani Medicine offers '*Ilāj bi'l-Tadbīr*' (regimen therapy), such as *Hijāma* (cupping), *Ta'liq al-'Alaq* (leeching), *Dalk* (massage), *Ḥammām Yābis* (sauna), *Ḥammām al-Bukhār* (steam bath), etc. for certain disease conditions. During the reporting period, various regimenal therapy procedures were performed in a total of 21,276 patients with different diseases. These patients showed significant therapeutic effects in subsiding the signs and symptoms of the diseases.

Hijāma bilā-Sharṭ (dry cupping) was performed in 4,067 patients with different diseases including *Taḥajjur al-Mafāṣil* (osteoarthritis), *'Irq al-Nasā* (sciatica), *Taḥajjur Mafāṣil al-'Unuq* (cervical spondylosis), *Taḥajjur Mafāṣil al-Ẓahr* (lumbar spondylosis), *Katif Mujammad* (frozen shoulder), *Waja' al-Ẓahr* (backache), *Waja' al-Katif* (shoulder pain), *Waja' al-'Unuq* (neck pain), *Waja' al-Rukba* (knee pain), *Waja' al-'Aqib* (achillodynia), *Dawālī* (varicose veins), *Kathrat al-Ṭamth* (menorrhagia), *'Usr al-Ṭamth* (dysmenorrhoea), *Ṣudā'* (headache), *Ṣala'* (baldness), *Ḥuzn* (depression), etc. at NRIUMSD, Hyderabad; CRIUM, Lucknow; RRIUMs, Chennai, Bhadrak, Patna, Mumbai, Srinagar, New Delhi and Silchar; Co-Location Centre, AIIA, New Delhi; Unani Medical Centre, Dr. Ram Manohar Lohia Hospital, New Delhi; Unani Medical Centre, VMMC & Safdarjung Hospital, New Delhi; and Ayush Wellness Centre, Rashtrapati Bhavan, New Delhi.

Hijāma bi'l-Sharṭ (wet cupping) was performed in 1,495 patients with different diseases including *Nār Fārsī* (eczema), *Buthūr Labaniyya* (acne vulgaris), *Dā' al-Tha'lab* (alopecia), *Bawāsīr* (haemorrhoid), *Ḍaghṭ al-Dam Qawī* (hypertension), *'Uqr* (infertility), *Waja' al-Mafāṣil* (rheumatoid arthritis), *Taḥajjur al-Mafāṣil* (osteoarthritis), *'Irq al-Nasā* (sciatica) and other musculoskeletal disorders at CRIUM, Lucknow; RRIUMs, Chennai, Bhadrak, Patna, Srinagar, and Silchar; Co-Location Centre, AIIA, New Delhi and Ayush Wellness Centre, Rashtrapati Bhavan, New Delhi.

Hijāma bi'l-Nār (fire cupping) was performed in 411 patients with different diseases including *Waja' al-Mafāṣil* (rheumatoid arthritis), *Taḥajjur al-Mafāṣil* (osteoarthritis), *'Irq al-Nasā* (sciatica), *Waja' al-Ẓahr* (backache), *Katif Mujammad* (frozen shoulder), *Waja' al-Katif* (shoulder pain) and *Waja' al-Rukba* (knee pain) at RRIUMs, Srinagar, Patna and Chennai; and Ayush Wellness Centre, Rashtrapati Bhavan, New Delhi.

Hijāma Muzliqa (moving cupping) was performed in 3,928 patients with different diseases including *Waja' al-Ẓahr* (backache) and *Katif Mujammad* (frozen shoulder) at RRIUMs, Srinagar and Chennai; Co-location Centre, AIIA, New Delhi; and Ayush Wellness Centre, Rashtrapati Bhavan, New Delhi.



Ḥammām al-Bukhār (steam bath) was performed in 727 patients with diseases including *Waja' al-Katif* (shoulder pain), *Qūbā* (dermatophytosis) and *Siman Mufriṭ* (obesity) at CRIUM, Lucknow; RRIUM, Srinagar; and Ayush Wellness Centre, Rashtrapati Bhavan, New Delhi.

Dalk Mu'tadil (moderate massage) was performed in 1,249 patients with different diseases including *Waja' al-Mafāṣil* (rheumatoid arthritis), *Taḥajjur al-Mafāṣil* (osteoarthritis), *Taḥajjur Mafāṣil al-'Unuq* (cervical spondylosis), *Katif Mujammad* (frozen shoulder), *Waja' al-Ẓahr* (backache), *Waja' al-Katif* (shoulder pain) and *Waja' al-'Aqib* (achillodynia) at RRIUMs, Chennai, Bhadrak, Patna, New Delhi; and Ayush Wellness Centre, Rashtrapati Bhavan, New Delhi.

Ḥammām Yābis (sauna) was performed in 38 patients with different diseases including *Waja' al-Katif* (shoulder pain), *Taḥajjur al-Mafāṣil* (osteoarthritis), *Siman Mufriṭ* (obesity) at RRIUM, New Delhi.

Naṭūl (Irrigation) was performed in 218 patients of *Waja' al-Mafāṣil* (rheumatoid arthritis) at RRIUMs, Srinagar and Chennai.

Inkibāb (vaporisation) was performed in 3,450 patients of *Waja' al-Mafāṣil* (rheumatoid arthritis) and *Waja' al-Katif* (shoulder pain) at RRIUMs, Chennai and Srinagar.

Mundij-Mushil therapy was performed in 233 patients of *Baraṣ* (vitiligo) at RRIUMs, Chennai and New Delhi.

Ta'līq (leeching) was performed in 359 patients of *Dawālī* (varicose veins) and *Takhaththur al-Dam* (deep vein thrombosis) at RRIUMs, Chennai, Bhadrak, Patna, Mumbai, Srinagar and Silchar.

Takmīd (fomentation) was performed in 806 patients of *Waja' al-Mafāṣil* (rheumatoid arthritis), *Taḥajjur al-Mafāṣil* (osteoarthritis), *Siman Mufriṭ* (obesity) and *Katif Mujammad* (frozen shoulder) at CRIUM, Lucknow; and RRIUMs, Chennai, and Bhadrak.

Faṣd (venesection) was performed in 09 patients of *Ḥummā Ajāmiyya* (malaria), splenic disorders, *Bawāsīr Dāmiya* (haemorrhoid), *Jarab-o-Ḥikka* (scabies and pruritus), *Khurāj* (boils), and *Ilṭihāb-i-Kabid* (hepatitis) at RRIUM, Bhadrak and Patna.

Other therapies '*Amal-i-Kayy* (cauterization), cleaning & dressing, and mechanical massage) were performed in 120 patients at Ayush Wellness Centre, Rashtrapati Bhavan, New Delhi.

Validation of Fundamentals

Theory of *Akhlāṭ wa Mizāj* (humours and temperament)

The CCRUM has been conducting studies to validate the fundamentals of Unani Medicine at NRIUMSD, Hyderabad. The objective is to scientifically examine the concepts of *Akhlāṭ* (humours) and *Mizāj* (temperament) and their relevance to health and disease states. This project at NRIUMSD, Hyderabad, aims to explore the clinical, genetic, physiological, pathological, and biochemical parameters of participants across various temperaments, conduct clinical assessments of *Mizāj* (temperament) in different diseases, and establish scientific correlations among these factors.

Genetic Studies on the Theory of Humours

Genetic studies on humours, with a focus on conditions such as diabetes mellitus, essential hypertension, vitiligo, gastritis, and psoriasis, were conducted, with healthy volunteers



serving as a control group. Pharmacogenomics studies of Unani formulations in vitiligo were also completed.

During the 2023–2024 period, 138 healthy volunteers and 10 patients were enrolled. Since the program's inception until 2023, a total of 2,057 participants were included, bringing the total to 2,205 as of March 2024. This project consists of an observational study to analyse dominant temperament according to *Ajnās 'Ashara*, followed by genetic, biochemical, physiological, pathological, and pulse wave analysis studies in healthy volunteers and patients.

Studies completed in 2023–2024

Project 01: *A molecular approach towards understanding Unani philosophy – Temperament susceptibility and gene expression studies (IFN- γ)*

The study involved 240 participants, including individuals with diabetes, cholelithiasis, psoriasis, and vitiligo, alongside 120 healthy participants matched to four Unani temperaments. The study highlights the significance of IFN- γ in disease susceptibility. Findings suggest that monitoring IFN- γ mRNA expression levels may enhance understanding of disease activity, with potential implications for personalized treatment. Technical report submitted in December 2023; paper under communication.

Project 02: *Genetic studies of lipid metabolism genes in relation to clinical phenotyping as per Unani philosophy (APOE gene)*

APOE gene polymorphisms were studied in relation to diabetes, cholelithiasis, psoriasis, and vitiligo. Findings indicate a significant relationship between APOE E4 and E2 alleles and disease susceptibility, with E3 potentially protective. Technical report submitted in December 2023; paper under communication.

Project 03: *Genetic variants of IFN- γ (+874/A and +2109A/G polymorphism) in vitiligo*

This study explored IFN- γ expression and serum levels in vitiligo patients, identifying an association between the +874T allele and vitiligo progression. Findings support IFN- γ 's role in Th1 immune response in vitiligo. Technical report submitted in December 2023; one paper communicated.

Ongoing studies

Apart from the above, nine studies involving the following components continued during the reporting period:

- Determination of dominant temperament by *Ajnās 'Ashara*
- Determination of dominant temperament by special CRF on assessment of temperament
- Genetic marker studies in relation to temperament of each subject
- Study of biochemical, physiological and pathological parameters and pulse wave component analysis in relation to temperament of each subject
- In projects VII, VIII and IX, listed below, only biochemical, physiological and pathological parameters for patients and participants were included.

Study-wise summary of the progress made during the year 2023–2024 is as under:

- **Project I:** *miRNA 146a and Th1/17 Cells in Vitiligo Pathogenesis:* 41 healthy volunteers (27 *Damawī*, 14 *Balghamī*) and 10 vitiligo patients were enrolled.



- **Project II:** *In-vitro anti-psoriatic activity of UNIM formulation by multiparametric analysis:* Extraction and analysis of UNIM 401 completed, with 13 Sawdāwī healthy volunteers enrolled.
- **Project III:** *Effect of Unani formulation on diabetes mellitus in in-vitro and clinical studies:* 27 Damawī healthy volunteers enrolled; extraction and analysis of UNIM 221 completed.
- **Project IV:** *Gene expression analysis in type-2 diabetes pathogenesis:* 27 Damawī healthy volunteers enrolled.
- **Project V:** *Gene expression and polymorphism in rheumatoid arthritis:* 17 Şafrāwī healthy volunteers enrolled.
- **Project VI:** *Leptin gene expression in psoriasis:* 13 Sawdāwī volunteers enrolled.
- **Project VII-IX:** Initiated in September 2023, with focus on molecular markers related to bronchial asthma, gastritis, and psoriasis.

Clinical Assessment of Mizāj (Temperament)

During the reporting period, temperament of 411 patients attending the OPD of NRIUMSD, Hyderabad was assessed. Of them, 112 were Damawī, 216 Balghamī, 78 Şafrāwī and 05 Sawdāwī. These included patients of *Ḍīq al-Nafas* (bronchial asthma), *Ḍuʿf al-Miʿda* (functional dyspepsia), *Buthūr al-Jild* (skin eruptions), *Qūbā* (dermatophytosis), *Kathrat al-Bawl* (overactive bladder), *Ḥaṣāt al-Kulya* (nephrolithiasis), *Ḍuʿf al-Dimāgh* (cerebrasthenia), *Ḥummā* (fever), *Sūʿ al-Qinya* (anaemia), *Taḥajjur al-Mafāṣil* (osteoarthritis), *Litha Dāmiya* (bleeding gums/scurvy) and *Amrāḍ-i-Litha* (periodontal diseases).

Of 67 patients of *Ḍīq al-Nafas* (bronchial asthma), 17 were Damawī, 42 Balghamī, and 08 Şafrāwī. In 37 cases of *Ḍuʿf al-Miʿda* (functional dyspepsia), 13 were Damawī, 19 were Balghamī, and 05 were Şafrāwī. In case of *Buthūr al-Jild* (skin eruptions), out of 30 patients 15 were Şafrāwī, 07 were Damawī, 06 were Balghamī, and 02 were Sawdāwī. In *Qūbā* (dermatophytosis), 43 patients were registered, with 30 classified as Damawī, 10 as Şafrāwī, and 03 as Balghamī. In *Amrāḍ-i-Litha* (periodontal diseases), 98 patients were registered, of whom 69 were Balghamī, 15 were Damawī, and 14 were Şafrāwī.

In *Kathrat al-Bawl* (overactive bladder), 45 cases were registered, with 33 identified as Balghamī, 07 as Damawī, and 5 as Şafrāwī. In the case of *Ḥummā* (fever), 02 Balghamī patients were registered. For *Litha Dāmiya* (bleeding gums), 04 patients were registered, 01 of whom were Damawī and 03 Balghamī. In *Ḥaṣāt al-Kulya* (nephrolithiasis), 14 cases were registered, with 09 identified as Balghamī and 05 as Damawī.

In *Ḍuʿf al-Dimāgh* (cerebrasthenia), 04 patients were registered: 2 were Damawī, 01 was Şafrāwī, and 1 was Sawdāwī.

For *Sūʿ al-Qinya* (anaemia), 50 patients were registered, of which 19 were Balghamī, 19 were Şafrāwī, and 12 were Damawī. In *Taḥajjur al-Mafāṣil* (osteoarthritis), 17 patients were registered, of whom 11 were Balghamī, 03 Damawī, 02 Sawdāwī, and 01 Şafrāwī.

In these patients, susceptibility for acquiring diseases in relation to different temperaments was also studied. An interim analysis of data revealed that individuals of Balghamī temperament were more susceptible to conditions such as *Kathrat al-Bawl* (overactive bladder), *Amrāḍ-i-Litha* (periodontal diseases), and *Ḍīq al-Nafas* (bronchial asthma). Similarly, individuals of Damawī temperament showed a higher susceptibility to *Qūbā* (dermatophytosis). This suggests a potential correlation between specific temperaments and the likelihood of developing certain health conditions.



Research-oriented Healthcare

General Outpatient Department (GOPD) Programme

The CCRUM undertakes GOPD Programme which also includes Geriatric OPD and RCH / MCH OPD. It is aimed at promoting, protecting, and preserving public health through Unani Medicine. Besides, OPDs for post-trial treatment access (PTA) are also conducted to provide treatment facilities to the research patients after completing the trial.

During the reporting period, this programme continued at National Research Institute of Unani Medicine (NRIUMSD), Hyderabad; Central Research Institute of Unani Medicine (CRIUM), Lucknow; Regional Research Institutes of Unani Medicine (RRIUMs), Chennai, Bhadrak, Patna, Aligarh, Mumbai, Srinagar, Kolkata, New Delhi and Silchar; Regional Research Centre (RRC), Prayagraj; Clinical Research Units (CRUs), Bengaluru, Bhopal, Burhanpur, Meerut, Kurnool, Edathala and Imphal; Hakim Ajmal Khan Institute for Literary and Historical Research in Unani Medicine, New Delhi; Ayush Wellness Centre, President's Estate, New Delhi; and Co-location Centre, All India Institute of Ayurveda, New Delhi. A total of 8,88,663 beneficiaries comprising 7,06,810 in GOPDs, 55,267 in Geriatric OPDs, 16,012 in RCH / MCH OPDs, 55,142 in NCD's OPDs and 55,432 in OPDs for Post-trial Treatment Access (PTA) were treated at different centres. These beneficiaries were also assessed for their temperaments and various other factors responsible for the occurrence of the disease, thus generating data for research feedback. They were treated with Unani pharmacopoeial formulations.

In-patient Department (IPD) Programme

The CCRUM also has IPD facilities at its select research institutes. During the reporting period, IPD programme continued at NRIUMSD, Hyderabad; CRIUM, Lucknow; and RRIUM, Chennai, Bhadrak, Patna, Srinagar and New Delhi. A total of 14,402 beneficiaries were treated with Unani pharmacopoeial formulations at these facilities.

Mobile Clinical Research Programme

The Mobile Clinical Research Programme is aimed at providing healthcare to the population residing in rural areas, urban slums, scheduled caste and scheduled tribe pockets, besides reducing the disease burden in the society by creating health awareness among them. Under this programme, rural areas, urban slums, and pockets predominantly inhabited by Scheduled Caste (SC) / Scheduled Tribe (ST) population with no medical facility are covered. The Council's researchers visit the adopted pockets at regular intervals and provide free Unani treatment to the patients at their door steps, and thus serve as a potential source of healthcare delivery to the masses. Patients are also referred to CCRUM institutes / units and other hospitals for treatment of specific diseases or clinical research. Besides, health awareness is created among the population under coverage particularly women and senior citizens through health lectures and group meetings on the preventive, promotive and curative health aspects based on the principles of Unani Medicine. They are also made aware of the therapeutic uses of medicinal plants growing in their vicinity in the management of different common / seasonal ailments.

During the reporting period, this programme continued at NRIUMSD, Hyderabad; CRIUM, Lucknow; RRIUMs, Chennai, Patna, Mumbai, New Delhi and Srinagar; and RRC, Prayagraj. During the reporting period, 20 rural pockets / urban slums covering over 1.79 lakh population were covered. A total of 34,129 patients were treated in 475 mobile visits made to these



pockets. Predominant diseases as observed were rheumatoid arthritis, cough, fever, skin infections, joint pain, constipation, headache, dysentery, leucorrhoea, piles, etc.

3.1.2.4. Literary Research

Under the Literary Research Programme, the CCRUM published *Adwiya Kulwiyya* (A Compendium of Classical and Evidence-Based Unani Drugs Acting on the Kidneys) in English. This book provides a comprehensive account of Unani drugs for kidney protection and disease management, structured into five chapters: introduction, time-tested Unani prescriptions, single and compound drugs, and evidence-based Unani formulations. Information is drawn from classical sources cited at the end of each chapter.

The CCRUM also published *Adwiya Qalbiyya: Qadīm-o-Jadīd Taḥqīqāt kī Roshnī mein* (A Compendium of Classical and Evidence-Based Unani Drugs Acting on the Heart) in Urdu, following a similar structure and providing details on drugs for heart protection and management of cardiac diseases.

Both compendia are part of a series on 'organ-specific Unani drugs' and represent the first of their kind to offer such comprehensive insights.

Additionally, the CCRUM published a special issue of *Jahān-e-Tibb* titled '*Ālamī Wabā Number*'. It features 20 papers discussing the Unani concept of epidemics, preventive measures, treatments, and post-pandemic complications.

The CCRUM completed a pioneering project aimed at developing *Standard Operating Procedures (SOPs) for Hijāma (Cupping Therapy)*, a crucial regimenal therapy of Unani Medicine. *Hijāma* is widely recognized for its therapeutic benefits in pain relief, detoxification, and restoring humoral balance, yet lacked formal guidelines to ensure its safe and effective practice across wellness centers, clinics, and hospitals.

To address this need, the CCRUM developed comprehensive SOPs that provide detailed guidelines for the pre-cupping, cupping, and post-cupping stages of the procedure. These SOPs were formulated through extensive consultations with domain experts, covering patient evaluation, treatment planning, procedural administration, and post-treatment care.

This publication, developed under the *Literary Research Programme*, marks a significant milestone in the standardization of *Hijāma* practice, ensuring adherence to strict sterilization and infection control protocols. The SOPs will serve as an essential resource for practitioners, promoting the safe, effective, and consistent delivery of cupping therapy within Unani Medicine.

Furthermore, the CCRUM completed the *Systematized Nomenclature of Medicine-Clinical Terminology (SNOMED CT) Extension for Unani Medicine*, integrating Unani Medicine into a global clinical healthcare framework.

Work on updating NUMC Version 1.0 continued, with 198 new codes added for the NAMASTE Portal and AHMIS.

Inclusion of Unani Morbidity Codes in WHO ICD-11, Chapter-26, Module-2 (Launched on 10 January, 2024)

Researchers of CCRUM actively contributed to *ICD-11, Chapter 26 - Module 2*. The International Classification of Diseases (ICD) is a globally used system for categorizing diseases, health conditions, and causes of injury and death. ICD-11, adopted by the World



Health Assembly in 2019 and effective from January 2022, provides vital data for understanding global disease patterns. Chapter 26 of ICD-11 includes traditional medicine conditions, with Module 1 covering conditions from China, Japan, and Korea, and Module 2 dedicated to Ayurveda, Siddha, and Unani systems of medicine. The Council's contributions to Module 2 represent a significant milestone in harmonizing Unani Medicine with global health standards, allowing for dual coding of traditional medicine conditions alongside conventional disease classifications. This will enhance global recognition and integration of Unani Medicine in healthcare reporting and research and will provide a common language that allows health professionals to share standardized information across the world. This inclusion acknowledges the richness of traditional medicine and fosters collaboration advancing global health standards.

3.2. Studies under IMR Policy

To utilize full potential of the researchers working in the different centres and to conduct studies based on region-specific needs, the CCRUM has an Intramural Research (IMR) Policy. The policy aims to conduct studies in a time-bound manner. During the reporting period, the following studies under the IMR policy were conducted:

[A clinical study to evaluate the efficacy of *Mundij-Mushil* therapy along with coded Unani drugs UNIM-318 & UNIM-319 and dry fomentation in patients of primary *Tahajjur al-Mafāṣil* \(osteoarthritis grade I & II\)](#)

A study was conducted at CRIUM, Lucknow to evaluate the efficacy of *Mundij-Mushil* therapy in combination with coded Unani drugs UNIM-318 & UNIM-319 and dry fomentation in patients suffering from primary *Tahajjur al-Mafāṣil* (osteoarthritis grade I & II). During the reporting period, a total of 5 patients were screened, and 4 were enrolled in the study. Of these, no patient completed the study. There was 1 dropout, and 3 patients were under study. The study drug was found to be well-tolerated, with no adverse effects reported among the patients.

[A study to evaluate the effect of coded Unani formulations \(UNIM-004-oral and UNIM-005-topical\) on certain biomarkers in vitiligo patients](#)

This study, conducted at NRIUMSD, Hyderabad, aimed to evaluate the effect of coded Unani formulations UNIM-004 (oral) and UNIM-005 (topical) on specific biomarkers in vitiligo patients. During the reporting period, 16 patients were enrolled in the study, with 5 completing it. Four patients dropped out, and 7 were under follow-up. Additionally, 25 healthy samples were taken. The study drug was found to be well-tolerated, with no adverse effects reported.

[Evaluation of the effect of UNIM-301 on selected inflammatory molecules associated with *Waja' al-Mafāṣil* \(rheumatoid arthritis\) pathogenesis](#)

A study to evaluate the efficacy of UNIM-301 on selected inflammatory molecules related to the pathogenesis of *Waja' al-Mafāṣil* (rheumatoid arthritis) was conducted at RRIUM, Srinagar. A total of 62 patients were screened during the reporting period, and 24 were enrolled in the study. Out of these, 19 patients completed the study, 2 dropped out, and 3 were under observation. The sample size of 19 patients has been achieved so far, and the study drug was found to be well-tolerated, with no adverse effects reported.



Clinical evaluation of the efficacy of *Hijāma bilā Sharṭ* (dry cupping) in *Waja' al-Rukba* (knee osteoarthritis) and its relation to the frequency of *Hijāma bilā Sharṭ* (dry cupping) for SOP formation

During the reporting period, a total of 26 patients were screened, and 22 were enrolled in the study at RRIUM, New Delhi. Out of these, 10 patients completed the study, 6 dropped out, and 6 cases were under study. A sample size of 10 completed cases has been achieved so far.

Shelf-life study on five commonly used Unani pharmacopoeial formulations

A shelf-life study was initiated on November 6, 2023, at RRIUM, Chennai, to determine the real-time stability of five commonly used Unani formulations: *Habb Sūranjān*, *Habb Hiltīt*, *Habb Bawāsīr Dāmiya*, *Qurṣ Dhayābītus Khāṣ*, and *Ḍarūr Qulā'*. Three batches of each formulation were prepared using classical methods at the GMP-certified pharmacy of NRIUMD, Hyderabad, and supplied to the study site.

During the reporting period, 15 samples were withdrawn from the stability chamber at 0 months, 3 months, 6 months, and 9 months (60 samples in total). The quality and stability of the formulations were analysed using standard protocols, including physical, chemical, microbiological, and toxicological parameters. The study was completed for 45 samples (0-, 3-, and 6-month samples), while the 9-month samples (15 in total) were under study. No significant changes were observed in organoleptic characteristics, physico-chemical parameters, HPTLC fingerprinting, or GC-MS analysis. Safety parameters, including heavy metal analysis and microbial studies, were within permissible limits, in line with World Health Organization guidelines.

IMR projects initiated

The following IMR projects were initiated at various institutes of the CCRM:

- A randomized controlled clinical trial of the effectiveness of *Asbī* and Pregabalin in *Ḍu'f al-A'ṣāb* (peripheral neuropathy)
- Development of Unani treatment protocol comprising oral medication (*Iṭrīfal Mushīl*) and regimnal procedures (*Naṭūl* [irrigation] and *Dalk* [massage]) by *Rowghan Banafsha* in *Shaqīqa* (migraine without aura) – An open-label single-arm clinical trial
- Evaluation of certain Unani formulations on severity, serum uric acid, and C-reactive protein in patients of psoriasis with reference to associated metabolic syndrome and its components
- A single-blind pilot study to evaluate the efficacy and safety of coded Unani formulations UNIM-001 + UNIM-003 with NB UVB therapy in cases of *Baraṣ* (vitiligo)
- A clinical study to evaluate the efficacy of *Qurṣ Ṭabāshīr Kāfūrī Lu'luwī* and *Rowghan Ispand* in patients with diabetic peripheral neuropathy
- Clinical evaluation of *Hijāma bi'l-Sharṭ* (wet cupping) and *Ma'jūn 'Ushba* in the management of persistent non-specific *Waja' al-Ẓahr* (low back pain)
- English translation of *Sharḥ al-Asbāb wa al-'Alāmāt* – A complete book of Unani Medicine (*Mu'ālajāt*) in Arabic



3.3. Collaborative Research

Development of sugar-free dosage forms, quality control and pharmacological evaluation of *Khamīra Banafsha*, *Khamīra Abresham*, *La'ūq Katān*, *Sharbat Tūt Siyāh*, *La'ūq Sapistān* and *Sharbat Zūfā*

A study on the development of sugar-free dosage forms, quality control, and pharmacological evaluation of *Khamīra Banafsha*, *Khamīra Abresham*, *La'ūq Katān*, *Sharbat Tūt Siyāh*, *La'ūq Sapistān*, and *Sharbat Zūfā* was carried out at the Faculty of Pharmacy, Jamia Hamdard, New Delhi. The findings showed that these Unani formulations possess potent antioxidant as well as immunomodulatory potential, with *Khamīra Abresham* and *La'ūq Sapistān* exhibiting stronger activity compared to others.

Pharmacokinetics, stability and quality control studies on *Iṭrīfal*'s of the Unani Pharmacopoeia of India (Part 2, v1 & v2) using chromatographic analysis by HPTLC and LC-MS

This study, conducted at the Department of Pharmacognosy and Phytochemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, examined the pharmacokinetics, stability, and quality control of *Iṭrīfal* formulations listed in the Unani Pharmacopoeia of India. Using HPTLC and LC-MS for analysis, the study determined that *Iṭrīfal* formulations should ideally be consumed within 17 months after opening, provided they are stored at cool temperatures. The developed methods also provided an excellent analytical tool for determining the shelf life of these formulations.

Development of DNA barcodes for medicinal plants used in the Unani system of India

A study on the development of DNA barcodes for medicinal plants used in Unani Medicine was conducted at Shivaji College, Delhi University, New Delhi. The study evaluated commonly used markers for DNA barcoding, such as ITS (Internal Transcribed Spacer), *rbcL* (Ribulose-1,5-bisphosphate carboxylase/oxygenase large subunit), and *matK* (maturase K). ITS, found in nuclear ribosomal DNA, was determined to have high variability, making it suitable for distinguishing closely related species. *rbcL*, located in the chloroplast genome, is highly conserved across plants, enabling successful amplification and sequencing in a wide range of taxa. *matK*, also located in the chloroplast genome, exhibits moderate variability and is often used alongside *rbcL* to improve species discrimination.

Pharmacokinetic and pharmacodynamic studies of a specific Unani formulation known to have anti-arthritic potential

The University of Kashmir, Srinagar conducted a study on the pharmacokinetic and pharmacodynamic properties of a specific Unani formulation with anti-arthritic potential. The research involved developing and quantifying an HPLC method for the active compounds, including withaferin-A, gingerol, thymol, and piperine in *Habb Asgand*. A bio-analytical method was also developed for conducting pharmacokinetic studies.

Reverse pharmacology of *Asrīn* and *Dawā' al-Shifā'* to evaluate their anti-hypertensive efficacy, safety, and mechanism of action

A study on the reverse pharmacology of *Asrīn* and *Dawā' al-Shifā'* to evaluate their anti-hypertensive efficacy, safety, and mechanism of action was carried out at the Division of Pharmacology, CSIR-Central Drug Research Institute, Lucknow (U.P.). The findings showed that biochemical and haematological parameters in treated animals remained within normal limits, and histopathological examination revealed no abnormalities related to the test items.



The NOAEL (No Observed Adverse Effect Level) of *Asrīn* was established at 500 mg/kg body weight BID.

Exploring the anti-inflammatory mechanism of action of a specific Unani formulation

A study on exploring the anti-inflammatory mechanism of action of a specific Unani formulation was conducted at the Department of Biochemistry, Islamiah College, Vaniyambadi, Tamil Nadu. The results of the MTT assay demonstrated that L-132 normal cells treated with the formulation remained viable at various concentrations, indicating that the drug does not induce cytotoxicity at these concentrations.

Evaluation of neuroprotective potential of *Ma'jūn Nisyān*: A mechanistic study

A study on the neuroprotective potential of *Ma'jūn Nisyān* was conducted at the Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM's NMIMS University, Mumbai. The findings revealed significant improvement in antioxidant parameters following treatment, which indicated a reduction in oxidative stress-related damage.

In-vitro evaluation of antiviral activity of Unani drugs and their green nanoparticles against dengue virus

A study on the *in-vitro* evaluation of antiviral activity of Unani drugs and their green nanoparticles against the dengue virus was conducted at the Centre for Interdisciplinary Research in Basic Science, Jamia Millia Islamia, New Delhi. The results indicated that *Sharbat Anjibār* significantly inhibited the dengue virus in Vero cells, as shown by PCR and cytopathic effect (CPE). Although the antiviral effects of *Habb Papīta* and *Khamīra Marwārīd* were less pronounced, they were still significant.

Pharmacological studies on the probable mechanism of action of *Khamīra Ga'uzabān Sāda* (KGS) in the management of hypertension, involving quality control and formulation optimization studies

A study on the probable mechanism of action of *Khamīra Ga'uzabān Sāda* (KGS) in managing hypertension was conducted at the Department of Pharmaceutical Technology, Jadavpur University, Kolkata. The findings revealed that the hysteresis area and relative hysteresis area of the KGS formulation were high, but its viscosity decreased as temperature increased, indicating that the formulation behaves as a shear-thickening fluid (non-Newtonian fluid).

Evaluation of immune-modulatory and antioxidant potential of a Unani formulation

A study evaluating the immune-modulatory and antioxidant potential of a Unani formulation was conducted at the Department of Ocular Biochemistry, AIIMS, New Delhi. This study explored the cytotoxicity of *Habb Papīta*, *Khamīra Marwārīd*, and *Sharbat Anjibār* using MTT assays in Vero cells. The active phytoconstituents were identified through LC-MS/MS, and the cytotoxic activity was analyzed using cultured lymphocytes.

Determination of anti-aging and antioxidant potential of *Habb Asgand*

A study on the anti-aging and antioxidant potential of *Habb Asgand* was conducted at the Department of Geriatric Medicine, AIIMS, New Delhi. The study involved collecting, identifying, and extracting the ingredients of *Habb Asgand*. The extraction was done in an aqueous medium, followed by identification of active phytoconstituents through LC-MS/MS.





Peripheral blood collection, isolation, and culturing of lymphocytes were also conducted, and cytotoxic activity was assessed in cultured lymphocytes.

Redesigning and pharmacological evaluation of some classical Unani formulations with specific reference to immune-modulatory activity, safety profile, and stability studies

A study on redesigning and evaluating the pharmacological properties of classical Unani formulations with a focus on immune-modulatory activity, safety, and stability was carried out at the Department of Pharmacognosy and Phytochemistry, Jamia Hamdard, New Delhi. Formulations such as *Dawā' al-Kurkum*, *Halwā Ghīkwār*, and *Iṭrīfāl Uṣṭūkhūdūs* were prepared, and their quality control and standardization were conducted to ensure consistency in efficacy and safety.

Evaluation of Unani polyherbal formulations, acting as *Muqawwī-i-Dimāgh*, their potential to inhibit acetylcholinesterase and ameliorate beta-amyloid toxicity

A study on evaluating Unani polyherbal formulations acting as *Muqawwī-i-Dimāgh* and their potential to inhibit acetylcholinesterase and reduce beta-amyloid toxicity was conducted at the Department of Clinical Biochemistry, School of Biological Sciences, University of Kashmir. Antioxidant activities were assessed through FRAP and DPPH assays, with *Ma'jūn Balādur* emerging as the most potent formulation, outperforming both *Ma'jūn Falāsfa* and *Ma'jūn Būlis*.

Unravelling the cardioprotective mechanism of an Unani formulation using in-silico, in-vitro, and in-vivo (New Zealand rabbit) models: A step towards planning a clinical trial

A study on unraveling the cardioprotective mechanism of a Unani formulation was conducted at PGIMER, Chandigarh. The research involved site-specific molecular docking studies using phytochemicals from Unani formulations such as *Terminalia chebula*, *Terminalia bellerica*, *Borago officinalis*, *Rosa damascena*, *Emblica officinalis*, *Coriandrum sativum*, and *Pimpinella anisum*. The docking studies were performed against important targets like Neprilysin, HMG-CoA reductase, and ACE-2 receptor, which regulate cardioprotective activity. Three-dimensional target structures were analyzed, and potential drug-binding sites were identified to facilitate future clinical trials.

Evaluation of a Unani formulation for improving mental retardation and exploration of underlying molecular mechanisms using animal model

A study on evaluating a Unani formulation for improving mental retardation and exploring the underlying molecular mechanisms using an animal model was carried out at CSIR-Indian Institute of Chemical Technology, Hyderabad. The formulation *Harīra* was investigated for its effects on anxiety and depression-like behaviors in mice exposed to prenatal stress. While preliminary observations suggest positive outcomes in adulthood, some negative effects were observed during adolescence.

Assessment of the modulation of anticancer activity of standard cancer drugs by nutraceuticals and Unani drugs in colorectal cancer

A study on assessing the modulation of anticancer activity of standard cancer drugs by nutraceuticals and Unani drugs in colorectal cancer was carried out at the Department of Biosciences, Jamia Millia Islamia, New Delhi. During the course of the study, standard drugs such as 5-Fluorouracil and Oxaliplatin were tested on colorectal cancer cell lines HCT116 and SW480.



Redesigning and evaluation of antifungal potential and mechanism of action of *Marham Hinā*, a Unani pharmacopoeial formulation, against resistant *Candida* strains and dermatophytes

A study on redesigning and evaluating the antifungal potential and mechanism of action of *Marham Hinā*, a Unani pharmacopoeial formulation, against resistant *Candida* strains and dermatophytes was conducted at the Department of Biosciences, Jamia Millia Islamia, New Delhi. The study found that *T. mentagrophytes*/*T. indotineae* were more susceptible to thymol than *T. interdigitale* with lower MIC values, and all the constituents of *Marham Hinā* showed antifungal efficacy against both *Candida* and dermatophytes, except camphor.

Formulation, development, and preclinical evaluation of novel Unani dispersible tablets for immunomodulatory activity and as adjuvants to anticancer therapy

A study on the formulation, development, and preclinical evaluation of novel Unani dispersible tablets for immunomodulatory activity and as adjuvants to anticancer therapy was carried out at the Amity Institute of Pharmacy, Amity University, Noida. Nine formulations were developed, and ratios were optimized to find the best-fit formulation.

Pre-clinical and immunotherapeutic assessment of *Ma'jūn Najāh*, a Unani formulation, in cervical carcinoma

A study on the pre-clinical and immunotherapeutic assessment of *Ma'jūn Najāh* (MN), a Unani formulation, in cervical carcinoma was conducted at the Department of Biotechnology, Amity University, Noida. The antioxidant activity of four solvent extracts of *Ma'jūn Najāh* and ascorbic acid against DPPH assay was tested. The study revealed that the highest antioxidant activity was found in MN-methanol (93.36%), MN-50% ethanol (94.17%), and MN-ethyl acetate (95.04%) extracts at 50 µg/ml concentration, while MN-n-hexane showed lower activity (63.75%).

Study and validation of the anticancer potential of prominent Unani medicine and their nano formulations as an adjuvant against liver carcinoma

A study on the validation of anticancer potential of prominent Unani medicine and their nano formulations as adjuvants against liver carcinoma was carried out at the Department of Bio-Engineering, Integral University, Lucknow. The study showed that the cumulative drug release percentages for the nano-formulations SNNE, CINE, and NEcomb were approximately 92.33%, 92.37%, and 96.45%, respectively, suggesting sustained drug release over 24 hours.

Effect of Unani formulations against mitochondrial-mediated cellular mechanisms: A strategy to combat Alzheimer's disease

A study on the effect of Unani formulations against mitochondrial-mediated cellular mechanisms as a strategy to combat Alzheimer's disease was carried out at the Department of Toxicology, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi. The findings showed that the Unani formulation markedly prevented Aβ1-42-induced hippocampal injury, as confirmed through histopathology, and restored neurons from damage.





Evaluation of Unani drug on FoxP3 expressing regulatory T cells in the modulation of rheumatoid arthritis

A study on the evaluation of a Unani drug on FoxP3 expressing regulatory T cells in the modulation of rheumatoid arthritis is being carried out at the Central University of South Bihar, Gaya. The study explores how FoxP3 T cells are influenced by the Unani drug in managing rheumatoid arthritis.

Development of nano-formulation based microneedle patches of Unani medicinal plants in the management of diabetes mellitus and associated complications: An in-silico, cost-benefit analysis and clinical trial approach

A study on the development of nano-formulation-based microneedle patches using Unani medicinal plants for managing diabetes mellitus and associated complications is being carried out at the Department of Pharmacognosy, Delhi Institute of Pharmaceutical Sciences and Research, New Delhi.

Molecular investigations towards the nephroprotective action of *Zar'ūnī Sāda* (ZS); in-vivo and in-vitro studies followed by proof of concept (POC) clinical trials

A study on molecular investigations into the nephroprotective action of *Zar'ūnī Sadā* (ZS) was being conducted at the Department of Pharmacology, AIIMS, New Delhi. This research includes in-vivo and in-vitro studies followed by POC clinical trials.

Effect of selected Unani formulation on oxidative stress in patients with type 2 diabetes mellitus: A randomized double-blind placebo-controlled clinical trial

A study on the effect of a selected Unani formulation on oxidative stress in patients with type 2 diabetes mellitus was in progress at AIIMS, New Delhi. The study is a randomized double-blind placebo-controlled clinical trial aimed at understanding the formulation's effects on oxidative stress markers.

Design and development of a standardized dry and wet cupping therapy device: An efficient way to perform cupping therapy

A study on the design and development of a standardized dry and wet cupping therapy device was in progress at the Department of Design, IIT Delhi. This project aims to improve the efficiency and safety of performing cupping therapy as part of Unani medicine practices.

Evaluation of a Unani polyherbal formulation, acting as a brain tonic, and its constituents for potential anti-Alzheimer activity

A study on evaluating a Unani polyherbal formulation, acting as a brain tonic, for its potential anti-Alzheimer activity was being conducted at the Neuropharmacology Laboratory, Indian Institute of Integrative Medicine – CSIR, Srinagar.

Effects and molecular mechanisms of cardioprotective Unani drugs *Khamīra Abresham* on nitric oxide (NO) production, uncoupling, and reactive oxygen species (ROS) generation in atherosclerosis

A study on the effects and molecular mechanisms of cardioprotective Unani drugs like *Khamīra Abresham* on nitric oxide production, uncoupling, and reactive oxygen species generation in atherosclerosis was being conducted at the Department of Biotechnology, Jamia Millia Islamia, New Delhi.



Exploring the therapeutic potential of *Ma'jūn 'Ushba*, a Unani medicine, against psoriasis (*Dā' al-Ṣadaf*) with reference to IL-17 cytokine signaling

A study exploring the therapeutic potential of *Ma'jūn 'Ushbā*, a Unani medicine, against psoriasis with reference to IL-17 cytokine signaling was being carried out at the School of Biosciences and Technology, Vellore Institute of Technology, Tamil Nadu.

Investigating the therapeutic and chemo-sensitizing efficacy of Unani pharmacopoeial formulation *Dawā' al-Kurkum* on head and neck squamous cell carcinoma

A study investigating the therapeutic and chemo-sensitizing efficacy of *Dawā' al-Kurkum* on head and neck squamous cell carcinoma was being carried out at the Islamic University of Science & Technology, Avantipoora, Jammu & Kashmir.

Colon targeting of Unani medicine via gum (polysaccharide) based oral formulations for effective treatment of irritable bowel syndrome: Clinical intervention by gamma scintigraphy

A study on colon targeting of Unani medicine via gum (polysaccharide)-based oral formulations for effective treatment of irritable bowel syndrome (IBS) was being conducted at the Amity Institute of Pharmacy, Amity University, Noida.

To investigate the pharmacological effect of certain Unani formulations in a preclinical animal model of polycystic ovary syndrome (PCOS)

A study investigating the pharmacological effect of certain Unani formulations in a preclinical animal model of PCOS was being carried out at the SVKM Institute of Pharmacy, Mumbai.

Design and development of *Sharbat Aḥmad Shāhī* into tablet form along with its physico-pharmaceutical and pharmacological evaluation

A study on the design and development of *Sharbat Aḥmad Shāhī* into tablet form was being carried out at the Department of Saidla (Pharmacy), Faculty of Unani Medicine, Aligarh Muslim University, Aligarh.

Assessment of the effect of Unani formulation loaded nanoparticle tablets against streptozotocin-induced diabetes

A study on the assessment of the effect of Unani formulation-loaded nanoparticle tablets against streptozotocin-induced diabetes was being carried out at the Department of Pharmaceutics, School of Pharmaceutical Education & Research, Jamia Hamdard, New Delhi.

Preclinical and clinical validation of safety and efficacy of traditional Unani formulation *Sharbat Mundī* pertaining to its hepatoprotective effect

A study on the preclinical and clinical validation of the safety and efficacy of traditional Unani formulation *Sharbat Mundī* pertaining to its hepatoprotective effect was being carried out at the Sathyabama Institute of Science & Technology, Chennai.

Phytochemical profiling, assessment of safety, and validation of anti-amnestic effect of *Ma'jūn Būlis*: A preclinical investigation

A study on the phytochemical profiling, safety assessment, and validation of the anti-amnestic effect of *Ma'jūn Būlis* was being carried out at the Department of Pharmaceutical Sciences, Dibrugarh University, Assam.



Anti-diabetic and immune-modulatory effect of Unani formulation *Safūf Dhayābītus*

A study on the anti-diabetic and immune-modulatory effects of the Unani formulation *Safūf Dhayābītus* was being conducted at the Department of Biotechnology, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu.

Studies on evaluating the anti-fibrotic potential of a Unani formulation (*Majūsī Formula*)

A study on evaluating the anti-fibrotic potential of a Unani formulation, *Majūsī Formula*, was being carried out at SRM Medical College Hospital and Research Centre, Chennai.

Effect of Unani drugs on the transgenic *Drosophila* model of Parkinson's disease

A study on the effects of Unani drugs on transgenic *Drosophila* model flies of Parkinson's disease was being conducted at the Department of Zoology, Aligarh Muslim University, Aligarh.

Structural characterization, pharmacokinetics, pharmacodynamics, and herb-drug interactions of major constituents of compound Unani formulations for diabetes

A study on the structural characterization, pharmacokinetics, pharmacodynamics, and herb-drug interactions of major constituents of compound Unani formulations for diabetes was being carried out at the Department of Pharmaceutical Analysis, NIPER, Hyderabad.

Evaluation of safety and efficacy of Unani pharmacopoeial formulations as therapeutic adjuvants to antiepileptic drugs in drug-resistant epilepsy

A study on the evaluation of safety and efficacy of Unani pharmacopoeial formulations as therapeutic adjuvants to antiepileptic drugs in drug-resistant epilepsy was initiated at the Department of Pharmacology, AIIMS, New Delhi.

3.4. Publications

3.4.1. Books, Monographs, Reports, etc.

During the reporting period, the CCRUM brought out the following books, monographs, reports, journals, etc.:

S. N.	Title	Language	Category
1.	<i>Adwiya Kulwiyya</i> - A Compendium of Classical and Evidence-based Unani Drugs Acting on the Kidneys	English	Book
2.	<i>Adwiya Qalbiyya – Qadīm-o-Jadīd Tahqīqāt kī Raushnī mein</i> (A compendium of classical and evidence-based Unani drugs acting on the heart)	Urdu	Book
3.	Safety and Efficacy of UNIM-001 and UNIM-003 in <i>Baras</i> (Vitiligo) - A Technical Report	English	Book
4.	UPLC Fingerprinting and Pharmacopoeial Studies of Unani Coded Compound Formulation UNIM-040	English	Book
5.	<i>Muhit-i-Azam</i> , vol. 1	Urdu	Ebook
6.	<i>Kitabul Mi'at fit-Tib</i>	Arabic	Ebook
7.	Standard Operating Procedures for <i>Hijāma</i> (Cupping Therapy)	English	Ebook
8.	Hippocratic Journal of Unani Medicine, Volume-16, Number-3	English-Hindi	Journal
9.	Jahan-e-Tib, Volume-24, Issue 1–4	Urdu	Journal



S. N.	Title	Language	Category
10.	CCRUM Annual Report – 2022-23 (English)	English	Annual Report
11.	CCRUM Annual Report – 2022-23 (Hindi)	Hindi	Annual Report
12.	Regional Research Institute of Unani Medicine, Chennai - Activities & Achievements	English	IEC Booklet
13.	Central Council for Research in Unani Medicine - At a Glance	English	IEC Brochure
14.	Central Council for Research in Unani Medicine - At a Glance	Hindi	IEC Brochure
15.	Unani Food Supplements	English	IEC Leaflet
16.	Unani Food Supplements	Hindi	IEC Leaflet

3.4.2. Research Papers

During the reporting period, the following research papers authored by the CCRUM officers were published in reputed national and international journals:

1. Ahmad, A., Ansari, A. S., Khan, A. S., Devi, U., & Wasim, M. (2023). Pharmacognostical authentication of heartwood of *Pterocarpus marsupium* Roxb. - An important drug used in traditional systems of medicine. *Journal of Pharmacognosy and Phytochemistry*, 12(2), 138–145.
2. Ahmad, M., Rajesh, Alam, M. M., Goswami, A., Alam, M. I., Ansari, M. E., & Ahmad, N. (2023). A holistic approach of gout (Niqris) in Unani system of medicine. *International Journal of All Research Education and Scientific Methods*, 11(3), 1472–1475.
3. Ahmad, N., Nawab, M., Kazmi, M. H., & Shaikh, M. (2023). Efficacy of a Unani regimen in the treatment of Dhyabitus Sukkari Qism Thani (diabetes mellitus type 2): A case report. *Hippocratic Journal of Unani Medicine*, 16(03), 65–72.
4. Ahmed, F., Ahmad, S. S., Alam, M. M., Khatoon, A., Ali, R., Ahmad, J., Amina, N., Najmi, A. K., & Khan, M. A. (2023). Hyperglycaemia induced osteoporosis: Is there a hope with dipeptidyl peptidase-4 inhibitors? *Health Sciences Review*, 9, 100135. <https://doi.org/10.1016/j.hsr.2023.100135>
5. Ahmed, N. Z., Jamal, M. A., Anwar, N., & Qamri, M. A. (2022). COVID-19 mein Tiryaaq-e-Wabai ki ahmiyat wa efadiyat: Jadid tahqiqat ke tanazur mein (Urdu). *Jahan-e-Tib*, 24(1-4), 129–138.
6. Ahmed, R., Ahmed, M. W., Khan, A. S., & Ahmad, A. (2023). Pharmacognostical and physico-chemical studies of Unani formulation Zuroor-E-Qula. *International Journal of Herbal Medicine*, 11(5), 64–68. <https://doi.org/10.22271/flora.2023.v11.i5a.891>
7. Ahmed, R., Ahmed, M. W., Khan, A. S., & Ahmad, A. (2023b). *Cyperus rotundus* commonly used drug in Unani medicine. *Journal of Drug Delivery and Therapeutics*, 13(8), 81–84. <https://doi.org/10.22270/jddt.v13i8.5933>
8. Ahmed, R., Ahmed, M. W., Khan, A. S., & Sagar, P. K. (2023). Unani chikitsa mein paryog hone wali ek mahottow purn aushdhi Barg e Bed Saada (*Selics alba* / Safed Villo). *International Journal of Multidisciplinary Educational Research*, 2(8), 73–76.
9. Akbar, W. A. S., Arokiarajan, M. S., Christopher, J. J., Ahmed, N. Z., & Meena, R. (2023). Evaluation of bioactive compounds as antimicrobial and antidiabetic agents from the crude extract of *Heliotropium curassavicum* L. *Biocatalysis and Agricultural Biotechnology*, 50, 102745. <https://doi.org/10.1016/j.bcab.2023.102745>





10. Akhlaq, S., Jamal, A., Siddiqui, A., Ara, S. A., & Itrat, M. (2023). The sequelae of sleeping issues and their management in post COVID-19: A Unani and contemporary narrative review. *Current Traditional Medicine*, 10. <https://doi.org/10.2174/2215083810666230822113646>
11. Ansari, A. P., Arokiarajan, M. S., Akram, W., Akbar, S., Ahmed, N. Z., & Anwar, N. (2024). Investigating the quality control, antimicrobial, and antioxidant evaluation of the ointment "Marham-i-Raal" used in the Unani system of medicine. *Pharmaceutical and Biomedical Research*, 10(1), 47–56. <http://dx.doi.org/10.32598/PBR.10.1.1228.1>
12. Ansari, F. A., Ahmad, I., & Khan, A. S. (2024). Recent molecular tools for analyzing microbial diversity in the rhizosphere ecosystem. In S. Das & H. R. Dash (Eds.), *Microbial diversity in the genomic era* (2nd ed., pp. 233–246). Academic Press. <https://doi.org/10.1016/B978-0-443-13320-6.00007-X>
13. Ansari, H., Ansari, A. P., Goswami, P., Qayoom, I., Hasib, A., Reshi, B. M., & Akbar, S. (2023). Comparative physicochemical evaluation and acute toxicity study of crude and processed (detoxified) samples of Saqmunia (*Convolvulus scammonia* L.) in albino Wistar rats. *Journal of Natural Remedies*, 1461–1474. <https://doi.org/10.18311/jnr/2023/33454>
14. Ansari, T., Asif, M., Saleem, M., Ahmed, N. Z., & Meena, R. (2023). *Rubus moluccanus* L.: A valuable medicinal plant of traditional system of medicine. *Natural Product Research*, 1–11. <https://doi.org/10.1080/14786419.2023.2291706>
15. Ansari, U. A. M. A., Uddin, Q., Husain, N., Ahmad, T., Fatima, S. H., & Minhajuddin, A. (2024). Evaluation of the efficacy and safety of a herbal formulation for rheumatoid arthritis – A non-inferiority randomized controlled trial. *Journal of Ethnopharmacology*, 325, 117833. <https://doi.org/10.1016/j.jep.2024.117833>
16. Anwar, N., Ahmed, N. Z., Fathima, A. F., & Khan, A. A. (2023). Analytical review of Tiryāq-i-Wabāī: A Unani panacea for the control of COVID-19. *Journal of Herbal Medicine*, 39, 100653. <https://doi.org/10.1016/j.hermed.2023.100653>
17. Anwar, N., Ahmed, N. Z., Fathima, A. F., Ansari, A. P., Farhan, K. M., & Viswanathan, A. J. (2023). Roghan Mālīsh: A topical formulation that attenuates joint pain, down-regulates C-reactive protein level, and improves quality of life in patients with Waja' al-Mafāṣīl (NUMC: L-4) (arthralgia) – A pilot clinical study. *Journal of Natural Remedies*, 23(2), 593–602. <https://doi.org/10.18311/jnr/2023/32427>
18. Anwar, N., Davis, G. D. J., Ibrahim, S., Meena, R. P., Afnan, Z., & Ahmed, N. Z. (2024). In silico preliminary evaluation of bioactive compounds from five Unani drugs as potential SARS-CoV-2 inhibitors. *Indian Journal of Traditional Knowledge*, 23(3), 247–261. <https://doi.org/10.56042/ijtk.v23i3.1412>
19. Anwar, N., Jamal, M. A., Ahmed, N. Z., & Faris, A. A. (2022). COVID-19 mein Arq e Ajib ki tibbi efadiat: Ek jaiza (Urdu). *Jahan-e-Tib*, 24(1-4), 163–172.
20. Asad, M., Ashraf, N., Rahman, S., Ahmad, K., Minhajuddin, A., & Zakir, M. (2023). Traditional uses, phytochemistry, and pharmacological activities of Anisun (*Pimpinella anisum* L.): A comprehensive review. *Annals of Forest Research*, 65(1), 5212–5227.
21. Aziz Hazari, S., Kaur, H., Karwasra, R., Abourehab, M. A. S., Ali Khan, A., & Kesharwani, P. (2023). An overview of topical lipid-based and polymer-based nanocarriers for treatment of psoriasis. *International Journal of Pharmaceutics*, 638, 122938. <https://doi.org/10.1016/j.ijpharm.2023.122938>
22. Bader, R., Imam, A., Alnees, M., Adler, N., Ilia, J., Zugayar, D., Dan, A., & Khalaileh, A. (2024). Successful management of an iatrogenic portal vein and hepatic artery injury in



- a 4-month-old female patient: A case report and literature review. *Radiology Case Reports*, 19(6), 2106–2111. <https://doi.org/10.1016/j.radcr.2024.02.037>
23. Bankuru, J., Battula, V. R., Santhoshkumar, S. T., Gopal, S., Meena, R. P., & Ahmed, N. Z. (2023). A catalyst-free, green, and efficient protocol for the synthesis of methyleneisoxazole-5(4H)-ones supported by ultrasonic irradiation. *JCIS Open*, 12, 100097. <https://doi.org/10.1016/j.jciso.2023.100097>
24. Binth Siraj, M., Khan, A. A., Jahangir, U., Hashimi, A., Ahmad, Y., & Husain, N. (2024). Evaluation of the efficacy of hydro-alcoholic extract of *Evolvulus alsinoides* L. for the treatment of primary hypertension - A randomized controlled trial. *Journal of Ethnopharmacology*, 323, 117661. <https://doi.org/10.1016/j.jep.2023.117661>
25. Chandra, J., Molugulu, N., Annadurai, S., Wahab, S., Karwasra, R., Singh, S., Shukla, R., & Kesharwani, P. (2023). Hyaluronic acid-functionalized lipoplexes and polyplexes as emerging nanocarriers for receptor-targeted cancer therapy. *Environmental Research*, 233, 116506. <https://doi.org/10.1016/j.envres.2023.116506>
26. Christopher, J., Wasim Akram, S. A., Mageswari, S., Rajan, M. S. A., Kumar, S. T. S., Ahmed, N. Z., & Meena, R. (2023). Development of standardization parameters for *Hyocyamus niger* L. seeds with special reference to its pharmacognostical, physicochemical, and HPTLC fingerprinting studies. *World Journal of Pharmaceutical Research*, 12(16), 671–689.
27. Dash, S. L., Mohapatra, R., Mekap, S. K., Masanta, S. R., Katiyar, A., Sharma, N., Karwasra, R., & Mishra, S. K. (2023). Toxicological study of n-hexane and chloroform extracts of *Lantana camara* L. in experimental animals. *Indian Journal of Pharmaceutical Education*, 57(2s), s370–s380. <https://doi.org/10.5530/ijper.57.2s.43>
28. Devi, U., Sharma, P., Sharma, J. C., Murugeswaran, R., Ahmed, A., & Khan, A. S. (2023). Assessment of economically and medically important plant resources in Sangla Valley region of Indian Himalaya. In *Plants for immunity and conservation strategies* (pp. 259–310). Springer. https://doi.org/10.1007/978-981-99-2824-8_14
29. Devi, U., Ansari, S. A., Khan, A. S., Ahmad, A., Ahmed, M. W., & Meena, R. (2024). Pharmacognostic evaluation and development of quality control parameters for Fufal (*Areca nut*). *The Journal of Phytopharmacology*, 13(3), 220–229. <https://doi.org/10.31254/phyto.2024.13305>
30. Devi, U., Khan, A. S., Ahmed, A., Ansari, S. A., Ahmed, M. W., & Meena, R. (2023). Pharmacognostic evaluation and development of quality control parameters for Berg-e-Bed-Sada (leaf of *Salix alba* L.). *Journal of Pharmacognosy and Phytochemistry*, 12(1), 672–678. <https://doi.org/10.22271/phyto.2023.v12.i1f.14612>
31. Devi, U., Sharma, P., Ahmad, A., & Khan, A. S. (2023). Wild plant resources used as food in Spiti Valley: A cold arid zone of Himachal Pradesh, India. *Journal of Medicinal Plants Studies*, 11(4), 106–114. <https://doi.org/10.22271/plants.2023.v11.i4b.1576>
32. Dhane, A. S. (2024). Exploring the role of ChatGPT in traditional medicine: A friend or foe? *Traditional and Integrative Medicine*, 9(1), 1–2. <https://doi.org/10.18502/tim.v9i1.15083>
33. Dwivedi, D. K., & Jena, G. B. (2023). Dimethyl fumarate-mediated Nrf2/ARE pathway activation and glibenclamide-mediated NLRP3 inflammasome cascade inhibition alleviate type II diabetes-associated fatty liver in rats by mitigating oxidative stress and inflammation. *Journal of Biochemical and Molecular Toxicology*, 37(7). <https://doi.org/10.1002/jbt.23357>
34. Dwivedi, D. K., Sahu, C., & Jena, G. B. (2023). Simultaneous intervention against oxidative stress and inflammation by targeting Nrf2/ARE and NLRP3 inflammasome pathway mitigates thioacetamide-induced liver fibrosis in rats. *Canadian Journal of*





- Physiology and Pharmacology*, 101(10), 509–520. <https://doi.org/10.1139/cjpp-2023-0018>
35. Fatima, N., Siddiqui, M., Riyazuddin, M., & Shahid, A. (2023). Efficacy of Sharbat-e-Afsanteen (*Artemisia absinthium* L.) on altered liver enzymes among alcoholics: A randomized single-blind controlled clinical trial. *Journal of Herbal Medicine*, 37, 100623. <https://doi.org/10.1016/j.hermed.2023.100623>
 36. Fatima, N., Uddin, Q., & Kazmi, M. (2023). Role of *Aloe vera* in the management of rheumatoid arthritis. *Journal of Emerging Technologies and Innovative Research*, 10(8), 193–199.
 37. Fatima, S. H., Khadeerunisa, S., Ahmad, T., Javed, G., Minhajuddin, A., & Kazmi, M. H. (2023). An open-label prospective clinical study to evaluate the lithotriptic effect of Safuf Hajar al-Yahud in patients of Hasa-al-Kulya (nephrolithiasis). *Hippocratic Journal of Unani Medicine*, 16(03), 39–48.
 38. Globra, G., Sagar, L. P. K., Khan, A., Kashyap, S., & Sagar, P. (2023). Useful medicinal plants having anti-cancerous and anti-tumorous medicinal potential of *Withania somnifera* (L.) Dunai, *Andrographis paniculata* (Burm.f.) Nees, and *Glycyrrhiza glabra* (L.). *International Journal of Pharmaceutical Sciences and Research*, 14(7). <https://doi.org/10.13040/ijpsr.0975-8232>
 39. Gujarathi, N. A., Abriata, J. P., Keservani, R. K., & Sharma, A. K. (2023). *Topical and transdermal drug delivery systems*. Apple Academic Press. <https://doi.org/10.1201/9781003284017>
 40. Huma, A. H. (2024). Efficacy and safety of Unani formulation in loss of appetite. *Journal of Complementary and Alternative Medical Research*, 24(04), 38–48.
 41. Husain, M. K., Pratap, G. P., Alam, M., Javed, G., Minhajuddin, A., & Khan, A. A. (2023). Traditional uses and properties of Indian medicinal plants in the treatment of vitiligo. In *Medicinal and aromatic plants of the world* (pp. 191–212). https://doi.org/10.1007/978-3-031-44914-7_10
 42. Ismail, B. A., Nawab, M., & Fatima, S. H. (2024). A single centre demographic and clinico-epidemiological profile of pityriasis versicolor in adults: A cross-sectional study. *Bangladesh Journal of Medical Science*, 23(1), 141–149. <https://doi.org/10.3329/bjms.v23i1.70707>
 43. Jahangir, U., Khan, A., Kapoor, P., Jalees, F., & Urooj, S. (2023). Comparative efficacy of Safoof Muhazzil and its compressed tablets on parameter of weight reduction. *International Journal of Pharmaceutical Sciences and Research*, 14(6). [https://doi.org/10.13040/ijpsr.0975-8232.14\(6\).2977-83](https://doi.org/10.13040/ijpsr.0975-8232.14(6).2977-83)
 44. Javed, A., Uzma, V., Kalam, M. A., Haque, S. U., Abid, M., & Husain, G. M. (2023). Sanā makkī (*Cassia angustifolia* Vahl.): Pharmacognostic, pharmacological, and therapeutic profile—a review. *International Journal of Research and Analytical Reviews*, 10(3), 556–561.
 45. Javed, G., Kuna, L., Thulasamma, S., Pallapolu, P., Kazmi, M. H., Chakraborty, A., & Khan, A. A. (2023). Vascular oxidative stress study of hypertension in relation to clinical phenotyping as per Unani philosophy in South Indian population. *Biochemical and Cellular Archives*, 23(1), 137–142. <https://doi.org/10.51470/bca.2023.23.1.137>
 46. Kalam, M. A., Ahmad, R., Avid, M., Rahim, A., & Habib, A. (2023). Khatmī (*Althea officinalis* L. and *Althea rosea*): Medicinal importance in the perspective of Unani medicine and pharmacological studies. *Journal of Drug Delivery and Therapeutics*, 13(12), 270–277. <https://doi.org/10.22270/jddt.v13i12.6155>
 47. Kalam, M. A., Habib, A., Arzoo, K. S., Ahmad, W., Ahmad, R., & Avid, M. (2024). Khuzāma (*Lavandula angustifolia* Mill.): Pharmacological action and therapeutic uses in perspective of Unani medicine: A review. *Journal of Complementary and Alternative Medical Research*, 25(1), 18–25. <https://doi.org/10.9734/jocamr/2024/v25i1511>



48. Karwasra, R., Ahmad, S., & Singh, S. (2023). Potential profound fluctuation in tacrolimus concentration on consumption of pomegranate rind extract: A pharmacokinetic experiment. *Frontiers in Pharmacology*, 14, 1140706. <https://doi.org/10.3389/fphar.2023.1140706>
49. Kashif, H. M. (2023). Nanotechnology and current advances in plant tissue culture. *Journal of Phytonanotechnology and Pharmaceutical Sciences*, 3(1), 1–8.
50. Khan, A. A., Parveen, N., Raza, R., Akhtar, J., Anjum, N., Kumar, P., Kumar, P., Javed, G., Meena, R. P., Urooj, S., Thapa, H., & Alam, S. (2022). Effectiveness of Unani regimen in protecting high-risk population from COVID-19: A pilot study. *Indian Journal of Natural Products and Resources*, 13(2), 248–254. <https://doi.org/10.56042/ijnpr.v13i2.58610>
51. Khan, A. S., Ansari, S. A., Devi, U., Ahmed, M. W., Kashyap, S., & Ahmed, A. (2023). Pharmacognostical evaluation and HPTLC fingerprinting of classical Unani formulation: Itrifal–Kishneezi. *World Journal of Pharmaceutical and Medical Research*, 09(11), 223–231.
52. Khan, A. S., Ansari, S. A., Devi, U., Ahmed, R., Kashyap, S., & Ansari, F. A. (2023). Physico-chemical standardization studies of an important Unani drug: Arq-e-Mussaffi-e-Khoon. *World Journal of Pharmaceutical and Medical Research*, 12(17), 1242–1251.
53. Khan, A. S., Ansari, S. A., Devi, U., Ansari, F. A., Kashyap, S., Ahmed, R., & Meena, R. P. (2024). Pharmacognostical and HPTLC fingerprinting studies of a classical Unani formulation Habb-e-Asgand. *World Journal of Pharmaceutical Research*, 13(4), 744–757. <https://doi.org/10.20959/wjpr20244-31388>
54. Khan, J. A., & Khan, P. J. (2023). An overview on bias in clinical research studies. *Journal of Emerging Technologies and Innovative Research*, 10(8), F413–416.
55. Khan, J. A. (2023). A view of epidemiology and selecting appropriate statistical tests for analysis and importance of publication. *Journal of Emerging Technologies and Innovative Research*, 10(10), 386–391.
56. Khan, J. A., Khan, P. J., Munshi, Y. I., Ahmed, A., Jabeen, A., Gulnawaz, S., & Aslam, H. C. M. (2023). Study design in clinical trials. *International Journal for Innovative Research in Multidisciplinary Field*, 9(11), 102–103.
57. Khan, K. A., Khan, R. A., Zakir, M., & Taha, M. N. (2023). A narrative study about the role of Qurs Zarishk as Unani formulation in management of hepatic insufficiency and anemia with hypoproteinaemia. *Chelonian Conservation and Biology*, 18(2), 210–229. [https://doi.org/10.18011/2023.11\(4\).210-229](https://doi.org/10.18011/2023.11(4).210-229)
58. Khan, N., Raza, R., Khan, R., Ahmed, F., Urooj, S., & Chishti, D. K. (2023). A study to assess the knowledge and practice regarding sanitation and hygiene among women in parts of Delhi, India. *Journal of Drug Delivery and Therapeutics*, 13(9), 28–32. <https://doi.org/10.22270/jddt.v13i9.6196>
59. Khan, P., Ahmad, S., Raheem, A., Ahmed, F., Parveen, S., & Afza, S. (2023). Study of water resources and waterborne diseases in rural population of Aligarh, Uttar Pradesh, India. *Journal of Advanced Zoology*, 44(S7), 952–959.
60. Khan, P., Verma, R. S., Ayub, S., Afza, S., Akhtar, J., & Khan, A. A. (2023). The efficacy and safety of a Unani pharmacopoeial formulation—raughan kahu in sahar (insomnia): A preliminary study. *International Journal of Unani and Integrative Medicine*, 7(1), 46–51. <https://doi.org/10.33545/2616454x.2023.v7.i1a.230>
61. Khatoon, F., Azahar, M., Uddin, Q., Husain, N., Moin, M. S., & Khan, S. (2024). A comprehensive review on *Trigonella foenum-graecum* L. with special reference to Unani medicine. *Combinatorial Chemistry & High Throughput Screening*, 27(2), 187–202. <https://doi.org/10.2174/1386207326666230504112848>





62. Kishore, J., Kumar, R., Nazli, T., Ahmad, A., Kumar, P., & Khan, A. A. (2023). Efficacy of the Unani regimen as an add-on to standard treatment in hospitalized RT-PCR-confirmed mild to moderate COVID-19 patients: An open-label randomized controlled trial. *Cureus*. <https://doi.org/10.7759/cureus.38574>
63. Komala, M., Rajaram, M., Swathi, M., & Ashok, M. (2023). Concept of leucorrhoea & its understanding in the light of Unani medicine. *International Journal for Multidisciplinary Research*, 5(5). <https://doi.org/10.36948/ijfmr.2023.v05i05.7647>
64. Malik, A., Ahmad, W., & Sofi, G. (2024). Inter-rater judgement analysis for item selection in the development of the questionnaire to determine *Mizaij-i-Insani*. *Bangladesh Journal of Medical Science*, 23(2), 429–437. <https://doi.org/10.3329/bjms.v23i2.72165>
65. Masihuzzaman, A. M., & Iftikhar, M. Y. (2023). Anjeer (*Ficus carica* Linn.): A famous fruit with distinct pharmacological properties: A review. *International Journal of Unani and Integrative Medicine*, 7(1), 38–42. <https://doi.org/10.33545/2616454x.2023.v7.i1a.228>
66. Moin, M. S., Siddiqui, J. I., Khan, S., Alam, M. A., Khatoon, F., & Alam, A. (2023). Therapeutic potential and traditional values of frequently used medicinal plant *Berberis aristata* DC. (Rasaut): A comprehensive review. *Research Journal of Pharmacy and Technology*, 16, 2035–2043. <https://doi.org/10.52711/0974-360x.2023.00335>
67. Moin, M. S., Siddiqui, J. I., Naikodi, M. A. R., Khan, S., Alam, M. A., & Khatoon, F. (2023). Development of standard operating procedures (SOPs) of a polyherbal formulation *Qurs-i Musaffi* recommended for the treatment of skin diseases. *Journal of Young Pharmacists*, 15(1), 74–82. <https://doi.org/10.5530/097515050409>
68. Mustafa, A., Sidfdiqui, Z. A., Alvi, A. I., Akhter, G., & Javed, G. (2024). Physico and phyto-chemical evaluation of seeds and their extracted crude oil's characteristics of a nutritionally important plant *Daucus carota* Linn. *Research Journal of Pharmacognosy and Phytochemistry*, 16(1), 17–22. <https://doi.org/10.52711/0975-4385.2024.00004>
69. Naseem, S., Khan, A. A., Uddin, Q., Jabeen, A., Ahmad, K., & Asad, M. (2023). A comprehensive review on applicability and bioactivity of *Rogan-I-Kunjad* (*Sesamum indicum* L-Oil): Unani prospective. *Annals of the National Academy of Medical Sciences (India)*, 59(4), 175–185. <https://doi.org/10.1055/s-0043-1775599>
70. Negi, R. K., Sajwan, S., Gopal, S., Khan, A. S., & Meena, R. P. (2023). Standardization of polyherbal formulation *Sufoof-e-Ziabetus Dulabi*. *International Journal of Creative Research Thoughts*, 11(5), e322–e336.
71. Negi, R. K., Sajwan, S., Naikodi, M. A. R., Khan, A. S., & Meena, R. P. (2023). Qualitative estimation of a Unani poly-herbal formulation *Habb-e-Yarqaan*. *International Journal of Creative Research Thoughts*, 11(8), 115–123.
72. Niukhat, S., Parray, S. A., & Khan, J. A. (2023). Assessment of temperament of outdoor patients of DUMC: An observational study. *Journal of Emerging Technologies and Innovative Research*, 10(7), e45–e51.
73. Patel, D. K., Singh, G. K., Husain, G. M., & Prasad, S. K. (2024). Ethnomedicinal importance of patuletin in medicine: Pharmacological activities and analytical aspects. *Endocrine, Metabolic & Immune Disorders Drug Targets*, 24(5), 519–530. <https://doi.org/10.2174/1871530323666230816141740>
74. Qayoom, I., Ansari, A. P., Huzaifa, A., Bhat, M. M., Reshi, B. M., Goswami, P., & Anwar, N. (2023). Quality control and acute toxicity study of *Habb-i-Hayat* (Unani formulation) in albino Wistar rats. *Pharmacognosy Research*, 16(1), 98–109. <https://doi.org/10.5530/pres.16.1.12>
75. Rajaram, M., Komala, M., Swathi, M., & Ashok, M. (2023). Prevention of lifestyle diseases through *Asbab-e-Sitta Zarooriyah* (six essential factors) of Unani medicine: A review. *International Journal of AYUSH*, 12(6), 1–8.



76. Rajesh, Ahmad, M., Alam, M. M., Goswami, A., & Alam, M. I. (2023). *Ashwagangha ka chikitsya udhaiyan: Ek samiksha. International Journal of Creative Research Thoughts*, 11(3), 894–897.
77. Rasheed, N. M. A., Talluri, M. V. N. K., Negi, R. K., Kazmi, M. H., Waheed, M. A., & Meena, R. P. (2023). Standardization and phytochemical screening of a Unani coded formulation *UNIM 040* with TLC and UPLC analytical techniques. *Hippocratic Journal of Unani Medicine*, 16(3), 9–22.
78. Raza, R., Urooj, S., Khan, N., & Hussain, M. T. (2023). Dermatophytosis (Qooba): Control and management in both modern and Unani medicines: A comparative review. *Indian Journal of Research*, 12(8), 1–4.
79. Sagar, P. K., Ahmed, N. Z., Khan, A. S., Meena, R. P., Ahmed, A. W., Ansari, S. A., Sajwan, S., & Kashyap, S. (2023). Pharmacopoeial standard development, HPTLC fingerprinting, and physicochemical research studies of polyherbal classical drug *Raughan-e-Mukhtara. International Journal of Scientific Research in Chemistry*, 8(4), 28–52. <https://doi.org/10.32628/ijsrch>
80. Sagar, P. K., Ahmed, N. Z., Khan, A. S., Meena, R. P., Ahmed, A. W., Ansari, S. A., Sajwan, S., & Kashyap, S. (2023). Pharmacopoeial standard development, HPTLC fingerprinting, and physicochemical research studies of polyherbal classical drug *Raughan-e-Muqawwi-e-Dimagh: A brain booster medicated oil. International Journal of Scientific Research in Chemistry*, 8(4), 53–69. <https://doi.org/10.32628/IJSRCH>
81. Sagar, P. K., Khan, A. S., Ahmed, M. W., Meena, R. P., Ansari, S. A., Sajwan, S., & Kashyap, S. (2023). Scientific standard validation and HPTLC fingerprinting studies of polyherbal Unani formulation *Jawarish-e-Usquf. International Journal of Scientific Research in Chemistry*, 8(4), 1–13. <https://doi.org/10.32628/ijsrch>
82. Sagar, P. K., Khan, A. S., Meena, R. P., Ansari, S. A., Sajwan, S., & Kashyap, S. (2023). Scientific standard validation and HPTLC fingerprinting studies of polyherbal Unani formulation *Majoon-e-Maddat-ul-Hayat Jadwari. International Journal of Scientific Research in Chemistry*, 8(4), 14–19. <https://doi.org/10.32628/ijsrch>
83. Sajid, M., Sharma, A., Choudhry, A., & Chaudhry, S. A. (2023). Synthesis, characterization and potential application of functionalised binary metallic sulphide for water reclamation. *Colloids and Surfaces C: Environmental Aspects*, 1, 100011. <https://doi.org/10.1016/j.colsuc.2023.100011>
84. Sajwan, S., Negi, R. K., & Khan, A. S. (2023). *Aushdhiye paudhe env jiwan shaili-uch raktchaapke liye wardaan. International Journal of Multidisciplinary Educational Research*, 12(5), 101–111.
85. Shah, A., Huma, Iqbal, A., Jahangir, U., Shah, K., Sabia, Hanga, A. H., Urooj, S., & Rafiqi, T. A. (2023). Prospective role of Unani pharmacopoeial formulation *Safoof Hijrul Yahood* in preventing recurrence of nephrolithiasis: An open labelled clinical study. *Asian Journal of Biological and Life Sciences*, 12(1), 144–150.
86. Shahid, A., Quamri, M. A., & Riyazuddin, M. (2023). A comprehensive review of Quba and its correlation with dermatophytosis. *Current Traditional Medicine*, 9(5). <https://doi.org/10.2174/2215083809666221116111933>
87. Shahid, A., Quamri, M. A., & Riyazuddin, M. (2024). Management of Tinea incognito with Unani medicine: A case report. *Journal of Ayurveda Case Reports*, 7(2), 109–113. https://doi.org/10.4103/jacr.jacr_197_23
88. Shaikh, M., Urooj, M., Viqar, U., Javed, G., Kazmi, M. H., & Husain, G. M. (2023). Effect of *Majoon-e-Nisyan* (a traditional polyherbal Unani formulation) in animal models of learning and memory. *Traditional & Kampo Medicine*, 11(1), 22–29. <https://doi.org/10.1002/tkm2.1394>





89. Shamim, J., Ansari, A. P., Goswami, P., Akbar, S., Ansari, H., Wadud, A., & Dar, P. A. (2023). Protective effects of hydro-alcoholic extract of the root of *Kasondi* (*Cassia occidentalis* L.) against gentamicin-induced nephrotoxicity in albino Wistar rats. *Cell Med*, 13(6), e5.
90. Sharma, I., Bhardwaj, S., Karwasra, R., Kaushik, D., & Sharma, S. (2023). The emergence of nanotechnology in the prognosis and treatment of myocardial infarctions. *Recent Patents on Nanotechnology*. Advance online publication. <https://doi.org/10.2174/1872210517666230721123453>
91. Sharma, N., Khanna, K., Kumar, N., Karwasra, R., Janakiraman, A. K., & Rajagopal, M. S. (2023). Illuminating insights: Clinical study harnessing pharmacoscintigraphy for permeation study of radiolabeled nimesulide topical formulation in healthy human volunteers. *Assay and Drug Development Technologies*, 21(7), 325–330. <https://doi.org/10.1089/adt.2023.053>
92. Sharma, S., Sharma, N., Sharma, A., Kurmi, B. D., Khanna, K., Karwasra, R., Singh, A. K., & Chaudhary, A. (2023). Amelioration of experimental colitis by a site-specific novel plant polysaccharide (*Opuntia ficusindica*) based macroparticles containing probiotic biomass and mesalazine. *Journal of Drug Delivery Science and Technology*, 86, 104763. <https://doi.org/10.1016/j.jddst.2023.104763>
93. Siddiqui, U., Amir, M., Jamali, M. A. H., & Azmi, A. (2023). Assam—An asset of Unani medicine. *World Journal of Pharmaceutical Research*, 12(17), 376–387. <https://doi.org/10.20959/wjpr202317-29733>
94. Singh, S. K., Singh, S., Kumar, R., Rana, P., Sharma, A., Karwasra, R., Kesharwani, P., & Sahebkar, A. (2023). Influence of vitamin D level on inflammatory and prognostic markers in COVID-19: A retrospective study. *Recent Advances in Food, Nutrition & Agriculture*, 14(3), 190–196. <https://doi.org/10.2174/2772574X14666230808095649>
95. Sudharma, A. A., Siginam, S., Husain, G. M., Mullapudi, S. V., & Ismail, A. (2023). Atrophic remodeling of the heart during vitamin D deficiency and insufficiency in a rat model. *The Journal of Nutritional Biochemistry*, 119, 109382. <https://doi.org/10.1016/j.jnutbio.2023.109382>
96. Sumaiya, S., Siddiqui, A., Choudhary, S. S., Aslam, M., & Jamal, A. (2023). Phytochemistry, ethno-pharmacology and pharmacognostical appraisal of *Izkharr* (*Cypripogon jwarancusa* (Jones) Schult.) in Unani medicine. *International Journal of Biology, Pharmacy & Allied Science*, 12(8), 3628–3647.
97. Swathi, M., Uddin, Q., Haq, M. S., Amanullah, Rajaram, M., & Kazmi, M. H. (2023). A prospective open-label, single-arm clinical study to evaluate the efficacy and safety of a Unani pharmacopoeial formulation *Dawa-i-Gurda* in the management of *Hasal-al Kulya* (nephrolithiasis). *Hippocratic Journal of Unani Medicine*, 16(03), 49–63.
98. Tahseen, Z. A., Sofi, G., Shahid, A., Sofia, & Aazam, S. (2023). Unani approach to graded management of thrombosis in COVID-19 patients. *Current Traditional Medicine*. Advance online publication. <https://doi.org/10.2174/2215083810666230914103404>
99. Thakur, R., Karwasra, R., & Umar, T. (2023). Understanding Alzheimer's disease and its metal chelation therapeutics: A narrative review. *Current Pharmaceutical Design*, 29(30), 2377–2386. <https://doi.org/10.2174/0113816128263992231012113847>
100. Venketasan, K., Asif, M., Ahmed, P., Ahmed, K., & Ahmed, N. Z. (2023). Survey of millets explored for traditional food and medicine by the rural inhabitants of Salem District, Tamil Nadu, India. *International Journal of Reviews in Life Sciences*, 14(4), 1–9. <https://doi.org/10.26452/ijrls.v14i4.1501>
101. Verma, P. (2022). Alkaline phosphatase: A review article. *International Journal of Biochemistry and Biomolecules*, 8(1), 23–28.
102. Verma, P. (2022). Carbohydrate deficiency. *Research & Reviews: A Journal of Health Professions*, 12(2), 17–19.



103. Verma, P. (2022). Increase of glucose in fasting condition: A review. *Research & Reviews: A Journal of Immunology*, 12(3), 23–26.
104. Verma, P. (2022). Protein – deficiency and poisoning. *Research & Reviews: A Journal of Medicine*, 13(1), 9–14.
105. Verma, P. (2023). Ginger – a review article. *Research & Reviews: A Journal of Health Professions*, 13(2), 27–30.
106. Verma, P. (2023). Guava: A wonder fruit. *Research & Reviews: A Journal of Pharmacognosy*, 10(2), 1–5.
107. Zahid, U., Kazmi, M. H., Siddiqui, J. I., Naikodi, M. A. R., & Ahmad, I. (2023). Quality control and HPTLC analysis of a polyherbal Unani formulation Habb-i-Shahtara recommended for skin diseases. *Indian Journal of Traditional Knowledge*, 22(3), 624–632. <https://doi.org/10.56042/ijtk.v22i3.5751>
108. Zaidi, S. S., Perveen, A., Alam, M. A., Kishore, J., & Bhardwaj, U. D. (2024). Study to assess the effectiveness of behavioural change communication aid for the anger management in adolescents: A quasi-experimental study in the selected juvenile aid center, New Delhi. *Brain Behavior & Immunity. Integrative*, Article 100057. <https://doi.org/10.1016/j.bbii.2024.100057>
109. Zakir, M., Ashraf, N., Ahmad, T., Fatima, S. H., Minhajuddin, A., & Javed, G. (2023). Ethno-pharmacology of Dammul Akhwain (*Dracaena cinnabari*), a commonly used drug in the Unani system of medicine: A review. *Annals of Forest Research*, 65(1), 4517–4526.
110. Zakir, M., Ashraf, N., Asad, M., Minhajuddin, A., & Javed, G. (2023). Ethno-medicinal properties of Parsioshan (*Adiantum capillus-veneris* L.): An important herb of the Unani system of medicine. *Journal of Clinical Otorhinolaryngology, Head, and Neck Surgery*, 26(2), 21–36.

3.5. Extension of Healthcare Services

3.5.1. School Health Programme

The School Health Programme is aimed at improving the health and hygiene status of school children and to reduce morbidity rate among them through healthcare and health education. Under this programme, the Council's researchers visit selected Primary and Secondary Schools, particularly those in rural areas and urban slums. A baseline health check-up of school children is conducted and those found suffering from any ailment are treated with Unani medicines. Thereafter, health education is provided to them through lectures on different preventive, promotive, and curative health aspects, and health related literature is distributed. The children are also educated about the potentialities of the commonly available plants in their vicinity for the management of different diseases. Specific lectures are given on oral hygiene, cleanliness of body and environment, safe drinking water, nutrition, balanced diet, etc.

During the reporting period, this programme continued at NRIUMSD, Hyderabad; CRIUM, Lucknow; and RRIUMs, Aligarh, Srinagar, Chennai, Patna, Mumbai and New Delhi. The Council's physicians visited 16 schools that were adopted under the School Health Programme particularly those falling in the pockets adopted under Mobile Clinical Research Programme. A total of 4,267 school children were covered under this programme. Out of them, 2,593 children were found suffering from different ailments and 2,285 of them were treated in 121 visits made to these schools. With a view to educate the children on healthy living, 110 lectures were delivered on preventive and promotive health aspects. The most



common diseases found among them included cold & cough, dental cavities, tonsillitis, helminthiasis, skin infections, otorrhoea and conjunctivitis.

3.5.2. Unani Medical Centres in Allopathic Hospitals

Under the scheme of collocation of Ayush centres in Allopathic hospitals in Delhi, a Unani Medical Centre was established at Dr. Ram Manohar Lohia (RML) Hospital on 14 January 1998 with a view to provide Unani treatment facility to the patients desirous of taking treatment of this system. On public demand, another Unani Specialty Centre started functioning at Deen Dayal Upadhyay (DDU) Hospital, New Delhi on 01 November 2010. A new Unani Medical Centre was established at VMMC & Safdarjung Hospital, New Delhi on September 13, 2020. These centres are run by the Council. Besides the General Outpatient Department (GOPD) facilities, these centres provide specialized Unani treatment for some selected disorders like vitiligo, eczema, psoriasis, rheumatoid arthritis, bronchial asthma, sinusitis, infective hepatitis, diabetes mellitus, etc.

During the reporting period, 32,158 patients were treated at Unani Medical Centre in Dr. RML Hospital, 25,598 patients at Unani Speciality Centre in DDU Hospital, New Delhi and 21,111 patients at Unani Medical Centre at Vardhman Mahavir Medical College & Safdarjung Hospital, New Delhi. Patients visiting the centres were suffering from chronic diseases. Counseling of patients, particularly senior citizens, was also done to improve their physical activities and mental health.

3.5.3. Health Melas / Camps

The Council organized health camps through its Institutes/Units with a view to create health awareness among the masses and to provide treatment through Unani system of medicine. During the reporting period, 54 health camps were organized and 2,585 patients were treated in these camps. Lectures on preventive and promotive health aspects were also delivered by the physicians of the Council. Referral of the patients to the Council's centres as well as other hospitals was also done.

3.5.4. Activities under Gender Component Plan for Women

The Council continued research and treatment facilities for women under Gender Component Plan. Treatment facilities were made available to women at all clinical centres of the Council. Besides, female patients in the pockets adopted under Mobile Clinical Research Programme were also treated by the physicians in the Mobile OPD Scheme. During the reporting period, 4,71,486 female patients in different OPDs were treated. Efficacy of Unani pharmacopoeial formulations was also validated under this component. Health lectures / group meetings on preventive and promotive health aspects were also organized in the pockets adopted under Mobile Clinical Research Programme. Published literature on preventive, promotive, and curative health aspects was also distributed among the masses. Clinical studies on the diseases specific to female such as *Ihtibās al-Ṭamth* (amenorrhoea), *Kathrat al-Ṭamth* (Menorrhagia), *Sayalān al-Raḥim* (leucorrhoea) and *Sū' al-Qinya* (anaemia) also continued.

3.5.5. Activities in the North-Eastern Region

The two centres of the Council in the North-Eastern Region – Regional Research Institute of Unani Medicine Silchar and Clinical Research Unit, Imphal – continued Research/GOPD Programmes.



During the reporting period RRIUM, Silchar and CRU, Imphal continued Research/GOPD Programmes. A total of 96,800 beneficiaries were treated. The most commonly occurring diseases were *Waja' al-Mafāṣil* (rheumatoid arthritis), *Ishāl* (diarrhoea), *Ḥummā* (fever), *Sayalān al-Raḥim* (leucorrhoea), *Sū' al-Haḍm* (dyspepsia), *Ḥummā Ajāmiyya* (malaria) and *Zaḥīr* (dysentery). The patients were treated with Unani pharmacopoeial drugs.

3.5.6. Ayush Wellness Centre - President Estate

Ayush Wellness Clinic was established in President Estate, in the year 2015 with a view to provide medical care through various streams of Ayush (viz. Ayurveda, Yoga and Naturopathy, Unani, Siddha & Homeopathy) to the President, officials of President's Secretariat and residents of the President's Estate.

During the reporting period, health care services were provided through OPD and Regimenal therapy to the patients. A total of 3,679 patients were treated in Unani OPD and 1,790 were treated in Regimenal Therapy Section.

3.5.7. Unani Speciality Clinic at AIIA, New Delhi

A Unani Speciality Clinic was established at All India Institute of Ayurveda (AIIA), New Delhi with a view to provide medical care through Unani Medicine.

During the reporting period, health care services were provided through OPD and regimenal therapy. A total of 3,156 patients were treated in Unani OPD and 1,864 in Regimenal Therapy Section by Unani physicians.

3.5.8. Mobile Healthcare Programme under Scheduled Caste Sub-Plan

The CCRUM operates a Mobile Healthcare Programme under the Scheduled Caste Sub-Plan (SCSP) at 12 centers: NRIUMSD, Hyderabad; CRIUM, Lucknow; RRIUM, New Delhi; and facilities in Chennai, Mumbai, Aligarh, Patna, and Kolkata; RRC, Prayagraj; and CRU, Bhopal, Meerut, and Bengaluru. This program aims to extend healthcare services to the Scheduled Caste (SC) population at their doorstep.

The objectives include screening and examining the health status of the SC population through Mobile OPDs and health camps, and providing Unani treatment to patients suffering from various diseases. The program also seeks to raise awareness among the masses regarding preventive, promotive, and curative health aspects through lectures, group meetings, health camps, and the distribution of educational literature. Five villages with a predominantly SC population were identified for the program at each center.

During the reporting period, a total of 13,25,686 individuals were covered, including 7,91,909 from the SC population, with 141,265 individuals benefiting from the program.

3.5.9. Mobile Healthcare Programme under Tribal Sub Plan

Similar to the Mobile Healthcare Programme under the Scheduled Caste Sub-Plan, the CCRUM operates a Mobile Healthcare Programme under the Tribal Sub-Plan (TSP) at RRIUM in Bhadrak and Srinagar, and CRU in Burhanpur and Kurnool. This program extends healthcare services to the Scheduled Tribe (ST) population at their doorstep.

The program aims to screen and examine the health status of the ST population in Mobile OPDs and health camps, providing Unani treatment to patients suffering from various diseases. Additionally, it strives to create awareness among the masses on preventive, promotive, and curative health aspects through lectures, group meetings, health camps, and



the distribution of literature. Five villages with a predominantly ST population were identified for the program at each center.

During the reporting period, a total of 60,100 individuals were covered, including 47,059 from the ST population, with 44,931 individuals benefiting from the program.

3.6. Linking Education with Research

To integrate education with research and leverage the comprehensive facilities available at its institutes, the CCRUM has been conducting postgraduate (MD) programmes in Unani Medicine at the National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad, and the Regional Research Institute of Unani Medicine (RRIUM), Srinagar. These programmes are affiliated with Kaloji Narayana Rao University of Health Sciences, Warangal (Telangana), and the University of Kashmir, Srinagar, respectively. During the reporting period, thirty-three students were admitted, with an intake of nine students in each discipline of *Mu'ālajāt* (Medicine) and *ʿIlm al-Adwiya* (Pharmacology) at NRIUMSD, Hyderabad, and nine students in *Mu'ālajāt* and six students in *ʿIlm al-Adwiya* at RRIUM, Srinagar. Thirty-two students were awarded degrees in both disciplines across both institutes during this period.

The students underwent rigorous training through a structured academic schedule, which included theoretical classes, hands-on practical sessions, bedside teaching, and dissertation projects. The institutes also organized monthly meetings for postgraduate training, focusing on clinical and research skills, the development of protocols, case presentations, and discussions. Students were posted in various OPDs and IPD wards for clinical training on a rotational basis. Additionally, the academic activities encompassed seminars, journal clubs, and tutorials, with faculty members conducting classes in accordance with the prescribed syllabus. Alongside their classes, students were actively engaged in their thesis work.

During the reporting period, several meetings of the Departmental Research Committee, Board of Studies, and Institutional Ethics Committee were held to discuss, evaluate, and approve research proposals for thesis work.

3.7. Pharmacovigilance Programme

The Ministry of Ayush has a Central Sector Scheme of Pharmacovigilance of Ayurveda, Siddha, Unani and Homoeopathy Drugs which intends to facilitate the establishment of three-tier network of National Pharmacovigilance Centre (NPvCC), Intermediary Pharmacovigilance Centres (IPvCCs) and Peripheral Pharmacovigilance Centres (PPvCC). Prime objective of the scheme is to develop the culture of documenting adverse effects and undertake safety monitoring of Ayurveda, Siddha, Unani and Homoeopathy drugs and surveillance of misleading advertisements appearing in the print and electronic media.

The CCRUM is implementing the pharmacovigilance programme and eight of its research centres have been designated as Peripheral Pharmacovigilance Centres (PPvC). These centres are actively engaged in monitoring, assessing, understanding, preventing, and reporting adverse drug reactions (ADRs), scrutinizes misleading or objectionable advertisements appearing in print and electronic media, and reporting them to state drug licensing authorities. Further, they conduct awareness lectures, workshops, seminars and other IEC activities aiming to create awareness and foster a reporting culture among stakeholders including practitioners, pharmacists, health workers, and patients. Since inception of pharmacovigilance program of ASU&H drugs, the CCRUM through its periphe ral



institutes, has reported 308 ADRs, 5,556 misleading advertisements, and conducted nearly 450 awareness programs including 4 national level seminars.

During the reporting period, a total of 57 ADRs reported by different PPvCs of CCRUM:

S. N.	Name of PPvC	ADRs Reported
1.	NRIUMSD, Hyderabad	10
2.	CRIUM, Lucknow	01
3.	RRIUM, Mumbai	10
4.	RRIUM, Chennai	03
5.	RRIUM, Srinagar	14
6.	RRIUM, New Delhi	08
7.	RRIUM, Kolkata	04
8.	RRIUM, Bhadrak	07
Total		57

Other activities conducted by the CCRUM PPvCs under the Pharmacovigilance Programme are summarized in the table below:

S. N.	Event /Activity	Date	Venue
1.	Pharmacovigilance awareness camp	Jun 15, 2023	Ghosh Para, North 24 Parganas, West Bengal
2.	Pharmacovigilance awareness programme for patients and general public	Jun 24, 2023	RRIUM, Chennai
3.	National webinar on pharmacovigilance	Jul 24, 2023	RRIUM, Chennai
4.	Pharmacovigilance awareness programme	Sep 25, 2023	RRIUM, Srinagar
5.	National seminar on pharmacovigilance of ASU&H drugs	Nov 23, 2023	RRIUM, Chennai
7.	Seminar-cum-awareness programme on pharmacovigilance of ASU&H drugs	Mar 07, 2024	RRIUM Srinagar
8.	National seminar on pharmacovigilance of ASU&H drugs	Mar 07, 2024	RRIUM, Silchar
9.	Awareness programme on pharmacovigilance of ASU&H drugs for Ayush healthcare professionals (hybrid mode)	Mar 21, 2024	RRIUM, Chennai
10.	Capacity building program on pharmacovigilance of ASU&H drugs	Feb 23-24, 2024	NIUM, Bengaluru

3.8. Development of Benchmarks for *Hijāma* (Cupping Therapy)

The CCRUM completed a pioneering project to develop 'Standard Operating Procedures (SOPs) for *Hijāma* (Cupping Therapy)', a key regimenal therapy in Unani Medicine known for its effectiveness in pain relief, detoxification, and humoral balance restoration. Addressing the absence of formal practice guidelines, the CCRUM formulated SOPs covering every



stage—pre-cupping, cupping, and post-cupping. Developed through extensive and collaborative consultations with domain experts, these SOPs incorporate input from a diverse range of specialists. Their feedback shaped every aspect of the document, from its structure to specialised technical details. This publication ensures adherence to sterilisation and infection control standards, providing practitioners with essential protocols for safe, consistent, and effective delivery of *Hijāma* therapy.

3.9. Development of STGs for Musculoskeletal Disorders

In a landmark achievement, the CCRUM contributed to *Standard Treatment Guidelines on Management of Common Musculoskeletal Disorders in Unani System of Medicine*, developed by the Ayush Vertical, Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India. Developed by leading experts and contributors mostly from the CCRUM, these guidelines underscore the efficacy of Unani medicine in addressing public health challenges, especially in managing musculoskeletal disorders like osteoarthritis, rheumatoid arthritis, cervical and lumbar spondylosis, fibromyalgia, and adhesive capsulitis.

The STGs provide a comprehensive framework, including case definitions, epidemiological context, and Unani perspectives on etiology, pathology, and clinical presentation. Detailed treatment protocols outline preventive measures, do's and don'ts, and recommended Unani medicines—both single and compound formulations for internal and external use. Additionally, the guidelines feature diagnostic criteria, differential diagnoses, clinical examination methods, and principles of management, thoughtfully integrating conventional medical terminology for accessibility and clarity.

This publication reflects CCRUM's ongoing dedication to incorporating Unani medicine into mainstream healthcare, enhancing public well-being through the integration of traditional and evidence-based practices.

3.10. Setting Benchmarks: Contribution to BIS Standards for Unani Medicine

The Bureau of Indian Standards (BIS), India's National Standards Body, has taken significant strides in advancing the Ayush sector by establishing a dedicated Ayush department to enhance the safety, efficacy, and quality of Ayush products and practices. Under this department, the BIS has formed seven sectional committees, each focused on a specific system and working alongside stakeholders, scientific bodies, and regulatory authorities to set evidence-based standards that meet both national and international benchmarks.

The CCRUM has been pivotal in developing these standards for Unani medicine. With a CCRUM Research Officer as the member secretary of the Unani Sectional Committee, and additional officers contributing in various capacities, CCRUM's efforts have led to the BIS publishing the following critical Unani standards:

- IS 18750 (Part 1): 2024 – *Unani Medicine — Glossary of Terms* Part 1: Standardised Terminology Used for Fundamental Principles
- IS 18750 (Part 2): 2024 – *Unani Medicine — Glossary of Terms* Part 2: Standardised Terminology Used for Diseases of Head and Nervous System
- IS 18750 (Part 3): 2024 – *Unani Medicine — Glossary of Terms* Part 3: Standardised Terminology Used for Diseases of Eye



- IS 18754: 2024 – *Narjīl Daryāṭ* (*Lodoicea maldivica* Pers. Syn. *L. seychellarum* Labill.) Dried Endosperm for Use in Traditional Medicine — Specification
- IS 18760: 2024 – *Uṣṭūkhūdūs* (*Lavandula stoechas* L.) Dried Inflorescence for Use in Traditional Medicine — Specification
- IS 18774: 2024 – *Gulnār Fārsī* (*Punica granatum* L.) Dried Flower for Use in Traditional Medicine — Specification
- IS 18782: 2024 – *Anjīr Dashtī* (*Ficus hispida* L. f.) Dried Fruit for Use in Traditional Medicine — Specification

3.11. Strategic MoUs for Advancing Research and Development

Collaborative partnerships are essential for advancing research, fostering innovation, and building capacity across various disciplines. For the CCRUM, these partnerships enable access to diverse expertise, support interdisciplinary research, and promote Unani medicine nationally and globally. Through well-structured Memorandums of Understanding (MoUs) with leading research institutions, universities, and scientific organizations, the CCRUM facilitates knowledge exchange, skill enhancement, and joint initiatives in critical areas such as drug discovery, safety and efficacy studies, standardization, and molecular research. By leveraging the collective resources and expertise of its partners, the CCRUM strengthens its research impact, addresses contemporary healthcare challenges, and integrates Unani principles into modern healthcare, reinforcing its role in public health and policy.

During the reporting period, the CCRUM forged collaboration with the following 16 imminent institutions and signed MoUs for different purposes:

S. N.	Name of the Institute	Date	Purpose
1	SRMIST (Sri Ramaswamy Memorial Institute of Science and Technology), Tamil Nadu	Jul 03, 2023	To collaborate on research and education across various regional institutes, fostering research in areas of mutual interest, such as new drug development, preclinical safety and efficacy studies, pharmaceutical analysis, quality control, and microbiological studies of Unani formulations.
2	ICMR-NIRT (Indian Council of Medical Research-National Institute for Research in Tuberculosis)	Jul 04, 2023	To advance knowledge based on reciprocity and mutual benefits. Collaboration between CCRUM and ICMR-NIRT aims to address challenges related to the standardization and pharmacological evaluation of classical and new Unani formulations.
3	NCISM (National Commission for Indian System of Medicine), New Delhi	Aug 02, 2023	To undertake joint training, skill development, research, consultancy, and publications in various scientific aspects related to Unani System of Medicine (USM).
4	Integral University, Lucknow	Aug 24, 2023	To foster collaboration between CCRUM and Integral University, providing opportunities for mutual growth and development of Unani formulations. The MoU facilitates knowledge advancement based on reciprocity, mutual benefits, and regular interactions to address





S. N.	Name of the Institute	Date	Purpose
			challenges in formulation standardization and pharmacological evaluation.
5	SKUAST (Sher-e-Kashmir University of Agricultural Sciences and Technology), Kashmir, J&K	Sep 01, 2023	To advance knowledge through reciprocal efforts, mutual benefits, and frequent interactions. The CCRUM-SKUAST collaboration aims to address challenges in the standardization and evaluation of classical and new Unani formulations.
6	University of Kashmir, J&K	Sep 01, 2023	To foster collaboration with CCRUM, enhancing opportunities to develop and validate Unani formulations. The MoU supports the advancement of knowledge through mutual benefits, reciprocity, and regular interactions to address formulation challenges.
7	NIUM (National Institute of Unani Medicine), Bengaluru	Sep 16, 2023	To collaborate on research and education across various regional institutes, fostering research in areas of mutual interest, such as new drug development, preclinical safety and efficacy studies, pharmaceutical analysis, quality control, and microbiological studies of Unani formulations.
8	CCRH (Central Council for Research in Homeopathy), New Delhi	—	To house both the Homeopathy and Unani Research Institutes (RRIH and RRIUM) in Kharghar, Navi Mumbai, establishing a model for intra-Ayush collaboration through joint projects and experience sharing.
9	NIN (National Institute of Nutrition), Hyderabad	Dec 14, 2023	To collaborate on research and education in USM through regional institutes, encouraging joint efforts in areas of mutual interest, such as drug development, preclinical safety studies, pharmaceutical analysis, quality control, and microbiological studies of Unani formulations.
10	NIMSME (National Institute for Micro, Small, and Medium Enterprises), Hyderabad	Dec 14, 2023	To undertake joint training, skill development, research, consultancy, and publications in scientific areas related to USM.
11	NIPER (National Institute of Pharmaceutical Education and Research), Hyderabad	Dec 14, 2023	CCRUM and NIPER, along with NRIUMSD, Hyderabad, aim to foster collaboration in areas such as new drug development, preclinical safety and efficacy studies, pharmaceutical analysis, quality control, and microbiological studies of Unani formulations.
12	CSIR-IICT	Dec 14, 2023	To advance knowledge based on reciprocity and mutual benefits. This collaboration





S. N.	Name of the Institute	Date	Purpose
	(CSIR-Indian Institute of Chemical Technology), Hyderabad		between CCRUM and CSIR-IICT aims to tackle challenges in producing genuine herbal-based drugs and pharmacognostical evaluation.
13	IIT (Indian Institute of Technology), Bombay	Nov 20, 2023	To collaborate on research and education through various regional institutes, encouraging research in areas of mutual interest, including new drug development, preclinical safety and efficacy studies, pharmaceutical analysis, QC, and microbiological studies of Unani formulations.
14	CSIR-CCMB (Centre for Cellular and Molecular Biology), Hyderabad	Feb 12, 2024	To advance knowledge through a collaborative effort between CCRUM and CSIR-CCMB, addressing challenges related to understanding the molecular-level effects of Unani medicine.
15	SMC (Silchar Medical College), Silchar, Assam	Mar 07, 2024	To promote cooperation in healthcare education, research, and training, fostering interaction and collaboration among faculty, scientists, researchers, staff, and students through joint research, training, and resource sharing.
16	CSIR-NEIST (CSIR-North East Institute of Science & Technology), Jorhat, Assam	Mar 07, 2024	To advance knowledge based on reciprocity and mutual benefits. Collaboration between CCRUM and CSIR-NEIST focuses on producing genuine herbal-based Unani drugs and pharmacognostical evaluation.



4. INFORMATION, EDUCATION & COMMUNICATION

4.1. Library Services

The CCRUM has a Library and Information Centre (LIC) at its headquarters, dedicated to collecting and preserving literature on Unani Medicine while disseminating information to researchers, academicians, and practitioners in the field.

During the reporting period, the LIC's services were fully automated through a Wide Area Network (WAN). It provided services to readers via the e-Granthalaya Library Software, which manages the Web Online Public Access Catalogue (Web-OPAC), book circulation, and other functions. A total of 142 new books were acquired, comprising 106 purchased books and 36 received on a complementary basis. The data for these new additions was also uploaded to the e-Granthalaya cloud database.

In total, 1,768 books were in circulation, including 142 books circulated through the Inter-Library Loan Service to the Athens Academy Library and member libraries of DELNET. The library subscribed to 3,653 issues of daily newspapers and 134 issues of popular magazines. Additionally, it received 118 journal issues, of which 34 were in Hindi and 38 related to Unani Medicine. Alongside these journals, the library also received 12 newsletters.

The LIC undertook physical processing and barcoding of 53 books after binding. The centre provided spiral binding, photocopying, and reference services to readers. It carried out comb or thermal binding for 157 documents and photocopied a total of 12,645 pages. Long and short-range reference services were offered through WhatsApp and email to researchers and staff members of the CCRUM. A Facebook page was also maintained throughout the year to facilitate reference services and provide recent updates to researchers. The LIC collected Rs. 5,305.00 in user charges for annual membership, photocopying, spiral binding services, and consultations.

The library continued to digitally publish and circulate the Medical News Update Service among 780 subscribers daily. The Selective Dissemination of Information (SDI) service also remained operational at the LIC. Under this service, 314 news clippings were collected, with significant ones sent to the Director General and Deputy Director General (Unani) and displayed on the library notice board. In addition to digitizing rare manuscripts, books, and journals and developing a digital repository, the LIC also created a "Digital Archive of CCRUM News Clippings" to preserve news about the CCRUM and initiated work on the AYUSH Information Hub Project.

The LIC maintained its institutional memberships with the British Council Library, the Medical Library Association of India, the American Resource Centre, and the Developing Library Network (DELNET) throughout the year.

During the reporting period, 348 members and guest researchers visited the LIC to access its resources.

4.2. Organization of Conferences, Seminars, Workshops, etc.

4.2.1. Unani Day 2024 and National Conference on Unani Medicine

The CCRUM organized Unani Day 2024 and National Conference on "Unani Medicine for One Earth, One Health" at the A P Shinde Symposium Hall, NASC, Pusa, New Delhi, on February 12, 2024. The event marked the celebration of Unani Medicine's contributions to health and wellness, gathering leaders in traditional medicine, Ayush experts, researchers,



and stakeholders from diverse sectors. Vaidya Rajesh Kotecha, Secretary of the Ministry of Ayush, inaugurated the event, emphasizing India's growing role as a global leader in Traditional Medicine and the importance of evidence-based research in Ayush. He commended the expanding research data generated within the sector, a crucial factor in establishing the scientific foundation for Unani and other traditional medicines.

The event was also attended by Vaidya Jayant Deopujari, Chairman, National Commission for Indian System of Medicine, New Delhi, Prof. Shakil Ahmad Romshoo, Vice Chancellor, Islamic University of Science & Technology, Awantipora, J&K, Prof. (Dr.) Nazir Ah. Ganai, Vice Chancellor, SKUAST-Kashmir, Dr. Sunchu Glory Swarupa Director General, National Institute for Micro, Small and Medium Enterprises, Hyderabad, Dr. M. A. Qasmi, Adviser (Unani), Ministry of Ayush and Dr. N. Zaheer Ahmed, Director General, CCRUM and other officials from the Ministry of Ayush.

Speaking as the chief guest, Vaidya Rajesh Kotecha emphasized the significance of Unani Day in recognizing the substantial role Unani Medicine plays in alleviating the suffering of people. He highlighted the theme of Unani Day 2024, "Unani Medicine for One Earth, One Health," underscoring the shared responsibility for the planet's welfare and the importance of collaboration in addressing global health challenges. He reiterated the Indian government's commitment to integrate and promote traditional systems of medicine, including Unani, emphasizing their holistic approach to healthcare and preventive measures. He highlighted the visionary support and direction of Prime Minister Shri Narendra Modi, which has facilitated significant advancements in healthcare infrastructure, research collaborations, export promotion mechanisms, educational reforms, and the global expansion of India's traditional medicine system.

Earlier in his welcome address, Dr. N. Zaheer Ahmed, Director General, CCRUM paid tribute to revered freedom fighter and pioneer of scientific research in Unani Medicine in India, Hakim Ajmal Khan. He said that Unani Day is a special occasion when we acknowledge the significant role Unani Medicine has been playing in alleviating the suffering of the masses.

The inaugural function concluded with a vote of thanks by Dr. M. A. Qasmi, Adviser (Unani) at the Ministry of Ayush.

On this occasion, various publications and e-books, a Mobile App on Unani compound drugs, and a documentary, all developed by the CCRUM, were released during the event. Furthermore, NABH and NABL certificates were awarded to four CCRUM institutes, and a Memorandum of Understanding (MoU) exchanged between CCRUM and the Centre for Cellular and Molecular Biology, Hyderabad, marked a significant collaboration.

The valedictory function was addressed by Prof. (Dr.) Atul Goel, Director General, Directorate General of Health Services, Dr. M A Qasmi, Advisor (Unani), Ministry of Ayush, Shri Satyajit Paul, Deputy Director General, Ministry of Ayush, Prof. Dinesh Kumar, Vice Chancellor, Gurugram University, Gurugram, Prof. Shakil Ahmad Romshoo, Vice Chancellor, Islamic University of Science & Technology, J&K, Dr. Sunchu Glory Swarupa, Director General, National Institute for Micro, Small and Medium Enterprises, Hyderabad and Dr. Ranjana Aggarwal, Director, CSIR-National Institute of Science Communication and Policy Research, New Delhi.

During the technical sessions, experts and luminaries from the field of health sciences shared their knowledge, experiences and expertise on different aspects of the conference theme. Stakeholders from industry, academia and research organizations engaged in development



of Unani Medicine and related health sciences attended the conference in a large number. A panel discussion on the theme of conference was chaired by Prof. Asim Ali Khan, Chairman, SAC, CCRUM.

The titles of the CCRUM printed books released are 'Jahan-e-Tib (Alami Waba Number)', 'Adwiya Kulwiyya - A Compendium of Classical and Evidence-based Unani Drugs Acting on the Kidneys', 'Adwiya Qalbiyya – Qadīm-o-Jadīd Taḥqīqāt kī Raushnī mein' (A compendium of classical and evidence-based Unani drugs acting on the heart), 'Safety and Efficacy of UNIM-001 and UNIM-003 in Baraṣ (Vitiligo) - A Technical Report' and 'UPLC Fingerprinting and Pharmacopoeial Studies of Unani Coded Compound Formulation UNIM-040', while titles of e-books are 'Muheet-i-Azam, vol. 1 (Urdu)', 'Kitabul Mi-at fit-Tib (Arabic)' and 'Standard Operating Procedures for Hijama (Cupping)'. Appreciation certificates were also awarded to CCRUM scientists for Best Research Papers.

4.2.2. Inauguration of Pharmacy Block & 'Ilāj bi'l-Tadbīr (Regimenal Therapy) Unit

Dr. Munjpara Mahendrabhai Kalubhai, Minister of State for Ayush and Women & Child Development, Government of India, inaugurated a new Pharmacy Block and 'Ilāj bi'l-Tadbīr (Regimenal Therapy) Unit developed by the Central Council for Research in Unani Medicine (CCRUM) at the Regional Research Institute of Unani Medicine (RRIUM), Chennai, on January 6, 2024.

In his address, Dr. Munjpara highlighted India's leadership in Unani Medicine, supported by a vast network of educational, research, and healthcare institutions. He remarked that these state-of-the-art facilities will address the healthcare needs of the community.

The event commenced with the unveiling of the inauguration plaque for both facilities, in the presence of prominent dignitaries, including Dr. Kalanidhi Veeraswamy, Member of Parliament, Chennai North; Thiru. Idream R. Murthy, Member of Legislative Assembly, Royapuram, Chennai; Thiru. Gagandeep Singh Bedi, IAS, Additional Chief Secretary, Department of Health & Family Welfare, Government of Tamil Nadu; Smt. Mythili K. Rajendran, IAS, Commissioner, Directorate of Indian Medicine & Homeopathy, Government of Tamil Nadu; Dr. Kaustubh Upadhyaya, Advisor (Ayurveda), Ministry of Ayush; Prof. Rabinarayan Acharya, Director General, CCRAS; and Prof. Dr. R. Meenakumari, Director General, CCRS.

In his welcome address, Dr. N. Zaheer Ahmed, Director General of CCRUM, emphasized RRIUM, Chennai's longstanding contributions to quality healthcare and multidisciplinary research in Unani Medicine since its establishment on July 6, 1979.

The dignitaries released a publication titled *Regional Research Institute of Unani Medicine, Chennai – Activities and Achievements*, along with its digital version, which provides a comprehensive overview of the institute's history, objectives, infrastructure, and achievements in research and development, including efforts in standardization and quality control of Unani drugs, medicinal plant cultivation, clinical research, and public health initiatives. A video showcasing the institute's infrastructure and healthcare facilities was also launched.

The event was graced by officials from various Chennai-based institutions, including the Central Council for Research in Siddha, the National Institute of Siddha, SRM Institute of Science and Technology, ICMR-National Institute for Research in Tuberculosis, Government Unani Medical College, Government Siddha Medical College, Government Yoga & Naturopathy Medical College, Homoeopathy Research Institute for Disabilities, the Centre



for Technology in Traditional Medicine at Anna University, Justice Basheer Ahmed Sayeed College for Women, Sri Sairam Siddha Medical College, the University of Madras, the State Licensing Authority for ISM, Dr. MGR Medical University, M.V. Diabetes Research Centre, and the National Institute of Unani Medicine, Bengaluru.

The program concluded with a vote of thanks by Dr. R.P. Meena, Assistant Director (Chemistry), CCRUM, New Delhi.

4.2.3. National Workshop on Finalization of SOPs for *Hijāma*

The CCRUM organized a “National Workshop-cum-Brainstorming Session on Finalization of SOPs for *Hijāma*” at Jamia Millia Islamia, New Delhi on January 29, 2024.

In his introductory remarks, Dr. N. Zaheer Ahmed, Director General, CCRUM informed about the importance of bringing standards in healthcare services and procedures. He gave an update on the work already carried out since past two months by three working groups constituted for the purpose. He informed that the groups have members who are practically, scientifically and academically involved in the cupping procedure.

Prof. S. Shakir Jamil, Former DG, CCRUM gave a power point presentation on “Concept and methodology for developing of SOPs on *Hijāma* (cupping therapy) and briefed on the outline adopted for the same by the working groups.

Prof. Sunil Kohli, Department of Medicine, Hamdard Institute of Medical Sciences & Research, New Delhi appreciated the initiative of CCRUM for development of SoPs on *Hijāma* and gave his valuable inputs.

Under the visionary and futuristic approach of Director General, Dr. N. Zaheer Ahmed, the CCRUM is taking a giant leap towards establishing and enhancing standard in *Hijāma* (cupping) practices. Their collective efforts over the past two months have resulted in a comprehensive draft. This work will go down in the history of Unani medicine where “Standard Operating Procedures for *Hijāma* (Cupping)” during this one-day scientific event was finalized and adopted.

The program concluded with vote of thanks presented by Dr. Rashidullah Khan, Assistant Director (Unani), Incharge of Hakim Ajmal Khan Institute for Literary and Historical Research in Unani Medicine, New Delhi.

4.2.4. National Seminar on Pharmacovigilance of ASU&H Drugs

The CCRUM organized a National Seminar on the Pharmacovigilance of ASU&H (Ayurveda, Siddha, Unani, and Homoeopathy) drugs under the theme: *Good Pharmacovigilance Practices - Ensuring Medication without Harm*, at RRIUM, Chennai on November 23, 2023.

The inaugural session commenced with the Tamil Thaaivazhthu invocation, followed by a warm welcome from Dr. Athar Parvez Ansari, Research Officer (Unani), RRIUM, Chennai, to dignitaries, guests, and the audience. Dr. C. Muthamizhchelvan, Vice Chancellor of SRM Institute of Science and Technology (SRMIST), Chengalpattu, served as the Chief Guest, addressing the gathering with insightful remarks. The seminar was graced by the presence of Prof. (Dr.) R. Meenakumari, Director General of the Central Council for Research in Siddha (CCRS), Ministry of Ayush, and Dr. Ameer Jahan, Chairman of the All India Herbal Farmers, Traders, Exporters & Research Society, Chennai, who were Guests of Honour. Dr. N. Zaheer Ahmed, Director General of CCRUM, presided over the session and delivered the presidential address. Other esteemed attendees included representatives from the Central



Council for Research in Siddha (CCRS), the National Institute of Ayurveda (NIA), Jaipur, the National Institute of Siddha (NIS), Chennai, the National Institute of Unani Medicine (NIUM), Bengaluru, SRMIST, ICMR-National Institute for Research in Tuberculosis (ICMR-NIRT), Government Unani Medical College (GUMC), and Government Siddha Medical College (GSMC), all from Chennai.

The seminar featured two technical sessions, where prominent speakers explored the theme of *Good Pharmacovigilance Practices - Ensuring Medication without Harm*. Dr. Mohammad Khalid, Assistant Drug Controller (Unani), Govt. of NCT of Delhi, delivered the keynote address. Other notable speakers included Dr. Sudipta Kumar Rath, Associate Professor & Coordinator of the Intermediary Pharmacovigilance Centre (IPvC) at NIA, Jaipur; Prof. M. A. Quamari, HoD, Amraz-e-Jild wa Tazeeniyat & Coordinator of IPvC at NIUM, Bengaluru; Dr. P. Shanmugapriya, Associate Professor & Coordinator of IPvC at NIS, Chennai; Dr. Noman Anwar, Research Officer (Unani) & Coordinator of the Peripheral Pharmacovigilance Centre (PPvC) at RRIUM, Chennai; and Dr. Athar Parvez Ansari, Research Officer (Unani), RRIUM, Chennai.

The seminar witnessed enthusiastic participation from around 130 delegates, including Ayush professionals, researchers, and academicians from across the country. The sessions offered a platform for comprehensive, insightful, and engaging presentations, significantly contributing to the knowledge of Ayush researchers, professionals, and stakeholders. This event is expected to be a pivotal step in promoting patient safety and public health by ensuring the safe and effective use of ASU & H pharmaceuticals.

The program concluded with a vote of thanks by Dr. Usama Akram, Research Officer (Unani) S-II, CCRUM, New Delhi.

4.2.5. NABL Awareness Workshop

The CCRUM organized a NABL Awareness Workshop for Medical and Non-Medical Ayush Scientists at the Regional Research Institute of Unani Medicine, Mumbai on November 02, 2023.

In his introductory remarks, Dr. N. Zaheer Ahmed, Director General of CCRUM, emphasized the necessity of NABL accreditation for all Ayush research institutes. He underscored the importance of MoUs between CCRUM and leading institutions in India to produce evidence-based data in Unani Medicine, bridging Unani practices with the scientific community.

Dr. Kousthubha Upadhyaya, Advisor (Ayurveda) at the Ministry of Ayush and Chief Guest of the event, informed attendees that approximately 200 Ayush hospitals are NABH accredited, with the current focus now shifting toward NABL accreditation—a priority for both the Ministry and the Government.

Dr. Sunil Vilasrao Gitte, Director of the National Institute of Public Health Training and Research, Mumbai, elaborated on the significance of standardization in healthcare delivery and its impact on research. Professor Amit Agrawal, Dean at IIT Bombay, highlighted the potential of traditional medicine in advancing health through Research and Development initiatives.

The event concluded with a vote of thanks by Dr. Nirmala Devi, Research Officer Incharge, RRIUM, Mumbai. The workshop also featured the release of a CCRUM brochure in both Hindi and English, showcasing recent activities and achievements. Ayush scientists from various disciplines benefited significantly from the program.



4.2.6. National Seminar on Pharmacovigilance of ASU&H Drugs

The CCRUM organized a National Seminar on the Pharmacovigilance of ASU & H (Ayurveda, Siddha, Unani, and Homoeopathy) drugs. Held under the theme *"Good Pharmacovigilance Practices - Ensuring Safe Medication,"* the seminar took place on March 7, 2024 at RRIUM, Silchar, in collaboration with Government Silchar Medical College Hospital, Silchar.

Dr. N. Zaheer Ahmed, Director-General of CCRUM, presided over the inaugural session, delivering the presidential address. Prof. Bhaskar Gupta, Principal of Silchar Medical College and Hospital, attended as the chief guest, delivering a keynote speech to the gathering. The event was further honoured by Dr. Virendra M. Tiwari, Director of CSIR-North East Institute of Science and Technology (CSIR-NEIST), Jorhat, Assam, as the special guest of honour, and by distinguished guests Dr. Manjula Das, Principal of Government Dental College, and Mrs. Ruikiya Nabiya Ahmed, Principal of BSc Nursing College, Silchar, who shared valuable insights with attendees.

The inaugural session began with a welcome address by Dr. Jamal Akhtar, Research Officer (Unani) Scientist-IV, CCRUM headquarters.

Over the course of the day, two technical sessions were held, providing a platform for esteemed speakers to discuss the seminar's central theme, *"Good Pharmacovigilance Practices - Ensuring Safe Medication."* The sessions featured comprehensive, insightful presentations that underscored the program's success, making the seminar highly enriching and valuable for all participants.

The event concluded with a vote of thanks by Dr. Akhtar Hussain Jamali, Research Officer Incharge, RRIUM, Silchar, who acknowledged the contributions of all participants and attendees.

4.2.7. Awareness Programme on Pharmacovigilance of ASU&H Drugs

The RRIUM, Chennai organized an awareness programme on the Pharmacovigilance of ASU&H (Ayurveda, Siddha, Unani, and Homoeopathy) drugs for Ayush healthcare professionals in hybrid mode on March 21, 2024.

Dr. N. Zaheer Ahmed, Director General of CCRUM, attended the event virtually, delivering the presidential address.

The technical session featured three eminent speakers who explored various aspects of pharmacovigilance. Dr. R. Ilavarasan, Assistant Director Incharge, CCRAS-Captain Srinivasa Murthy Central Ayurveda Research Institute, Chennai, discussed *"Signal Detection, Risk Assessment, and Management."* Dr. P. Thenmozhi, Research Officer (Siddha) & Program Coordinator at the Peripheral Pharmacovigilance Centre (PPvC), CCRS-Siddha Central Research Institute, Chennai, presented on *"Quality Control Analysis of ASU Drugs from a Pharmacovigilance Perspective,"* and Dr. Athar Parvez Ansari, Research Officer (Unani) at RRIUM, Chennai, spoke on *"Monitoring and Understanding Drug Safety in Unani Medicine."* The technical session was presided over by Dr. K. Kabiruddin Ahmed, Deputy Director, RRIUM, Chennai.

The programme began with an inaugural session that included an invocation and recitation from the Holy Qur'an, followed by a welcome address by Dr. Noman Anwar, Research Officer



(Unani) and Coordinator of the Peripheral Pharmacovigilance Centre (PPvC), RRIUM, Chennai.

The event concluded with a vote of thanks by Dr. Athar Parvez Ansari, Research Officer (Unani), RRIUM, Chennai.

The program proved to be highly beneficial in terms of content and discussions, with comprehensive and insightful presentations as key highlights. Over 95 delegates, including Ayush professionals, researchers, and academicians, participated actively and enthusiastically.

4.2.8. Hands-on Training Programme for Administrative Staff

The CCRUM organized a two-day hands-on training programme for administrative, establishment, and account-related matters from November 28-29, 2023, at its headquarters in New Delhi. The event, graced by Director General Dr. N. Zaheer Ahmed, gathered officers and staff from various CCRUM peripheral institutes, including RRIUM Silchar, CRU Bhopal, and others. Dr. Ahmed provided insights into enhancing administrative efficiency and productivity. The training offered practical knowledge on centralized processes, fostering a collaborative environment for improved coordination across CCRUM's network. The programme reinforced CCRUM's commitment to building a standardized and efficient administrative framework across its branches.

4.2.9. Vigilance Awareness Webinar

On November 7, 2023, the CCRUM held a webinar on vigilance awareness for CCRUM's officers and staff across peripheral institutes. Director General Dr. N. Zaheer Ahmed, Shri Navin Kaul from Ernst & Young LLP, and former Under Secretary Shri Anil Kumar Deswal delivered addresses on vigilance standards and integrity in professional conduct. Dr. Ghazala Javed and Dr. Pradeep Kumar coordinated the session, underscoring the significance of transparent practices. This initiative aligns with CCRUM's objective of fostering a culture of accountability and vigilance within its operations, contributing to the wider goal of promoting ethical practices across the Ayush sector.

4.2.10. Orientation Programme on CCRUM's Vision and Activities

The CCRUM organized a four-day virtual Orientation Training Programme titled "CCRUM: Vision, Activities, and Achievements" from October 3-6, 2023. The programme commenced with opening remarks by Director General Dr. N. Zaheer Ahmad. Key speakers included Dr. Ghazala Javed on CCRUM's profile, Prof. A. Venkat Raman on self-motivation, and Dr. Bhupinder Chaudhary on effective communication. The programme catered to newly recruited and existing researchers, covering various topics from bioethics to Unani plant cultivation. This training empowered CCRUM personnel with essential knowledge, fostering research excellence and underscoring CCRUM's role in advancing Unani Medicine through comprehensive, evidence-based methodologies.

4.2.11. Other Events

S. N.	Name of Event	Place	Duration
1.	Observance of World Environment Day	CCRUM Headquarters and peripheral institutes	Jun 05, 2023



S. N.	Name of Event	Place	Duration
2.	Lecture on "How to write a quality paper and how to publish it in a quality journal"	RRIUM, Chennai	Jun 09, 2023
3.	Hands-on training programme on ' <i>Ilāj bi'l-Tadbīr</i> '	RRIUM, Chennai	Jun 12-14, 2023
4.	Pharmacovigilance awareness camp	RRIUM, Kolkata	Jun 15, 2023
5.	Pharmacovigilance awareness programme	PPvC, RRIUM, Chennai	Jun 24, 2023
6.	Seminar on ASU drugs	RRIUM, Chennai	Jul 04, 2023
7.	Public lecture on mental health and stress management	RRIUM, Chennai	Jul 11, 2023
8.	Public lecture on role of Ayush in mental health	RRIUM, Mumbai	Jul 18, 2023
9.	National webinar on pharmacovigilance	RRIUM, Chennai	Jul 24, 2023
10.	Lecture on role of Unani Medicine in management of depression	RRIUM, Kolkata	Aug 08, 2023
11.	Standards in development and manufacturing of plant-based products - current trends	New Delhi	Aug 08, 2023
12.	Lecture on mental health at workplace	RRIUM, New Delhi	Aug 16, 2023
13.	Lecture on "Individuals with different <i>Mizāj</i> have different sensitivity to pain - A hypothesis"	CRIUM, Lucknow	Aug 17, 2023
14.	NABL awareness and ISO/IEC	DSRI, Ghaziabad	Aug 23-24, 2023
15.	National seminar on design, innovation, and entrepreneurship startups in Unani healthcare	RRIUM, Srinagar	Sep 01, 2023
16.	Pharmacovigilance awareness programme	RRIUM, Srinagar	Sep 25, 2023
17.	Public lecture on Swachhata	RRIUM, Chennai	Oct 03, 2023
18.	Webinar on Swachhata	Not specified	Oct 06, 2023
19.	Public lecture on Swachhata	RRIUM, Bhadrak	Oct 07, 2023
20.	Public lecture on Swachhata	RRIUM, Chennai	Oct 09, 2023
21.	Public lecture on Swachhata	CRIUM, Lucknow	Oct 09, 2023
22.	Public lecture on importance of cleanliness for health	NRIUMSD, Hyderabad	Oct 10, 2023
23.	Public lecture on Swachhata	RRIUM, New Delhi	Oct 10, 2023
24.	Public lecture on benefits of hand hygiene	CRIUM, Lucknow	Oct 10, 2023
25.	Public lecture on importance of cleanliness and personal hygiene	Village Bahrauli, Barabanki, Lucknow	Oct 10, 2023





S. N.	Name of Event	Place	Duration
26.	Public lecture on importance of cleanliness and personal hygiene	Gram Panchayat Madaripur, Lucknow	Oct 10, 2023
27.	Public lecture on importance of cleanliness	CRU, Bhopal	Oct 10, 2023
28.	Public awareness lecture on importance of cleanliness	CRU, Burhanpur	Oct 11, 2023
29.	Public lecture on importance of health benefits of cleanliness	CRIUM, Lucknow	Oct 12, 2023
30.	Public lecture on Swachhata	RRIUM, Kolkata	Oct 12, 2023
31.	Public lecture on importance of handwash	CRIUM, Lucknow	Oct 12, 2023
32.	Public lecture on <i>Clean India, Disease-free India</i>	NRIUMSD, Hyderabad	Oct 12, 2023
33.	Public lecture on segregation of biomedical waste and record keeping	NRIUMSD, Hyderabad	Oct 12, 2023
34.	Public lecture on Swachhata	CRU, Bhopal	Oct 13, 2023
35.	Public lecture on Swachhata	CRU, Burhanpur	Oct 13, 2023
36.	Public awareness lecture on Swachhata	UMC, RML Hospital, New Delhi	Oct 14, 2023
37.	Public lecture on <i>Swachhata hi Sewa</i>	CRIUM, Lucknow	Oct 14, 2023
38.	Public lecture on personal hygiene and cleanliness linked to health	RRIUM, Kolkata	Oct 14, 2023
39.	Public lecture on significance of cleanliness	UMC, Safdarjung Hospital, New Delhi	Oct 16, 2023
40.	Public awareness lecture on significance of cleanliness	CRIUM, Lucknow	Oct 16, 2023
41.	Public awareness lecture on promoting cleanliness	RRIUM, Srinagar	Oct 16, 2023
42.	Public lecture on <i>Swachh Bharat Abhiyan: Garbage-free India</i>	RRIUM, Chennai	Oct 17, 2023
43.	Public lecture on significance of cleanliness	CRIUM, Lucknow	Oct 17, 2023
44.	Webinar on <i>Swachhata hi Sewa</i>	NRIUMSD, Hyderabad	Oct 18, 2023
45.	Webinar on importance of Swachhata campaign	HAKILHRUM, Lucknow	Oct 18, 2023
46.	Awareness lecture on <i>Swachhata hi Sewa</i>	CRU, Burhanpur	Oct 18, 2023
47.	Webinar on cleanliness of surroundings and health	RRIUM, Chennai	Oct 19, 2023
48.	Public Lecture on Swachhata	CRIUM, Lucknow	Oct 19, 2023
49.	Public lecture on living for environment	HAKILHRUM	Oct 19, 2023





S. N.	Name of Event	Place	Duration
50.	Public awareness lecture on significance of cleanliness	UMC, DDU Hospital, New Delhi	Oct 19, 2023
51.	Public lecture on Swachhata	CRU, Bhopal	Oct 19, 2023
52.	Public lecture on importance of clean and hygienic surroundings	NRIUMSD, Hyderabad	Oct 19, 2023
53.	Public lecture on importance of cleanliness	CRU, Burhanpur	Oct 20, 2023
54.	Public lecture on cleanliness and healthy environment	UMC, AIIA, New Delhi	Oct 21, 2023
55.	Webinar on harms of single use plastics	DSRU, New Delhi	Oct 27, 2023
56.	Lecture on vigilance awareness	RRIUM, Srinagar	Nov 06, 2023
57.	Lecture on early detection and prevention of diabetes mellitus	RRIUM, Chennai	Nov 14, 2023
58.	Lecture on critical appraisal of a clinical trial	NRIUMSD, Hyderabad	Nov 22, 2023
59.	Programme on innovations in medicinal and aromatic plants as potential ventures	RRIUM, Srinagar	Dec 09, 2023
60.	National seminar on innovation, design, entrepreneurship, and startups in Unani Medicine	NRIUMSD, Hyderabad	Dec 14, 2023
61.	Six-day CME programme on R&D trends	NRIUMSD, Hyderabad	Dec 15-20, 2023
62.	Seminar on the role of Unani Medicine in lifestyle disorders	RRC, Prayagraj	Jan 31, 2024
63.	National seminar on Unani Medicine in lifestyle disorders	RRC, Prayagraj	Jan 31, 2024
64.	Foundation Day Celebration	NRIUMSD, Hyderabad	Feb 02, 2024
65.	Seminar on Unani Medicine in behavioural disorders	UMC, Goa	Feb 05, 2024
66.	International Women's Day	CCRUM Headquarters	Mar 08, 2024
67.	6 th Poshan Pakhwada	NRIUMSD, Hyderabad	Mar 09-23, 2024
68.	6 th Poshan Pakhwada	RRIUM, Prayagraj	Mar 13, 2024
69.	Lectures on the importance of millets	Wazir Ganj, Lucknow	Mar 14, 2024
70.	6 th Poshan Pakhwada	ICMR-NITM, Belagavi	Mar 14, 2024
71.	6 th Poshan Pakhwada	RRIUM, Srinagar	Mar 19, 2024
72.	6 th Poshan Pakhwada	RRIUM, New Delhi	Mar 20, 2024



S. N.	Name of Event	Place	Duration
73.	Public awareness programme on seasonal fruits and vegetables	RRIUM, Aligarh and Bhadrak	Mar 20, 2024
74.	Awareness programme on Poshan Pakhwada	CRIUM, Lucknow, RRIUM Silchar, and RRC, Prayagraj	Mar 21, 2024

4.3. Participation in Training and Capacity Building Programmes

The CCRUM places a high priority on continuous learning and skills enhancement for its workforce to advance research and ensure the highest standards in Unani Medicine. Throughout the reporting year, CCRUM staff actively participated in various training sessions, workshops, and capacity-building programmes organised at both national and international levels. These initiatives aimed to deepen knowledge in specialised fields, enhance research methodologies, and foster collaborative skills. Following is an indicative list of such training sessions, workshops, and capacity-building programmes.

S. N.	Name of Event	Place	Duration	Participants
1	Training and Capacity Building Session on PM Gatishakti National Master Plan	Gandhinagar, Gujarat	Apr 12-13, 2023	Dr. Nirmala Devi
2	Round Table Brainstorming Session on Role of Academia in Popularizing Unani	New Delhi	Apr 30, 2023	Dr. Younis I. Munshi
3	National Ayush Mission Conclave	Vigyan Bhawan, New Delhi	May 18-19, 2023	CCRUM Officers
4	Scientific Conference	Jhansi, U.P.	Jun 21, 2023	4 Officers from DSRU, New Delhi
5	Workshops on Primary Trauma Care	AIAC Hall, Dhanwantari Bhawan, New Delhi	Jun 26-Jul 1, 2023	5 Officers
6	India Today Health Conclave, <i>Khayal Bharat Ki Sehat Ka</i>	New Delhi	Aug 4, 2023	Director General, CCRUM
7	Traditional Medicine Global Summit	Gandhinagar, Gujarat	Aug 17-18, 2023	5 Officers
8	Workshop on Medicinal Leeches	Bhubaneshwar, Odisha	Aug 25-26, 2023	Dr. Mohd Tarique
9	Training Programme on IPR	RAV, New Delhi	Aug 28-29, 2023	4 Officers
10	Training on Designing & Conducting Clinical Trials	Belagavi, Karnataka	Sep 14-15, 2023	7 Officers



S. N.	Name of Event	Place	Duration	Participants
11	Continuing Unani Medical Education Programme	Nund Rishi Hall, SKUAST, Srinagar	Sep 19, 2023	8 Officers
12	6th National Workshop on Statistical Methods in Biomedical Research	ICMR-NIOH, Ahmedabad, Gujarat	Nov 1-3, 2023	Shri Anirban Rej
13	National Workshop on 'Ilāj bi'l- Tadbīr	Aligarh	Nov 18, 2023	4 Officers
15	Hands-on Workshop on Integrated Omics	NCBS (TIFR), Bengaluru, Karnataka	Dec 4-8, 2023	Dr. Towseef Amin Rafeeqi
16	ICD-11 Traditional Medicine Chapter Module 2 Beta Draft Review Meeting	Mahaweli Reach Hotel, Kandy, Sri Lanka	Dec 6-8, 2023	A team from CCRUM
17	International Conference on Scientific Explanation and Understanding of Tibb Nabvi	Mansoor Campus, Malegaon	Dec 11-12, 2023	Dr. Mohammed Sheeraz
18	CoE Brainstorming Conclave 2023	Jamia Hamdard, New Delhi	Dec 12, 2023	8 Officers
19	Workshop on Interrupted Time Series Analysis-Quasi Experimental Research Design	New Delhi	Jan 22-25, 2024	Dr. Arif Habib Hanga
20	International Ayush Conclave	New Delhi	Feb 3-5, 2024	5 Officers
21	World Congress on Integrated Community Health	Aligarh, U.P.	Feb 8-10, 2024	9 Officers
22	International Conference on Safety of Medicines	Aligarh	Feb 10-11, 2024	2 Officers
23	International Conference on Traditional Medicine & Phytopharmaceuticals (ICTMP) & 11 th SFEC 2024	CSIR-IIIM, Jammu	Feb 16-18, 2024	2 Officers
24	Seminar on Oncology	Hyderabad	Feb 18, 2024	Officers of CCRUM
25	CME Programme	Jamia Hamdard, New Delhi	Feb 19-24, 2024	6 Officers





S. N.	Name of Event	Place	Duration	Participants
26	Training Programme on Gender Based Violence and Human Rights	Not specified	Feb 19-23, 2024	1 Officer
27	International Conference on Scientific Research in Unani Medicine	Jamia Hamdard, New Delhi	Feb 21-22, 2024	5 Officers
28	Capacity Building Programme	NIUM, Bengaluru	Feb 23-24, 2024	16 Officials
29	National Workshop on Capacity Building of Ayush Professionals	Jamia Hamdard, New Delhi	Feb 23-25, 2024	5 Officers
30	Training Programme on Building Knowledge Base in Traditional Medicine	NIHFW, New Delhi	Feb 26-Mar 1, 2024	A team of officers
31	CME Programme for Ayush Doctors on Lifestyle Diseases	Kashmir Tibbia College, J&K	Mar 15-20, 2024	A team of officers

4.4. Participation in Arogya Fairs/ Expos

The Ministry of Ayush, Government of India, in collaboration with state governments and other stakeholders, organizes and participates in Arogya fairs, expos, and similar events to promote Indian systems of medicine, highlight the activities and achievements of its research councils, provide free-of-cost diagnosis and treatment to visitors, and impart awareness about health, hygiene, and the curative aspects of ill-health. The CCRUM and its institutes, following the directives of the Ministry of Ayush, participated in national and state-level Arogya fairs and similar events held during the reporting period.

During these events, the CCRUM showcased its progress in clinical research, drug standardization, the survey and cultivation of medicinal plants, and literary research. It displayed posters and charts highlighting various concepts of Unani Medicine. Additionally, significant publications from the CCRUM, such as the *Unani Pharmacopoeia of India*, *National Formulary of Unani Medicine*, *Hippocratic Journal of Unani Medicine*, *Standard Unani Medical Terminology*, and *Standard Unani Treatment Guidelines for Common Diseases*, were made available for viewing. To create awareness about healthy living and the role of Unani Medicine in disease prevention and health promotion, free literature on Unani Medicine and success stories regarding the treatment of chronic and common diseases were distributed among visitors. The CCRUM also deployed its physicians to provide free consultations and treatments to visitors seeking Unani remedies, while lectures on various health issues were delivered by CCRUM researchers. The Council participated in approximately 29 Arogya fairs, exhibitions, and melas during 2023–2024. The list of events is as follows:

S. N.	Name of Event	Place	Duration
1.	Exhibition on 75 th Countdown Event	Dibrugarh, Assam	Apr 06–07, 2023





S. N.	Name of Event	Place	Duration
2.	National Arogya Fair	Jaipur, Rajasthan	Apr 20-23, 2023
3.	Cow Based Global Investment Summit & Expo	Rajkot, Gujarat	May 24-28, 2023
4.	3rd Health Working Group Meeting as part of G20 India Presidency	Hyderabad, Telangana	Jun 04-06, 2023
5.	Exhibition at 2nd Official Language Technical Conference	Dr. Ambedkar International Centre, New Delhi	Jun 06, 2023
6.	Conference on Traditional Medicine between India and ASEAN Countries	Vigyan Bhawan, New Delhi	Jul 20, 2023
7.	WHO Traditional Medicine Global Summit	Gandhinagar, Gujarat	Aug 17-18, 2023
8.	National Health Exhibition	Kolkata, West Bengal	Aug 24-27, 2023
9.	Ayurveda Parv	Srinagar, J & K	Sep 15-17, 2023
10.	IPU Health Mela	Talkatora Stadium, New Delhi	Oct 05-10, 2023
11.	National Tribal Festival	Jamshedpur, Jharkhand	Oct 07-16, 2023
12.	Ayurveda Parv	Tirupati, Andhra Pradesh	Oct 27-29, 2023
13.	World Food India	New Delhi	Nov 03-05, 2023
14.	Ayurveda Parv	Panchkula, Haryana	Nov 08-10, 2023
15.	India International Trade Fair	New Delhi	Nov 14-27, 2023
16.	Exhibition	Bengaluru, Karnataka	Nov 24-25, 2023
17.	National Arogya Fair	Thiruvananthapuram, Kerala	Dec 01-05, 2023
18.	Odisha Ayush Expo	KIIT Bhubaneswar, Odisha	Dec 14-15, 2023
19.	Rise in India	Ghaziabad, Uttar Pradesh	Dec 21-23, 2023
20.	State Arogya Fair	Nagaland	Jan 06-08, 2024
21.	Agri Vision	Cuttack, Odisha	Jan 19-21, 2024
22.	National Arogya Fair	Mumbai, Maharashtra	Jan 19-21, 2024
23.	Bharat Parv	Red Fort, New Delhi	Jan 23-31, 2024
24.	National Arogya Fair	New Delhi	Feb 01-04, 2024
25.	Surajkund International Crafts Mela	Faridabad, Haryana	Feb 02-18, 2024
26.	Ayush Health Mela	Jamia Millia Islamia, New Delhi	Feb 03-05, 2024
27.	International Arogya	Lucknow, U.P.	Feb 22-25, 2024
28.	Yoga Fest	Udaipur, Rajasthan	Mar 08-10, 2024
29.	State Arogya Fair	Jaipur, Rajasthan	Mar 09-12, 2024



4.5. Participation in Promotion of Official Language

The CCRUM puts its best efforts for promotion of the official language in day-to-day functioning and adopts appropriate measures as per time-to-time instructions and guidance from the Department of Official Language. The CCRUM has central as well regional official language implementation committees at its headquarters and regional research institutes/centres that monitor and review the status of the use of Hindi language in official dealings.

The third sub-committee of the Committee of Parliament on Official Language conducted review of DSRI, Ghaziabad on June 14, 2023; CRIUM, Lucknow on June 17, 2023; RRC, Prayagraj on June 19, 2023; RRIUM, Patna on July 14, 2023 and RRIUM, Mumbai on September 12, 2023 and the CCRUM achieved success in all these reviews.

The CCRUM conducted review meetings, organized Hindi workshops and observed Hindi Pakhwada at its headquarters and institutes during the period under report. The Pakhwada was observed to mark Hindi Diwas on September 14 and motivate employees to create an environment for implementation of the Official Language Policy in day-to-day work.

Apart from organizing the Hindi Pakhwada, the CCRUM participated in the meetings of Town Official Language Implementation Committee and meetings of the Ministry of Ayush pertaining to the official language. The Rajbhasha Section conducted quarterly meetings of official language implementation committee wherein matters related to the organization of workshops, promotion of letter writing in Hindi, review of Hindi works in various sections of the CCRUM, review of quarterly reports of various institutes/centres, etc. were discussed and specific strategy was formulated. Besides, information, education, and communication materials related to the promotion of Unani Medicine were printed in Hindi for distribution in health camps, Arogya fairs, and exhibitions.

4.6. Appointments

- **Dr. N. Zaheer Ahmed** was appointed Director General, CCRUM, on June 02, 2023. Previously, he was working as the Deputy Director of CCRUM's Regional Research Institute of Unani Medicine, Chennai.
- **Dr. Anees Ahmad** was appointed Research Assistant (Botany) at RRIUM, Srinagar, on June 19, 2023.
- **Shri Sumit Chouhan** was appointed Research Assistant (Botany) at RRIUM, Bhadrak, on June 30, 2023.
- **Dr. Mohd. Asif** was appointed Research Assistant (Botany) at RRIUM, Chennai, on July 11, 2023.
- **Ms. Pratima Verma** was appointed Research Assistant (Botany) at DSRI, Ghaziabad, on July 24, 2023.
- **Dr. Smिता Kumari** was appointed Research Officer (Pathology) at RRIUM, Aligarh, on August 3, 2023.
- **Dr. Zaryab Zaki** was appointed Research Officer (Pathology) at CRIUM, Lucknow, on August 3, 2023.
- **Dr. Ziaur Rahman** was appointed Research Officer (Unani) at RRIUM, Mumbai, on August 7, 2023.



- **Dr. Lavudya Sreenivasa Naik** was appointed Research Officer (Bio-Chemistry) at RRIUM, Silchar, on August 8, 2023.
- **Dr. Abdurrahman** was appointed Research Officer (Unani) at NRIUMSD, Hyderabad, on August 14, 2023.
- **Dr. Farooqui Shazia Parveen Barkat Ali** was appointed Research Officer (Unani) at RRIUM, Chennai, on August 18, 2023.
- **Dr. Nazim Husain** was appointed Research Officer (Unani) at RRIUM, Silchar, on August 23, 2023.
- **Dr. Bushra Sabir** was appointed Research Officer (Unani) at CRIUM, Lucknow, on August 23, 2023.
- **Ms. Nidhi** was appointed Senior Library Attendant at CCRUM headquarters, New Delhi, on August 29, 2023.
- **Dr. Zikra Tahseena** was appointed Research Officer (Unani) at RRIUM, Patna, on August 30, 2023.
- **Dr. Shagufta Parveen** was appointed Research Officer (Unani) at CRU, Meerut, on September 1, 2023.
- **Shri Md Zeeshan Raza** was appointed Urdu Assistant/Translator at CCRUM headquarters, New Delhi, on November 13, 2023.
- **Shri Piyush Yadav** was appointed Investigator (Statistics) at RRIUM, Mumbai, on January 18, 2024.
- **Shri Md. Zahid Ansari** was appointed Investigator (Statistics) at RRIUM, Aligarh, on January 18, 2024.
- **Shri Chandramani Yadav** was appointed Investigator (Statistics) at RRIUM, Patna, on January 19, 2024.
- **Ms. Monica** was appointed Investigator (Statistics) at RRC, Prayagraj, on January 19, 2024.
- **Dr. Raghubanshi** was appointed Research Officer (Unani) at CRIUM, Lucknow, on January 29, 2024.
- **Dr. Anurag Gupta** was appointed Investigator (Statistics) at RRIUM, Chennai, on February 7, 2024.

4.7. Promotions

- **Shri Taiyab Ali** was promoted to PA to the Director at CCRUM headquarters, New Delhi, on May 31, 2023.
- **Shri Mohi Ahmad Faridi** was promoted to UDC at CRIUM, Lucknow, on September 22, 2023.
- **Shri K. Ramesh Kadali** was promoted to UDC at NRIUMSD, Hyderabad, on September 22, 2023.
- **Smt. Usha Philip** was promoted to Administrative Officer at CCRUM headquarters, New Delhi, on January 12, 2024.
- **Smt. Pushpa Kumari** was promoted to Sister In-charge at RRIUM, New Delhi, on February 24, 2024.



- **Smt. Vasanthi Ganesh Pai** was promoted to Sister In-charge at NRIUMSD, Hyderabad, on February 24, 2024.
- **Mrs. Anju Ara Begum** was promoted to Sister In-charge at RRIUM, Kolkata, on February 29, 2024.

4.8. Retirements

- **Smt. Rubina Abbasi**, Assistant at CCRUM headquarters, New Delhi, retired on superannuation on April 30, 2023.
- **Dr. Ahmed Minhajuddin**, Director In-charge at NRIUMSD, Hyderabad, retired on superannuation on April 30, 2023.
- **Smt. Shobha Kamlakar Shewate**, Staff Nurse at RRIUM, Mumbai, retired on superannuation on May 31, 2023.
- **Shri Saudan Singh**, Laboratory Technician at CRIUM, Lucknow, retired on superannuation on May 31, 2023.
- **Smt. Akhtar Parveen**, Hindi Assistant at CCRUM headquarters, New Delhi, retired on superannuation on June 30, 2023.
- **Shri Harish Arya**, AD (Admn) at CCRUM headquarters, New Delhi, retired on superannuation on June 30, 2023.
- **Dr. Seema Akbar**, AD (Chem) at RRIUM, Srinagar, retired on superannuation on June 30, 2023.
- **Dr. Anwarul Islam**, Research Officer (Unani) at RRIUM, New Delhi, retired on superannuation on June 30, 2023.
- **Shri Syed Akhyar Ahmed**, Junior Stenographer at RRIUM, Aligarh, retired on superannuation on June 30, 2023.
- **Shri Mir Nasiruddin Khan**, MTS (Peon) at NRIUMSD, Hyderabad, retired on superannuation on June 30, 2023.
- **Smt. Sheela**, MTS (Aya) at CRIUM, Lucknow, retired on superannuation on June 30, 2023.
- **Shri Amjad Hial**, Pharmacist at RRC, Prayagraj, retired on superannuation on June 30, 2023.
- **Shri Mohammad Asif Abbasi**, Junior Administrative Officer at RRIUM, New Delhi, retired on superannuation on July 31, 2023.
- **Shri M. Iqbal Ali Khan**, Junior Administrative Officer at NRIUMSD, Hyderabad, retired on superannuation on July 31, 2023.
- **Shri Syed Sadiq Pasha**, UDC at RRIUM, Chennai, retired on superannuation on September 30, 2023.
- **Smt. Mahjabeen Asma**, Laboratory Technician at CRIUM, Lucknow, retired voluntarily on October 1, 2023.
- **Shri Abdul Rashid Mir**, Driver at RRIUM, Srinagar, retired on superannuation on October 31, 2023.
- **Shri Mohammad Shamim Ansari**, Junior Stenographer at CRIUM, Lucknow, retired on superannuation on October 31, 2023.



- **Shri Anwar Saeed**, MTS (Ward Boy) at CRIUM, Lucknow, retired on superannuation on November 30, 2023.
- **Shri H. A. Parmar**, MTS at RRIUM, Mumbai, retired on superannuation on December 31, 2023.
- **Shri Syed Golam Sabir**, MTS at RRIUM, Bhadrak, retired on superannuation on December 31, 2023.
- **Dr. Mohammad Ishtiyaque Alam**, Deputy Director (Unani) at RRIUM, Patna, retired on superannuation on January 31, 2024.
- **Dr. S. S. Hadi**, Research Officer (Unani) at CRU, Bangalore, retired voluntarily on February 28, 2023.
- **Shri Hussain Abbas**, Lab Attendant at CRU, Bhopal, retired on superannuation on February 29, 2024.
- **Smt. Usha Philip**, Administrative Officer at CCRUM headquarters, New Delhi, retired on superannuation on March 31, 2024.
- **Shri N. P. Sharma**, Junior Administrative Officer at RRIUM, Aligarh, retired on superannuation on March 31, 2024.
- **Dr. Aijaz Ahmed**, Research Officer (Unani) at NRIUMSD, Hyderabad, retired on superannuation on March 31, 2024.

4.9. Deaths

- **Dr. Afshan Qaiser**, Research Officer (Unani) at CRU, Bhopal, passed away in harness on October 12, 2023.



5. FINANCIAL STATEMENT

5.1. Audit Report

SEPARATE AUDIT REPORT OF THE COMPTROLLER & AUDITOR GENERAL OF INDIA ON THE ACCOUNTS OF CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE FOR THE YEAR ENDED 31 MARCH 2024.

We have audited the attached Balance Sheet of Central Council for Research in Unani Medicine (CCRUM) as at 31 March 2024, the Income & Expenditure Account and Receipts & Payments Account for the year ended on that date under Section 20(1) of the Comptroller and Auditor General's (Duties, Powers & Conditions of Service) Act, 1971. The audit has been entrusted for the period upto 2023-24. These financial statements include the accounts of nine regional offices of the CCRUM. These financial statements are the responsibility of the CCRUM's management. Our responsibility is to express an opinion on these financial statements based on our audit.

2. This Separate Audit Report contains the comments of the Comptroller and Auditor General of India on the accounting treatment only with regard to classification, conformity with the best accounting practices, accounting standards and disclosure norms, etc. Audit observations on financial transactions with regard to compliance with the Laws, Rules & Regulations (Propriety and Regularity) and efficiency-cum-performance aspects, etc., if any, are reported through Inspection Reports/ Comptroller and Auditor General's Audit Reports separately.

3. We have conducted our audit in accordance with auditing standards generally accepted in India. These standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatements. An audit includes examining, on a test basis, evidences supporting the amounts and disclosure in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management as well as evaluating the overall presentation of financial statements. We believe that our audit provides a reasonable basis for our opinion.

4. Based on our audit, we report that:

- i. We have obtained all the information and explanations, which to the best of our knowledge and belief were necessary for the purpose of our audit;
- ii. The Balance Sheet, Income & Expenditure Account and Receipts & Payments Account dealt with by this report have been drawn up in the format approved by the Ministry of Finance, Government of India.
- iii. In our opinion, proper books of accounts on double entry system of accounting have been maintained by the CCRUM in so far as it appears from our examination of such books.
- iv. We further report that:

A. Balance Sheet

A. 1 Assets

A.1.1 Fixed Assets (Schedule-8) - Rs.127.55 crore

A.1.1.1 CCRUM had awarded the construction of Regional Research Institute of Unani Medicine (RRIUM) Silchar, Assam to M/S National Projects Construction Corporation Limited (NPCC) and released Rs.46.62 crore as advance. The building was completed and handed over to RRIUM Silchar on 30.4.2022. As per fund utilization statement total expenditure incurred was Rs.50.83 Crore. However, CCRUM had depicted only Rs.26.12 crore as Capital Work-in Progress and the remaining amount was taken as advance. Further, CCRUM had not capitalized the same. This



has resulted in understatement of Fixed Assets-Buildings by Rs.46.62 crore and overstatement of Capital Work-in-progress by Rs.26.12 crore and overstatement of capital advances by Rs.20.50 crore.

A.1.2 Current Assets (Schedule - 11) – Rs.49.26 crore

A.1.2.1 CCRUM had earned an interest of 2.33 crore on advances issued to M/S NPCC upto 2022. However this was not included under Current Assets "Schedule-11" as receivable. This has resulted in understatement of Current Assets and understatement of Current Liabilities (refundable to Ministry) by Rs.2.33 crore.

A.1.2.2 CCRUM has released an advance of Rs.4.35 Crore to National Projects Construction Corporation Ltd. (NPCC) for procurement of Computers, Air Conditioners, Furniture and Kitchen items etc. for RRIUM, Silchar, Assam. However, out of total advance, inventories of Rs.2.92 crore supplied by M/S NPCC and taken over by RRIUM, Silchar were not capitalised in Annual Account. The Details are given below:

Sl.No.	Items	Amount in Rs.
1	Kitchen items	7937612
2	Computer items	1845000
3	Furniture	19402195
	Total	29184807

This has resulted in understatement of Fixed Assets and overstatement of Current Assets (Advances) by Rs.2.92 crore.

B. General

B.1 CCRUM is maintaining 7 Bank accounts at Headquarters. Scrutiny of bank reconciliation statement of these accounts revealed that amounts are lying un-reconciled in following accounts as detailed below:

Bank Account no.	Particulars	Amount (in Rs.)
16601	Cheque issued but not debited (Details not furnished)	23,310
16601	Demand draft deposited in bank, but not credited in account (Details f DD not furnished)	90,029
16602	Cheque issued but not debited (since February 2019 till march 2024)	2,70,95,800
16602	Demand draft deposited, but not credited in account (since July 2015 o August 2017)	40,367
16640	Cheque issued but not debited in account	3,990
16640	Demand draft deposited in bank, but not credited	58,602

This needs to be reconciled.

B.2 CCRUM has depicted huge outstanding Capital advance of Rs. 30.66 crore under Current Assets. This includes advances of Rs 23.67 crore pending for more than three years. These may be reconciled/ adjusted immediately.



- B.3** CCRUM has depicted huge outstanding contingent advance of Rs. 10.98 crore under current Assets. However, this includes an amount of Rs.9.90 crore pending for more than five years. This may be reconciled/ adjusted immediately.
- B.4** CCRUM has depicted outstanding travelling advance of Rs.2.41 lakh under current Assets. However, this includes an amount of Rs.201785 pending for more than six years. This may be adjusted immediately.
- B.5** CCRUM has made the provision of Rs.25.51 Crore (Sch. 7) in previous years for retirement benefits viz. gratuity, pension and leave encashment, however, the same is not based on actuarial valuation as prescribed in AS-15 of ICAI. The disclosure in Notes to Accounts is also not appropriate as it states 'retirement benefits are treated as per GOI Rules'. The Council made expenditure of Rs. 6.40 Crore in current year on employee retirement benefits (Sch. 20). The non-provisioning of retirement benefits on actuarial basis can have impact on the net excess of expenditure over income and the liabilities of the Council.

C. Grant-in-Aid

(i) AYUSH Account

CCRUM had received Grant in Aid of Rs.174.10 crore during 2023-24 from Ministry of AYUSH. It had an unspent balance of Rs.2.56 crore from Grant in Aid of previous year which was refunded during 2023-24 to the Ministry of AYUSH. CCRUM also earned interest on this unspent GIA of Rs.26.55 lakh. Thus out of available amount of Rs. 174.37 crore, CCRUM utilized Rs.174.10 crore leaving unspent balance of Rs.26.55 lakh as on 31.03.2024.

(ii) Specific Project Account


CCRUM also received grants of Rs.5.27 crore during the year for specific projects from various agencies, in addition to unspent balance of previous year of Rs.35.04 lakh. It had Miscellaneous receipts of Rs.14.89 crore. Thus, out of available amount of Rs.5.77 crore, CCRUM utilized Rs.3.22 crore, leaving an unutilized balance of Rs.2.55 crore as on 31.03.2024.

D. Management Letter

Deficiencies which have not been included in the Audit Report have been brought to the notice of management of the CCRUM through a management letter issued separately for remedial/corrective action.

- v.** Subject to our observations in the preceding paragraphs, we report that the Balance Sheet, Income & Expenditure Account and Receipts & Payments Account dealt by this report are in agreement with the books of accounts.
- vi.** In our opinion and to the best of our information and according to the explanations given to us, the said financial statements read together with the Accounting Policies and Notes on Accounts, and subject to the significant matters stated above and other matters mentioned in Annexure to this Audit Report give a true and fair view in conformity with accounting principles generally accepted in India.
- a. In so far as it relates to the Balance Sheet. of the state of affairs of the Central Council for Research in Unani Medicine as at 31 March 2024 and
- b. In so far as it relates to Income & Expenditure Account of the deficit for the year ended on that date.

For and on behalf of C&AG of India


(Rajiv Kumar Pandey)
Director General of Audit
(Central Expenditure)

Place: New Delhi
Date: 27.12.2024





Annexure

1. Adequacy of internal audit system

The internal audit of the CCRUM was conducted upto 2018-19 by the Ministry of Health & Family Welfare. However, report is yet to be received.

2. Adequacy of internal control system

Internal control system was not adequate as risk assessment was not done by the management. Further, 16 paras pertaining to the period 2015-16 to 2018-19 were outstanding for settlement.

Further, Annual Accounts of CCRUM disclosed assets valued at Rs 125.55 crore as on 31 March 2024. However, an Assets Register required to be maintained in Form GFR-22 under General Financial Rules 2017 has not been maintained by the CCRUM.

3. System of physical verification of fixed assets

The physical verification of fixed assets was conducted up to 2023-24 and no discrepancy was reported.

4. System of physical verification of inventory

The physical verification of Books and Publications was conducted up to 31.03.2024.

5. Regularity in payment of statutory dues

As per accounts, no payments for over six months in respect of statutory dues were outstanding as on 31.03.2024.



5.2. Audited Statement of Accounts

Index of the Annual Accounts for the Year 2023–2024

S. No.	Name of the Accounts	Page No.	Schedules at Page No.
1.	Balance Sheet	110	118–131
2.	Income & Expenditure Account	111	132–143
3.	Receipt & Payment Account	112–117	144–179
4.	Notes on Accounts	180	180



Balance Sheet as on 31st March 2024

Capital Fund and Liabilities		Schedule	Current Year	Previous Year
Corpus/Capital Fund		1	140,16,42,769.32	134,62,46,983.13
Reserve and Surplus		2	-	-
Earmarked/Endowment Funds		3	2,55,03,391.15	35,03,727.00
Secured Loans and Borrowings		4	-	-
Unsecured Loans and Borrowings		5	-	-
Deferred Credit Liabilities		6	-	-
Current Liabilities and Provisions		7	34,09,62,479.84	33,09,77,046.84
Current Liabilities and Provisions (Other A/Cs)			85,43,81,504.42	88,58,68,072.96
Total			262,24,90,144.73	256,65,95,829.93
Assets		Schedule	Current Year	Previous Year
Fixed Assets		8	127,54,71,881.00	124,46,88,837.00
Investments-from Earmarked/Endowment Funds		9	-	-
Investments Others		10	64,52,61,916.62	67,60,27,854.99
Current Assets, Loans, Advances, etc.		11	70,17,56,346.49	64,58,79,138.44
Current Assets (Other A/Cs)		-	-	-
Total			262,24,90,144.73	256,65,95,829.93

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

Income & Expenditure A/c for the Year Ending 31st March 2024

Income	Schedule	Current Year	Previous Year
Income from Sales/Services	12	-	-
Grants	13	166,10,00,000.00	173,42,56,000.00
Fees	14	44,12,488.00	47,86,680.00
Income from Investments (Income on Invest from earmarked/endow. Funds transferred to Funds)	15	-	-
Income from Publication, etc.	16	1,79,505.00	98,722.00
Interest Earned	17	-	65,87,434.0000
Other Income	18	5,23,73,291.37	2,99,27,036.01
Less: Capitalized	19	(-) 1,26,82,565.00	-
Total (A)	Schedule	Current Year	Previous Year
Expenditure			
Establishment Expenses	20	109,99,64,509.00	+30,13,061.00
Other Administrative Expenses etc.	21 (A- D)	62,42,08,984.18	111,14,35,795.00
Expenditure on Grants, Subsidies etc.	22	-	-
Interest	23	-	-
Depreciation (Net Total at the Year End – Corresponding to Schedule 8)	H - 21 (E)	1,86,78,283.00	1,94,65,525.00
Total (B)		174,28,51,776.18	176,88,87,596.88
Balance Being Excess of Income Over Expenditure (A-B)		(-) 3,75,69,056.81	67,68,275.13
Balance being Surplus/(Deficit) Carried to Capital Fund		(-) 3,75,69,056.81	67,68,275.13

Sd/-
(Shakaib Hasan)
Consultant (IA)Sd/-
(Mohammad Parvez)
Administrative OfficerSd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, AdministrationSd/-
(Dr. N. Zaheer Ahmed)
Director General



Receipt & Payment A/c for the Year Ending 31st March 2024

S. N.	Receipts	Current Year			Previous Year				
		Health A/c	Other Specific A/c	GPF/GIS/ Pension NPS A/c	Total	Health A/c	Other Specific A/c	GPF/GIS/ Pension NPS A/c	Total
I.	Opening Balance								
a.	Cash-in-Hand (Imprest)	5,83,336.22		-	5,83,336.22	5,83,336.22		-	5,83,336.22
b.	Cash at Bank	337,63,591.60	5,21,66,727.50	11,87,74,620.97	20,47,04,939.47	4,35,72,272.15	63,45,172.50	10,69,39,759.97	15,68,57,204.84
	Total (I)	3,43,46,927.22	5,21,66,727.50	11,87,74,620.97	20,52,88,275.69	4,41,55,608.37	63,45,172.50	10,69,39,759.97	15,74,40,540.84
II.	Grant in Aid From Govt. of India								
a.	Capital	8,00,00,000.00	-	-	8,00,00,000.00	4,87,50,000.00	-	-	4,87,50,000.00
b.	Revenue	1,66,10,00,000.00	42,50,378.00	-	166,52,50,378.00	168,55,06,000.00	-	-	168,55,06,000.00
	Total (II)	174,10,00,000.00	42,50,378.00	-	174,52,50,378.00	173,42,56,000.00	-	-	173,42,56,000.00
III.	Investments of GPF/GIS/Pension fund & NPS Funds	-	-	3,19,68,640.00	3,19,68,640.00			28,97,08,798.40	28,97,08,798.40
	Total (III)	-	-	3,19,68,640.00	3,19,68,640.00	0	0	28,97,08,798.40	28,97,08,798.40
IV	Interest Received								
a.	Bank Interest	23,62,097.00	12,37,825.65	20,89,458.00	56,89,380.65	61,88,004.00	1,56,992.00	31,80,526.00	95,25,522.00
	Total (IV)	23,62,097.00	12,37,825.65	20,89,458.00	56,89,380.65	61,88,004.00	1,56,992.00	31,80,526.00	95,25,522.00
V.	Other Income								
a.	Interest on Refundable Advances	67,292.00	-	-	67,292.00	1,31,055.00	-	-	1,31,055.00
b.	Other Misc. Income (As per Schedule H/8)	2,83,50,275.00	-	1,14,116.00	2,84,64,391.00	2,18,30,386.51	3,56,025.00	56,63,661.00	2,78,50,072.51
c.	Sale of Publications	1,79,505.00	-	-	1,79,505.00	98,722.00	-	-	98,722.00
d.	Unani Academic Courses Fee, etc.	44,12,488.00	-	-	44,12,488.00	47,86,680.00	-	-	47,86,680.00

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



Receipt & Payment A/c for the Year Ending 31st March 2024

S. N.	Receipts	Current Year			Previous Year				
		Health A/c	Other Specific A/c	GPF/GIS/ Pension NPS A/c	Total	Health A/c	Other Specific A/c	GPF/GIS/ Pension NPS A/c	Total
	Total (V)	3,30,09,560.00	-	1,14,116.00	3,31,23,676.00	2,68,46,843.51	3,56,025.00	56,63,661.00	3,28,66,529.51
VI.	Amount Borrowed								
VII	Other Receipts								
a.	Refund against by Adjustment of Advances Pertaining to Previous Year	23,06,314.00	-	-	23,06,314.00	29,00,330.50	-	-	29,00,330.50
b.	Recoveries of Refundable Advances to Govt. Servants	-	-	-	-	8,28,971.00	-	-	8,28,971.00
c.	Recoveries for Remittances	1,94,04,187.00	-	-	1,94,04,187.00	1,64,25,419.00	16,598.00	1,84,09,262.00	3,48,51,279.00
d.	Recoveries of Subscription & Advance	-	-	5,88,34,577.00	5,88,34,577.00	-	-	4,76,78,037.00	4,76,78,037.00
e.	Security Deposit (CCRUM)	1,06,500.00	-	-	1,06,500.00	1,50,000.00	-	-	1,50,000.00
f.	Receivable Amount Received	26,93,960.00	-	-	26,93,960.00	88,53,280.82	-	-	88,53,280.82
g	In-Transit Amount Received	-	-	-	-	-	-	-	-
h.	Amount Received but to be Refunded to Other Decentralized Institutes	-	-	-	-	-	-	-	-
i.	Investment Received	-	-	-	-	-	-	-	-

Sd/-
(Shakaib Hasan)
Consultant (IA)Sd/-
(Mohammad Parvez)
Administrative OfficerSd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, AdministrationSd/-
(Dr. N. Zaheer Ahmed)
Director General

Receipt & Payment A/c for the Year Ending 31st March 2024

S. N.	Receipts	Current Year			Previous Year				
		Health A/c	Other Specific A/c	GPF/GIS/ Pension NPS A/c	Total	Health A/c	Other Specific A/c	GPF/GIS/ Pension NPS A/c	Total
j.	LIC Amount Received from LIC for Disbursement	-	-	-	-	-	-	2,00,000.00	2,00,000.00
k.	Pension Fund Transfer from Health A/c Received in Pension Fund A/c	-	-	28,14,96,741.00	28,14,96,741.00	-	-	32,53,79,943.00	32,53,79,943.00
l.	Unani Day Fund	39,98,912.00	-	-	39,98,912.00	-	-	-	-
m.	Receipts on Closing Bank A/c	-	-	-	-	-	-	-	-
n.	NPS Trust	-	-	3,20,40,648.62	3,20,40,648.62	74,28,539.50	-	-	74,28,539.50
o.	Unspent Balance (Previous Year)	-	-	-	-	-	-	-	-
p.	Unspent Balance (Current Year)	1,24,74,386.50	-	-	1,24,74,386.50	81,67,538.12	-	-	81,67,538.12
q.	Interest on FDRs	-	-	-	-	-	-	1,51,96,655.00	1,51,96,655.00
r.	Fund Transfer	-	-	-	-	1,97,50,400.00	-	1,73,45,900.00	3,70,96,300.00
	Total (VII)	4,09,84,259.50	-	37,23,71,966.62	41,36,56,226.12	6,45,04,478.94	16,598.00	42,42,09,797.00	48,87,30,873.94
	Grand Total (I to VII) of Receipt Side	1,88,37,43,492.44	5,76,54,931.15	49,32,78,152.97	2,43,46,76,576.56	187,59,50,933.82	68,74,787.50	82,97,02,542.32	271,25,28,263.64

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

Receipt & Payment A/c for the Year Ending 31st March 2024

S. N.	Payments	Current Year			Total	Previous Year			Total
		Health A/c	Other Specific A/c	GPF/GIS/ Pension/ NPS A/c		Health A/c	Other Specific A/c	GPF/GIS/ Pension/ NPS A/c	
I. Expenses									
a. Establishment Expense		108,42,69,917.00	-	-	108,42,69,917.00	102,88,84,495.00	-	-	102,88,84,495.00
Total I		108,42,69,917.00	-	-	108,42,69,917.00	102,88,84,495.00	-	-	102,88,84,495.00
II. Administrative Expense (Corresponding to Schedule 21)		48,27,00,004.53	-	3897.17	48,27,03,901.70	29,77,53,870.00	-	4,012.00	29,77,57,882.00
i. Admn. Expenses		-	-	-	-	-	-	-	-
ii. Material & Supplies		12,58,22,137.00	-	-	12,58,22,137.00	20,99,95,515.00	-	-	20,99,95,515.00
iii. Other Charges		3,08,78,646.00	9,65,542.00	-	3,18,44,188.00	11,07,22,370.00	33,34,306.00	-	11,40,56,676.00
iv. Publication Expenses		-	-	-	-	-	-	-	-
Total (II)		63,94,00,787.53	9,65,542.00	3897.17	64,03,70,226.7	61,84,71,755.00	33,34,306.00	4,012.00	62,18,10,073.00
III. Investment Made Out of GPF, GIS, Pension Fund & NPS A/c		-	-	-	-	-	-	30,49,05,453.35	30,49,05,453.35
Total (III)		-	-	-	-	-	-	30,49,05,453.35	30,49,05,453.35
IV. Expenditure on Fixed Assets and Capital Work in Progress		5,54,89,253.00	-	2,51,71,290.00	8,06,60,543.00	3,38,55,422.00	-	-	3,38,55,422.00
a. Purchase of Fixed Assets		1,54,73,843.00	-	-	1,54,73,843.00	47,19,443.00	-	-	47,19,443.00
b. Fund Transfer		-	-	-	-	-	-	1,73,60,900.00	1,73,60,900.00
c. IPR Fund Transfer		-	-	-	-	-	-	-	-
Total (IV)		7,09,63,096.00	-	2,51,71,290.00	9,61,34,386.00	3,85,74,865.00	-	1,73,60,900.00	5,59,35,765.00

Sd/-
(Shakaib Hasan)
Consultant (IA)Sd/-
(Mohammad Parvez)
Administrative OfficerSd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, AdministrationSd/-
(Dr. N. Zaheer Ahmed)
Director General

Receipt & Payment A/c for the Year Ending 31st March 2024

S. N.	Payments	Current Year				Previous Year			
		Health A/c	Other Specific A/c	GPF/GIS/ Pension/ NPS A/c	Total	Health A/c	Other Specific A/c	GPF/GIS/ Pension/ NPS A/c	Total
V.	Refund of Surplus Money & Loans	-	-	-	-	-	-	-	-
a.	To Govt. of India	-	-	-	-	-	-	-	-
b.	To the States Govt.	-	-	-	-	-	-	-	-
c.	To Other Provider of Funds	-	-	-	-	-	-	-	-
VI.	Finance Charges (Interest)	-	-	-	-	-	-	-	-
VII	Other Payments	-	-	-	-	-	-	-	-
a.	Advances to Govt. Servants	9,25,849.07	-	-	9,25,849.07	31,48,260.00	-	-	31,48,260.00
b.	Remittance of Recoveries	-	-	1,64,87,977.00	1,64,87,977.00	8,66,48,988.00	16,598.00	2,40,92,059.00	11,07,57,645.00
c.	Amount Payable Paid/Adjusted	-	39,98,912.00	-	39,98,912.00	-	-	-	-
d.	Refund of EMD	2,38,198.00	-	-	2,38,198.00	15,89,152.00	-	-	15,89,152.00
e.	Amount disbursed to RRI Chennai	-	-	-	-	-	-	-	-
f.	Unspent Balance Refunded to the Ministry of Ayush	2,56,10,081.00	20,15,796.00	-	2,76,25,877.00	2,26,91,219.00	20,156.00	-	2,27,11,375.00
g.	LIC Amount Received from LIC Disbursed	-	-	-	-	-	-	2,00,000.00	2,00,000.00

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



Receipt & Payment A/c for the Year Ending 31st March 2024

S. N.	Payments	Current Year				Previous Year			
		Health A/c	Other Specific A/c	GPF/GIS/ Pension/ NPS A/c	Total	Health A/c	Other Specific A/c	GPF/GIS/ Pension/ NPS A/c	Total
h.	Other Misc. Payments, Transfer	1,48,66,604.96	-	35,74,37,433.00	37,23,04,037.96	1,97,50,400.00	-	36,43,65,497.00	38,41,15,897.00
i.	Undisbursed Amount Disbursed	-	-	-	-	-	-	-	-
j.	NPS Empl. Fund paid (Non-Pran)	1,32,24,296.00	-	-	1,32,24,296.00	30,13,061.00	-	-	30,13,061.00
k.	Funds Transfer on Specific A/c Closure	-	-	-	-	-	-	-	-
l.	Outstanding Advances	1,08,42,452.00	-	-	1,08,42,452.00	1,88,31,811.00	-	-	1,88,31,811.00
m.	NPS corpus amount paid	-	-	-	-	-	-	-	-
	Total (VII) (a to m)	6,57,07,481.03	60,14,708.00	37,39,25,410.00	44,56,47,599.30	15,56,72,891.00	36,754.00	38,86,57,556.00	54,43,67,201.00
VIII	Closing Balance								
a.	Cash-in-Hand (Imprest)	-	-	-	-	-	-	-	-
b.	Cash at Bank	2,34,01,411.44	2,55,03,391.15	11,93,48,845.80	16,83,07,533.39	3,43,46,927.82	35,03,727.50	11,87,74,620.97	15,66,25,276.29
	Total VIII (a+b)	2,34,01,411.44	2,55,03,391.15	11,93,48,845.80	16,83,07,533.39	3,43,46,927.82	35,03,727.50	11,87,74,620.97	15,66,25,276.29
	Total (I to VIII) of Payment Side	1,88,37,43,493.00	5,76,54,931.15	49,32,78,152.97	2,43,46,76,577.12	187,59,50,933.82	68,74,787.50	82,97,02,542.30	271,25,28,263.64

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General





Capital Fund of Balance Sheet for the Year Ending 31st March 2024 (Schedule-1)

S. N.		Current Year		Previous Year	
		Health A/c	F.W.	Health A/c	F.W.
	Balance at the Beginning of the Year	134,62,46,983.13		133,47,59,265.00	-
	Addition During the Year	1,29,64,843.00		47,19,443.00	-
	Less: Refunds	8,00,00,000.00		-	-
	Less: Write off	-		-	-
	Total (Rs.)	143,92,11,826.13		133,94,78,708.00	-
	Add/Deduct Balance of Net Income/Expenditure Transferred from the Income and Expenditure A/c	(-) 3,75,69,056.81		67,68,275.13	-
	Total (Rs.)	140,16,42,769.32		134,62,46,983.13	-
	Net Balance	140,16,42,769.32		134,62,46,983.13	-

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

Schedule Forming Part of Balance Sheet as on 31st March 2024
(Schedule-3) Earmarked/Endowment Funds

S.N.	Name of the Scheme	I.T. A/c	Herb Garden A/c	Publication of Text Books	UPS A/c I	DSOP A/c	Pharmacovigilance A/c	Unani Day	AIUM A/c	WHO A/c
		(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)
(a)	Opening Balance	24,15,961.00	2,64,252.00	-	-	-	-	5,45,529.50	-	-
	Total (a)	24,15,961.00	2,64,252.00	-	-	-	-	5,45,529.50	-	-
(b)	Additions	-	-	-	-	-	-	-	-	-
	Grant-in-Aid	-	-	-	-	-	-	39,98,912.00	-	-
	Other Additions A/c of	-	-	-	-	-	-	-	-	-
	• Bank Interest	-	-	-	-	-	-	-	-	-
	• From Health A/c	-	-	-	-	-	-	-	-	-
	• Recoveries for Remittances	-	-	-	-	-	-	-	-	-
	• Receivable received	-	-	-	-	-	-	-	-	-
	• Misc. Receipts	-	-	-	-	-	-	-	-	-
	Total (b)	-	-	-	-	-	-	-	-	-
	Total (a+b)	24,15,961.00	2,64,252.00	-	-	-	-	45,44,441.50	-	-
(c)	Utilization/Expenditure	-	-	-	-	-	-	-	-	-
	i) Capital expenditure	-	-	-	-	-	-	-	-	-
	• Assets	-	-	-	-	-	-	-	-	-
	• Others	-	-	-	-	-	-	-	-	-
	ii) Revenue Expenditure	-	-	-	-	-	-	-	-	-

Sd/-
(Shakaib Hasan)
Consultant (IA)Sd/-
(Mohammad Parvez)
Administrative OfficerSd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, AdministrationSd/-
(Dr. N. Zaheer Ahmed)
Director General

Schedule Forming Part of Balance Sheet as on 31st March 2024
(Schedule-3) Earmarked/Endowment Funds

S.N.	Name of the Scheme	I.T. A/c	Herb Garden A/c	Publication of Text Books	UPS A/c I	DSOP A/c	Pharmacovigilance A/c	Unani Day	AIUM A/c	WHO A/c
		(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)
•	Salaries/Wages Allowances	-	-	-	-	-	-	-	-	-
•	Other Administrative Expenditure	9,65,542.00	-	-	-	-	-	-	-	-
•	Material & Supplies	-	-	-	-	-	-	-	-	-
•	Remittance of Recoveries	-	-	-	-	-	-	-	-	-
•	Amount Payable Paid	-	-	-	-	-	-	39,98,912.00	-	-
•	Unspent Balance Refunded to Ministry	14,50,419.00	-	-	-	-	-	-	-	-
•	Transfer to Health A/c on A/c of Closure	-	-	-	-	-	-	-	-	-
	Total (c)	24,15,961.00	-	-	-	-	-	39,98,912.00	-	-
	Net Balance (a+b(-)c)	Nil	2,64,252.00	-	-	-	-	5,45,529.50	-	-

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

Schedule Forming Part of Balance Sheet as on 31st March 2024
(Schedule-3) Earmarked/Endowment Funds

S.N.	Name of the Scheme	IPR (10)	International Events Conference A/c (11)	DST A/c (12)	PMJKV A/c (13)	South African A/c (14)	Total	
							Current Year (15)	Previous Year (16)
(a)	Opening Balance	2,77,985.00	-	-	-	-	35,03,727.50	63,45,172.50
	Total (a)	2,77,985.00	-	-	-	-	35,03,727.50	63,45,172.50
(b)	Additions							
	Grant-in-Aid		-	-	4,86,63,000.00	-	5,26,61,912.00	
	Other Additions A/c of		-	-		-		
	• Bank Interest	62,445.00	-	-	11,75,380.65	-	12,37,825.65	1,56,992.00
	• From Health A/c		-	-		-		
	• Recoveries for Remittances		-	-		-		16,598.00
	• Receivable Received		-	-		-		
	• Misc. Receipts	2,51,466.00	-	-		-	2,51,466.00	3,56,025.00
	Total (b)	5,91,896.00	-	-	4,98,38,380.65	-	5,76,54,931.15	5,29,615.00
	Total (a+b)							68,74,787.50
(c)	Utilization/Expenditure							
	i) Capital Expenditure	-	-	-	2,51,71,290.00	-	2,51,71,290.00	-
	• Assets	-	-	-		-	-	-
	• Others	-	-	-		-	-	-
	ii) Revenue Expenditure	-	-	-		-	-	-
	• Salaries/Wages Allowances	-	-	-		-	-	-

Sd/-
(Shakaib Hasan)
Consultant (IA)Sd/-
(Mohammad Parvez)
Administrative OfficerSd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, AdministrationSd/-
(Dr. N. Zaheer Ahmed)
Director General

Schedule Forming Part of Balance Sheet as on 31st March 2024
(Schedule-3) Earmarked/Endowment Funds

S.N.	Name of the Scheme	IPR	International Events Conference A/c	DST A/c	PMJKV A/c	South African A/c	Total	
							Current Year (15)	Previous Year (16)
•	Other Administrative Expenditure	-	-	-	-	-	96,5542.00	33,34,306.00
•	Material & Supplies	-	-	-	-	-	-	-
•	Remittance of Recoveries	-	-	-	-	-	-	16,598.00
•	Amount Payable Paid		-	-	-	-	39,98,912.00	
•	Unspent Balance Refunded to Ministry	5,65,377.00	-	-	-	-	20,15,796.00	20,156.00
•	Transfer to Health A/c on A/c of Closure	-	-	-	-	-	-	-
	Total (c)	5,65,377.00	-	-	2,51,71,290.00	-	3,21,51,540.00	33,71,060.00
	Net Balance (a+b(-)c)	26,519.00	-	-	2,46,67,090.65	-	2,55,03,391.15	35,03,727.50

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

Current Liabilities & Provisions [Schedule-7 (2023-2024)]

S. N.	Name of the Scheme	Current Year	Previous Year
7(A)(5)	Statutory Liabilities: • Duties and taxes	32,75,599.57	32,83,280.00
	Total 7 (A) (5)	32,75,599.57	32,83,280.00
7(A)(6)	Other Current Liabilities	-	-
	Secured Deposits (CCRUM)	14,84,945.00	16,17,443.00
	Short Payments Payable	23,798.00	23,798.00
	Undisbursed amounts (Decentralized Instt)	79,948.00	79,948.00
	Recoveries not received details	2,289.00	2,289.00
	F.W. A/c	17090.00	17090.00
	Advances from Vidya Peeth	2,50,000.00	2,50,000.00
	Amount Received but Detail not Received (Kol)	16,469.00	16,469.00
	Received from CCRAS for UPC	30,00,000.00	30,00,000.00
	Payable by RRI., New Delhi to Hqrs, ND	36.00	36.00
	Security Deposit (CCCBC)	4,03,000.00	4,03,000.00
	Unspent Balance Payable to Ministry of Ayush	0.27	2,56,10,081.27
	Unspent Balance of Specific Accounts	2,02,17,495.70	2,02,17,495.70
	Expenses Payable	-	53,96,277.00
	Deduction from salaries	2708,655.00	37,70,588.00
	Salary payable	1,21,01,620.00	1,21,59,226.00
	Seminar Expense Payable	1,50,250.00	-
	I.T. Repair & Maintenance Payable	3,69,000.00	-
	Remittance to Ministry	26,55,151.00	-

Sd/-
(Shakaib Hasan)
Consultant (IA)Sd/-
(Mohammad Parvez)
Administrative OfficerSd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, AdministrationSd/-
(Dr. N. Zaheer Ahmed)
Director General

Current Liabilities & Provisions [Schedule-7 (2023-2024)]

S. N.	Name of the Scheme	Current Year	Previous Year
	Imprest	24,974.00	-
	Unani Day Expense Payable	61,357.00	-
	Wages Payable	15,51,402.00	-
	Release payable (Branches)	3,74,73,171.00	-
	T.A. Expense Payable	(-) 33,796.00	-
	Total	8,25,56,854.97	7,25,63,740.97
7(B)	Provisions For Retirement Benefits	25,51,30,025.30	25,51,30,025.30
	Total 7 (B)	25,51,30,025.30	25,51,30,025.30
	Total 7 (A+B) C/f	34,09,62,479.84	33,09,77,045.84
7(C)	NPS A/c • NPS Liability	1,42,43,150.31	1,26,98,039.30
7(D)	GPF A/c • GPF Liability to GPF Subscribers	44,77,55,692.39	45,16,31,316.29
7(E)	GIS A/c • GIS Liability to GIS Subscribers	2,52,58,527.19	2,43,47,509.84
7(F)	Pension Fund A/c • Pension Funds Bank Interest and Payment of Pension, FP Commutation of Pension From	36,71,24,134.53	39,71,91,207.53
	Total 7(C) to 7(F) Rs.	85,43,81,504.42	88,58,68,072.96

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

Consolidated Schedule of Fixed Assets as on 31st March 2024
(Schedule-8)

S.N	Name of the Assets	Gross Block				Total
		Opening Balance as on 01.04.2023	Addition	Deductions	Transferred to/from M/E A/c from WLP A/c	
		(1)	(2)	(3)	(4)	(5)
1.	Machinery (H) Equipment (FW)	17,23,86,252.00	4,27,82,594.00	-	-	21,51,68,846.00
2.	Furniture & (H) Fixture (FW)	9,87,06,011	22,31,814.00	-	-	10,09,37,825.00
3.	Computers	3,64,18,231.00	39,16,410.00	-	-	4,03,34,641.00
4.	Land	27,85,336.00	-	-	-	27,85,336.00
5.	Works in Progress	111,13,04,634.00	-	-	-	111,13,04,634.00
6.	Books & Journals (H) (FW)	3,57,93,223.00	5,30,509.00	-	-	3,63,23,732.00
7.	Vehicles	86,22,166.00	-	-	-	86,22,166.00
8.	Building	13,43,46,873.00	-	-	-	13,43,46,873.00
9.	Council's Publications (Priced)	-	-	-	-	-
	Total	-	-	-	-	-
10.	Councils Publications Priced not Fixed Assets so Deducted from here	-	-	-	-	-
	Total (H) (FW)	160,03,62,726.00	4,94,61,327.00	-	-	164,98,24,053.00

Sd/-
(Shakaib Hasan)
Consultant (IA)Sd/-
(Mohammad Parvez)
Administrative OfficerSd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, AdministrationSd/-
(Dr. N. Zaheer Ahmed)
Director General

Consolidated Schedule of Fixed Assets as on 31st March 2024
(Schedule-8)

S. N.	Name of the Assets	Depreciation				Net Block		
		Rate of Depreciation	Opening Balance As on 01.04.23	On addition	On Deductions	Total	As on 31.03.2024	As on 31.03.2023
		(6)	(7)	(8)	(9)	(10)	(11)	(12)
1.	Machinery (H) Equipment (FW)	10%	10,09,42,946.00	95,06,953.00	-	11,04,49,899.00	10,47,49,745.00	7,14,74,104.00
2.	Furniture & (H) Fixture (FW)	10%	6,92,21,827.00	30,73,345.00	-	7,22,95,172.00	2,86,47,442.00	2,94,88,973.00
3.	Computers	40%	3,42,64,343.00	17,86,214.00	-	3,60,50,557.00	42,84,084.00	21,53,888.00
4.	Land	-	-	-	-	-	27,85,336.00	27,85,336.00
5.	Works in Progress	-	-	-	-	-	111,13,04,634.00	111,13,04,634.00
6.	Books & Journals (H) (FW)	40%	2,64,72,544.00	19,31,142.00	-	2,84,03,686.00	31,57,480.00	45,58,113.00
7.	Vehicles	15%	68,56,569.00	2,64,840.00	-	71,21,409.00	15,00,787.00	17,65,597.00
8.	Building	10%	11,31,88,681.00	21,15,819.00	-	11,53,04,500.00	1,90,42,373.00	2,11,58,192.00
9.	Council's Publications (Priced)	-	-	-	-	-	-	-
	Total	-	-	-	-	-	-	-
10.	Councils Publications Priced not Fixed Assets so Deducted from here	-	-	-	-	-	-	-
	Total (H) (FW)	-	35,09,46,910.00	1,86,78,283.00	-	36,96,25,223.00	127,54,71,881.00	124,46,88,837.00

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

Schedule of Investments Out of the Following Funds as on 31st March 2024
(Schedule-10)

S. N.		Current Year	Previous Year
1.	GPF	37,02,54,780.77	37,04,86,711.00
2.	GIS	2,15,55,768.85	1,90,02,345.00
3.	Pension Fund	25,34,51,367.00	28,19,46,325.00
4.	NPS	-	45,92,473.99
	Total S/5C	64,52,61,916.62	67,60,27,854.99

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



Schedule of Current Assets (Schedule-11)

(A)	Health A/c	Current Year	Previous Year
1.	Contingent Advance	10,98,33,036.00	10,98,33,036.00
2.	Exhibitions Advance	73,000.00	73,000.00
3.	T.A. Advance	2,40,620.00	2,14,939.00
4.	Excess Paid to be Recovered/Adjusted	8,107.00	8,107.00
5.	LTC Advance	4,73,903.00	5,73,786.00
6.	Advance for Seminar	26,83,717.00	20,96,019.00
7.	Capital Advance	30,40,67,041.00	26,17,09,210.00
8.	Scooter Advance	27,456.00	37,956.00
9.	Fan Advance	768.00	768.00
10.	Car Advance	1,16,449.07	-
11.	Computer Advance	4,55,256.00	5,83,636.00
12.	House Building Advance	81,29,237.00	90,83,891.00
13.	In Transit Amount	18,200.15	18,200.15
14.	Security Deposits	4,70,311.00	4,70,311.00
15.	Medical Advance	3,28,265.00	3,28,265.00
16.	Receivable from IPR A/c	70,960.00	70,960.00
17.	Receivable from LIC	1,351.50	1,351.50
18.	Excess TDS to be Recovered/Adjusted	19,706.00	19,706.00
19.	Training Advance	3,78,552.00	3,53,552.00
20.	Ethics Committee Advance	1,46,524.00	1,17,024.00
21.	Share Amount Receivable from CCRYN, N. Delhi	2,62,992.00	2,62,992.00
22.	Advance for A-HMIS	1,34,200.00	1,34,200.00
23.	Receivable from F.W. A/c	17,090.00	17,090.00
24.	Swachhta Action Plan Advance	5,62,707.00	11,83,059.00
25.	Maintenance Advance	3,44,751.00	34,991.00
26.	Hindi Workshop	2,67,650.00	2,64,150.00
27.	IT Maintenance	95,674.00	12,700.00
28.	Machinery and Equipment Advance	88,47,512.00	88,47,512.00

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

Schedule of Current Assets (Schedule-11)

(A)	Health A/c	Current Year	Previous Year
29.	Material & Supplies Advance	-	4,50,000.00
30.	Office Expense Advance	8,43,309.10	1,42,066.50
31.	Security with Decentralised Institutes	-	24,03,000.00
32.	Bank Balance lying with RRI Kolkata to be Received/Adjustments	19,323.00	19,323.00
33.	Hindi Pakhwada Advance	136899.00	193100.00
34.	Advance for Health Camp	1,59,928.00	1,59,928.00
35.	Arogya Advance	167,765.00	1,51,706.00
36.	International Conference & Unani Day Advance	15,29,089.00	7,21,730.00
37.	Fuel advance	3,000.00	-
38.	Fuel Advance (NER)	2,00,000.00	-
39.	IT (Computer/Accessories) Advance	33,400.00	-
40.	Office Expense advance (SCSP)	15,000.00	-
41.	Office Expense advance (NER)	50,000.00	-
42.	Capital advance (NER)	25,00,000.00	-
43.	Expense paid	700.00	-
44.	Imprest Advance	49,943.00	-
	A Total (Rs.)	44,37,31,956.86	39,81,88,265.15
(B)	Family Welfare A/c:	-	-
	(i) Current Assets	-	-
(C)	NPS A/c	-	2,08,509.00
(D)	GPF A/c	-	-
	(i) Current Assets	5,79,04,589.00	5,76,28,160.00
(E)	GIS A/c	12,72,336.00	13,70,345.00
(F)	Pension Fund A/c	3,05,93,817.00	3,18,58,583.00
	Total (B to F) Rs. C/f	8,97,70,742.00	9,10,65,597.99

Sd/-
(Shakaib Hasan)
Consultant (IA)Sd/-
(Mohammad Parvez)
Administrative OfficerSd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, AdministrationSd/-
(Dr. N. Zaheer Ahmed)
Director General

Break-up of Closing Balance as on 31st March 2024
(Schedule-11)

(G) Bank of India (A)	Imprest 16602		4,51,987.15	Health A/c
	Total (A)		2,34,01,411.3	
-do- (B)	16601		1,95,96,322.00	GPF A/c
-do-	16640		24,30,422.34	GIS A/c
Bank of Baroda	8477		8,30,78,950.53	Pension A/c
SBI	1088		1,42,43,150.31	NPS A/c
	Total (B)		11,93,48,845.18	
	Grand Total (A + B) Schedule S/5A		14,27,50,256.48	
-do- (C)	3988		Nil	IT A/c
			-	CRISM A/c
-do-	11685		-	AIUM A/c
Bank of India	19612		-	UPS Aligarh
-do-	17450		2,64,252.00	Herb Garden A/c
-do-	17450		26,519.00	IPR a/c
-do-	2226		-	Publication of Text Books
-do-	25291		-	DSOP A/c
-do-	3654		-	International Events Conferences (DST)
-do-	6063		-	Unani Chair South African
-do-	190312		-	DST A/c

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

Break-up of Closing Balance as on 31st March 2024
(Schedule-11)

-do-	24656	-	WHO A/c
-do-		2,46,67,090.65	PMJV/K A/c
State Bank of India	7704	-	(i) Pharmacovigilance A/c
		5,45,529.50	(ii) Unani Day Conferences A/c
Total (C)		2,55,03,391.15	-
Total (A + B + C) of G		16,82,53,647.63	-
Total (A + B TO F+G)		70,17,56,346.49	-

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General





Schedule of Grant-in-Aid for the Year Ending 31st March 2024
Schedule of Income & Expenditure A/c
Schedule-13 (Grants)

Schedule of Income Forming Part of Income & Expenditure A/c for the Year Ending 31st March 2024

S. N.	Grant in aid	Current Year	Previous Year
A.	Central Government	166,10,00,000.00	173,42,56,000.00
	Total	166,10,00,000.00	173,42,56,000.00

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



Schedule-14 (Fees/Subscription)
Schedule of Income Forming Part of Income & Expenditure A/c for the Year Ending 31st March 2024

S.N.		Current Year	Previous Year
B.	Unani Academic Course/Fees	44,12,488.00	47,86,680.00
	Total	44,12,488.00	47,86,680.00

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General





Schedule-16 (Income from Publication)
Schedule of Income Forming Part of Income & Expenditure A/c for the Year Ending 31st March 2024

	Current Year	Previous Year
Income from Sale of Publication	1,79,505.00	98,722.00
Total	1,79,505.00	98,722.00

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



Schedule-17(2) (Interest Earned)
Schedule of Income Forming Part of Income & Expenditure A/c for the Year Ending 31st March 2024

	Current Year	Previous Year
On Saving Accounts	-	61,88,004.00
On Refundable Advances	-	3,99,430.00
Total	-	65,87,434.00

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



Schedule-18 (Other Income)
Schedule of Income Forming Part of Income & Expenditure A/c for the Year Ending 31st March 2024

S.N.	18(4) Miscellaneous Income	Current Year	Previous Year
1.	OPD/Regn fee from patients	2,66,90,515.00	1,80,45,220.00
2.	Recoveries of excess payment/provision in previous year	-	9,65,807.00
3.	RTI	238.00	370.00
4.	Sale of Raddi etc.	3,747.00	5,471.00
5.	Library user charges	5,305.00	-
6.	Water and electricity charges	23,307.00	28,080.00
7.	Licence fees	2,09,738.00	1,33,403.00
8.	DTL project	45,334.00	-
9.	Auction money	1,07,441.00	9,635.00
10.	Sale of Magazine	6,475.00	-
11.	Tender fee	-	19,500.00
12.	Sale of security paper	10,000.00	9,000.00
13.	Unani Funds	39,98,912.00	-
14.	Sale of Stamps	150.00	17,774.00
15.	Scrap/Condemn items	12,768.00	78,035.00
16.	Misc. receipts	10,07,633.00	29,23,725.51
17.	Other receipts (Decentralized Instt)	3,20,706.00	-
18.	Return wrongly paid	-	15,368.00
19.	NPS Corpus Amount	1,88,16,352.62	74,28,539.50
20.	Exam paid received	-	3,416.00
21.	EOL receipt	-	786.00
22.	DTL project	-	62,470.00
23.	Parking fees	3,000.00	6,000.00

Sd/- (Shakaib Hasan)
Consultant (IA)

Sd/- (Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/- (Mohammad Parvez)
Administrative Officer

Sd/- (Dr. N. Zaheer Ahmed)
Director General

Schedule-18 (Other Income)
Schedule of Income Forming Part of Income & Expenditure A/c for the Year Ending 31st March 2024

S.N.	18(4) Miscellaneous Income	Current Year	Previous Year
24.	Auditorium fees	-	20,000.00
25.	Refund/Receipt	2,02,046.00	1,54,436.00
26.	Electricity recovery	1,659.00	-
27.	Unspent balance	9,07,964.15	-
	Total	5,23,73,291.37	2,99,27,036.01

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General





Non-recurring/Capital Expenditure (Schedule-19)
Schedule of Expenditure Forming Part of Income & Expenditure A/c for the Year Ending 31st March 2024

S.N.	Non-Recurring/Capital Expenditure	Current Year	Previous Year
•	Machinery & Equipment	4,27,82,594.00	23,70,524.00
•	Vehicles	-	6,97,482.00
•	Furniture & Fixture	22,31,814.00	11,61,978.00
•	Books & Journals	5,30,509.00	1,75,127.00
•	Computers	39,16,410.00	3,14,332.00
	Total	4,94,61,327.00	47,19,443.00

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



Income & Expenditure A/c (Schedule-20) Establishment Expenses
Schedule of Expenditure Forming Part of Income & Expenditure A/c for the Year Ending 31st March 2024

S.N.		Current Year	Previous Year
(A)	Salaries	71,53,88,543.00	68,76,50,749.00
	Contribution to Other Fund	32,05,89,112.00	35,38,58,110.00
	NPS 3,90,92,371.00		
	Pension 28,14,96,741.00		
	DLIS NIL		
	Expenses on Employees Retirement Benefits	6,39,86,854.00	6,99,26,936.00
	Total (A)	109,99,64,509.00	111,14,35,795.00
(B)	NPS Corpus Amount Paid	-	30,13,061.00
	Total (A+B)	109,99,64,509.00	111,14,35,795.00
			30,13,061.00

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



Schedule-21 (Other Administrative Expenses, etc.)
Schedule of Expenditure Forming Part of Income & Expenditure A/c for the Year Ending 31st March 2024

S. N.	Description	Current Year	Previous Year
A.	Other Administrative Expenses		
1.	T.A.	95,75,569.00	69,56,476.00
2.	Wages Including Contractual Staff Remuneration		
3.	Office Expenses (Stationary & Printing, Electricity, Water, Telephone, Cartage/Freight, Advocate Fees, Refreshment, Advertisement Charges, etc.	5,32,36,361.00	11,71,05,378.00
4.	Rent & Taxes (Rent of Building & Property Tax)	2,46,79,398.53	8,46,93,563.88
5.	Maintenance & Repair, Petrol, Diesel Expenses, etc.	23,80,919.00	1,30,23,757.00
6.	Information Technology (Recurring Expenses, i.e. Repair of Computers Cartridge, Net Charges, Website Charges, etc.)	19,53,635.00	93,68,606.00
7.	Consolidated Expenses on A/c SCP/TSP Wages/Remuneration of Staff/Stationary & Other Miscellaneous expenses	1,05,22,631.00	64,33,243.00
8.	General Consolidation	6,51,29,050.00	5,69,27,902.00
		20,40,86,426.65	-
	Total Schedule -21 (A)	37,15,63,990.18	29,45,08,925.88
B.	Material & Supplies (Medicines, Chemicals, Glassware & Lab Investigation Charges, etc.)	11,36,62,905.00	20,01,19,612.00
	Total 21-(B)	11,36,62,905.00	20,01,19,612.00
C.	Other Charges		
	• Medical Expenses	58,81,136.00	1,35,45,094.00
	• Survey Expenses	39,46,042.00	-
	• Arogya Fair	-	1,77,178.00
	• Health Camps	-	-
	• Unani Academic Course	8,41,15,418.00	6,51,07,628.00
	• Swachhta Action Plan	35,66,352.00	32,76,226.00
	• COVID-19 Expenses	-	-
	• Mobile Health Visits	-	-
	• EMR Expenses	-	-

Sd/- (Shakaib Hasan) Consultant (IA) Sd/- (Mohammad Parvez) Administrative Officer Sd/- (Dr. Ram Pratap Meena) Assistant Director (Chemistry) & Incharge, Administration Sd/- (Dr. N. Zaheer Ahmed) Director General

Schedule-21 (Other Administrative Expenses, etc.)
Schedule of Expenditure Forming Part of Income & Expenditure A/c for the Year Ending 31st March 2024

S. N.	Description	Current Year	Previous Year
•	Research Activities	3,37,52,302.00	4,47,30,998.00
•	Training Programme	1,40,000.00	-
•	Seminar	10,59,278.00	14,59,332.00
•	Ethics Committee Expenses	-	63,283.00
•	Unani Day & Seminar	44,87,494.00	38,89,772.00
•	Hindi Pakhwada	5,51,048.00	7,20,853.00
•	GIA to Chemical Research Unit- Aligarh	-	-
•	IEC Expenses	12,920.00	20,650.00
•	Health Mela Expenses	-	-
•	Ayurveda Parv	-	-
•	NPCDCS	-	99,711.00
•	AHMIS	-	1,16,880.00
•	CGHS Contribution	8,14,604.00	25,19,973.00
•	Exhibition Mela	-	66,306.00
•	EOI Project Review Committee Expenses	-	-
•	Contribution to GIS	-	-
•	IPR Expenses	-	-
•	Ph.D. Programme	-	7,08,000.00
•	NABH	12,980.00	1,16,253.00
•	Hindi Workshop	1,92,515.00	37,26,541.00
•	Pharmacovigilance Expenses	4,50,000.00	-
	Total S. No. 21 (C)	13,89,82,089.00	14,03,44,678.00
	Grand Total Schedule 21 (A to C)	62,42,08,984.18	63,49,73,215.88

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



Schedule-21(E)
Schedule of Expenditure Forming Part of Income & Expenditure A/c for the Year Ending 31st March 2024

S.N. (D)	Depreciation	Current Year		Previous Year	
		Health	(F.W)	Health	(F.W)
(i)	Machinery & Equipment	95,06,953.00	-	7,83,786.00	-
(ii)	Furniture & Fixtures	30,73,345.00	-	3,21,605.00	-
(iii)	Computers	17,86,214.00	-	28,76,096.00	-
(iv)	Books & Journals	19,31,142.00	-	29,88,430.00	-
(v)	Vehicles	2,64,810.00	-	1,96,177.00	-
(vi)	Building	21,15,819.00	-	23,50,910.00	-
	Total Rs.	1,86,78,283.00	-	1,94,65,525.00	-
	Grand Total	1,86,78,283.00	-	1,94,65,525.00	-

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

Schedule of Income & Expenditure A/c (Unspent Balance Refundable to M/o Ayush)

S.N.	Unspent Balance	Current Year	Previous Year
•		-	2,56,10,081.00

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



Schedule of Receipts & Payments A/c
Schedule of Receipts for the Year Ending 31st March 2024

S. N.	Name of the Scheme	Opening Balance		GIA		Bank Interest	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(1)		(2)		(3)	
1.	(i) Health Scheme A/c						
	(a) Cash-in-Hand (Imprest)	-	5,83,336.22	(Capital) 8,00,00,000.00	4,87,50,000.00	23,62,097.00	61,88,004.00
	(b) Cash-in-Hand (Other than Imprest)	-	17,92,250.00	(Revenue) 1,66,10,00,000.00	1,68,55,06,000.00	-	-
	(c) Cash-at-bank	3,43,46,927.22	4,17,80,022.15	-	-	-	-
	Total (Health A/C) S.N.1	3,43,46,927.22	4,41,55,608.37	1,74,10,00,000.00	1,73,42,56,000.00	23,62,097.00	61,88,004.00
2.	Other Specific Accounts						
	(i) IPR	2,77,985.00	11,68,000.00	2,51,466.00	-	62,445.00	61,470.00
	(ii) Herb Garden A/c	2,64,252.00	1,90,232.00	-	-	-	74,020.00
	(iii) Pub. of Text Books A/c	-	-	-	-	-	-
	(iv) UPS A/c	-	-	-	-	-	-
	(v) DSOP	-	-	-	-	-	-
	(vi) AIUM A/c	-	-	-	-	-	-
	(vii) I.T. A/c	24,15,961.00	35,94,007.00	-	-	-	-
	(viii) National Conference on Unani Day	5,45,529.50	1,39,29,33.50	39,98,912.00	-	-	21,502.00
	(ix) PMJVK a/c	4,86,63,000.00	-	-	-	11,75,380.65	-
	(x) International Events Conference A/c	-	-	-	-	-	-

Sd/- (Shakaib Hasan)
Consultant (IA)

Sd/- (Mohammad Parvez)
Administrative Officer

Sd/- (Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/- (Dr. N. Zaheer Ahmed)
Director General

Schedule of Receipts & Payments A/c
Schedule of Receipts for the Year Ending 31st March 2024

S. N.	Name of the Scheme	Opening Balance		GIA		Bank Interest	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(1)		(2)		(3)	
	(xi) DST A/c	-	-	-	-	-	-
	(xii) Pharmacovigilance Workshop A/c	-	-	-	-	-	-
	(xiii) CRISM A/c	-	-	-	-	-	-
	(xiv) South African A/c	-	-	-	-	-	-
	Total S. N. 2	5,21,66,727.50	63,45,172.50	42,50,378.00	-	12,37,825.65	1,56,992.00
3.	(i) NPS A/c	78,97,056.31	76,88,547.31	-	-	1,61,737.00	2,08,509.00
	(ii) CPF/GPF A/c	2,35,16,445.29	5,02,49,455.29	-	-	5,64,946.00	11,06,892.00
	(iii) GIS A/c	39,74,819.84	50,09,435.84	-	-	98,009.00	1,36,274.00
	(iv) Pension Fund A/c	8,33,86,299.53	4,39,92,321.53	-	-	12,64,766.00	17,28,851.00
	Total S. N. 3	11,87,74,620.97	10,69,39,759.97	-	-	20,89,458.00	31,80,526.00
	Grand Total S. N. 1 to 3	20,52,88,275.69	15,74,40,540.84	1,74,52,50,378.00	1,73,42,56,000.00	56,89,380.65	95,25,522.00

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



Schedule of Receipts & Payments A/c
Schedule of Receipts for the Year Ending 31st March 2024

S. N.	Name of the Scheme	Miscellaneous Receipts		Interest on Refundable Advances		Refunds against by Adjustment of Advances Pertaining to Previous Years	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(4)		(5)		(6)	
1.	Health Scheme A/c	2,83,50,275.00	2,18,30,386.51	500.00	1,31,055.00	23,06,314.10	1,54,436.00
		-	-	66792.00	-	-	27,37,267.50
		-	-	-	-	-	8,626.00
	Total (H) S.N.1	2,83,50,275.00	2,18,30,386.51	67,292.00	1,31,055.00	23,06,314.10	29,00,329.50
2.	Other Specific Accounts						
	(i) IPR	-	1,23,609.00	-	-	-	-
	(ii) Herb Garden A/c	-	-	-	-	-	-
	(iii) Pub. of Text Books A/c	-	-	-	-	-	-
	(iv) UPS A/c I	-	-	-	-	-	-
	(v) DSOP	-	-	-	-	-	-
	(vi) AIUM A/c	-	-	-	-	-	-
	(vii) I.T. A/c	-	-	-	-	-	-
	(viii) National Conference on Unani Day	-	2,32,416.00	-	-	-	-
	(ix) PMJVK A/c	-	-	-	-	-	-
	(x) International Events Conference A/c	-	-	-	-	-	-
	(xi) DST A/c	-	-	-	-	-	-

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

Schedule of Receipts & Payments A/c
Schedule of Receipts for the Year Ending 31st March 2024

S. N.	Name of the Scheme	Miscellaneous Receipts		Interest on Refundable Advances		Refunds against by Adjustment of Advances Pertaining to Previous Years	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(4)		(5)		(6)	
	(xii) Pharmacovigilance workshop A/c	-	-	-	-	-	-
	(xiii) CRISM A/c	-	-	-	-	-	-
	(xiv) South African A/c	-	-	-	-	-	-
	Total S.N. 2	-	3,56,025.00	-	-	-	-
3.	(i) NPS A/c	-	-	-	-	-	-
	(ii) CPF/GPF A/c	-	-	-	-	-	-
	(iii) GIS A/c	-	-	-	-	-	-
	(iv) Pension Fund A/c	1,14,116.00	56,63,661.00	-	-	-	-
	Total S.N. 3	1,14,116.00	56,63,661.00	-	-	-	-
	Grand Total S.N. 1 to 3	2,84,64,391.00	2,78,50,072.51	67,292.00	1,31,055.00	23,06,314.10	29,00,329.50

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



Schedule of Receipts & Payments A/c
Schedule of Receipts for the Year Ending 31st March 2024

S. N.	Name of the Scheme	Recoveries of Refundable Advances		Sale of Council's Publications	
		Current Year	Previous Year	Current Year	Previous Year
		(7)		(8)	
1.	(i) Health Scheme A/c	-	8,28,971.00	1,79,505.00	98,722.00
	Total S.N.1	-	8,28,971.00	1,79,505.00	98,722.00
2.	Other Specific Accounts				
	(i) IPR	-	-	-	-
	(ii) Herb Garden A/c	-	-	-	-
	(iii) Pub. of Text Books A/c	-	-	-	-
	(iv) UPS A/c I	-	-	-	-
	(v) DSOP	-	-	-	-
	(vi) AIUM A/c	-	-	-	-
	(vii) I.T. A/c	-	-	-	-
	(viii) National Conference on Unani Day	-	-	-	-
	(ix) PMJVK A/c	-	-	-	-
	(x) International Events Conference A/c	-	-	-	-
	(xi) DST A/c	-	-	-	-
	(xii) Pharmacovigilance workshop A/c	-	-	-	-
	(xiii) CRISM A/c	-	-	-	-
	(xiv) South African A/c	-	-	-	-
	Total S.N. 2	-	-	-	-

Sd/- (Shakaib Hasan)
Consultant (IA)

Sd/- (Mohammad Parvez)
Administrative Officer

Sd/- (Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/- (Dr. N. Zaheer Ahmed)
Director General



Schedule of Receipts & Payments A/c
Schedule of Receipts for the Year Ending 31st March 2024

S. N.	Name of the Scheme	Recoveries of Refundable Advances		Sale of Council's Publications	
		Current Year	Previous Year	Current Year	Previous Year
		(7)		(8)	
3.	(i) NPS A/c	-	-	-	-
	(ii) CPF/GPF A/c	-	-	-	-
	(iii) GIS A/c	-	-	-	-
	(iv) Pension Fund A/c	-	-	-	-
	Total S.N. 3	-	-	-	-
	Grand Total S.N. 1 to 3	-	8,28,971.00	1,79,505.00	98,722.00

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General





Schedule of Receipts & Payments A/c
Schedule of Receipts for the Year Ending 31st March 2024

S. N.	Name of the Scheme	Recoveries for Remittance		Recovery of Subscription/Advances		Interest on FDRs	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(9)		(10)		(11)	
1.	Health Scheme A/c	1,94,04,187.00	1,64,25,419.00	-	-	-	-
	Total (H) S.N. 1	1,94,04,187.00	1,64,25,419.00	-	-	-	-
2.	Other Specific Accounts						
	(i) IPR	-	-	-	-	-	-
	(ii) Herb Garden A/c	-	-	-	-	-	-
	(iii) Pub. of Text Books A/c	-	-	-	-	-	-
	(iv) UPS A/c I	-	-	-	-	-	-
	(v) DSOP	-	-	-	-	-	-
	(vi) Allium A/c	-	-	-	-	-	-
	(vii) I.T. A/c	-	-	-	-	-	-
	(viii) National Conference on Unani Day	-	16,598.00	-	-	-	-
	(ix) PMJV/K A/c	-	-	-	-	-	-
	(x) International Events Conference A/c	-	-	-	-	-	-
	(xi) DST A/c	-	-	-	-	-	-
	(xii) Pharmacovigilance workshop A/c	-	-	-	-	-	-
	(xiii) CRISM A/c	-	-	-	-	-	-

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



Schedule of Receipts & Payments A/c
Schedule of Receipts for the Year Ending 31st March 2024

S. N.	Name of the Scheme	Recoveries for Remittance		Recovery of Subscription/Advances		Interest on FDRs	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(9)		(10)		(11)	
	(xiv) South African A/c	-	-	-	-	-	-
	Total S.N. 2	-	16,598.00	-	-	-	-
3.	(i) NPS a/c	-	-	-	-	-	-
	(ii) CPF/GPF A/c	-	-	5,81,58,957.00	4,67,60,317.00	-	61,36,816.00
	CPF/GPF A/c Subscription	-	-	6,75,620.00	8,83,928.00	-	3,00,103.00
	(iii) GIS A/c	-	-	-	-	-	-
	(iv) Pension Fund A/c	-	1,84,09,262.00	-	33,792.00	-	87,59,736.00
	Total S. No. 3	-	1,84,09,262.00	5,88,34,577.00	4,76,78,037.00	-	1,51,96,655.00
	Grand Total S. No. 1 to 3	1,94,04,187.00	3,48,51,279.00	5,88,34,577.00	4,76,78,037.00	-	1,51,96,655.00

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



Schedule of Receipts & Payments A/c
Schedule of Receipts for the Year Ending 31st March 2024

S. N.	Name of the Scheme	Receivable Amount Received		Security Deposit Lying with the Council	
		(12)		(13)	
		Current Year	Previous Year	Current Year	Previous Year
1.	Health Scheme A/c	26,93,960.00	88,53,280.82.00	1,06,500.00	1,50,000.00
	Total S.N.1	26,93,960.00	88,53,280.82.00	1,06,500.00	1,50,000.00
2.	Other Specific Accounts:				
	(i) IPR	-	-	-	-
	(ii) Herb Garden A/c	-	-	-	-
	(iii) Pub. of Text Books A/c	-	-	-	-
	(iv) UPS A/c I	-	-	-	-
	(v) DSOP	-	-	-	-
	(vi) AIUM A/c	-	-	-	-
	(vii) I.T. A/c	-	-	-	-
	(viii) National Conference on Unani Day	-	-	-	-
	(ix) PMJVK A/c	-	-	-	-
	(x) International Events Conference A/c	-	-	-	-
	(xi) DST A/c	-	-	-	-
	(xii) Pharmacovigilance workshop A/c	-	-	-	-
	(xiii) CRISM A/c	-	-	-	-
	(xiv) South African A/c	-	-	-	-
	Total S.N. 2	-	-	-	-

Sd/- (Shakaib Hasan) Consultant (IA)	Sd/- (Mohammad Parvez) Administrative Officer	Sd/- (Dr. Ram Pratap Meena) Assistant Director (Chemistry) & Incharge, Administration	Sd/- (Dr. N. Zaheer Ahmed) Director General
--	---	--	---

Schedule of Receipts & Payments A/c
Schedule of Receipts for the Year Ending 31st March 2024

S. N.	Name of the Scheme	Receivable Amount Received		Security Deposit Lying with the Council	
		Current Year	Previous Year	Current Year	Previous Year
		(12)		(13)	
3.	(i) NPS A/c	-	-	-	-
	(ii) CPF/GPF A/c	-	-	-	-
	(iii) GIS A/c	-	-	-	-
	(iv) Pension Fund A/c	-	-	-	-
	Total S.N. 3	-	-	-	-
	Grand Total S.N. 1 to 3	26,93,960.00	88,53,280.82.00	1,06,500.00	1,50,000.00

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



Schedule of Receipts & Payments A/c
Schedule of Receipts for the Year Ending 31st March 2024

S.N.	Name of the Scheme	In Transit Amount Received		Academic Course Fee		Amount Received but Payable to Other Institute/Units	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(14)		(15)		(16)	
1.	(i) Health Scheme A/c	-	-	44,12,488.00	47,86,680.00	-	-
	(ii) Health Scheme A/c					-	-
	(iii) T.D.S.					-	-
	Total S.N.1	-	-	44,12,488.00	47,86,680.00	-	-
2.	Other Specific Accounts	-	-	-	-	-	-
	(i) IPR	-	-	-	-	-	-
	(ii) Herb Garden A/c	-	-	-	-	-	-
	(iii) Pub. of Text Books A/c	-	-	-	-	-	-
	(iv) UPS A/c I	-	-	-	-	-	-
	(v) DSOP	-	-	-	-	-	-
	(vi) AIUM A/c	-	-	-	-	-	-
	(vii) I.T. A/c	-	-	-	-	-	-
	(viii) National Conference on Unani Day	-	-	-	-	-	-
	(ix) PMJVK A/c	-	-	-	-	-	-
	(x) International Events Conference A/c	-	-	-	-	-	-
	(xi) DST A/c	-	-	-	-	-	-

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

Schedule of Receipts & Payments A/c
Schedule of Receipts for the Year Ending 31st March 2024

S.N.	Name of the Scheme	In Transit Amount Received		Academic Course Fee		Amount Received but Payable to Other Institute/Units	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(14)		(15)		(16)	
	(xii) Pharmacovigilance workshop A/c	-	-	-	-	-	-
	(xiii) CRISM A/c	-	-	-	-	-	-
	(xiv) South African A/c	-	-	-	-	-	-
	Total S.N. 2	-	-	-	-	-	-
3.	(i) NPS A/c	-	-	-	-	-	-
	(ii) CPF/GPF A/c	-	-	-	-	-	-
	(iii) GIS A/c	-	-	-	-	-	-
	(iv) Pension Fund A/c	-	-	-	-	-	-
	Total S.N. 3	-	-	-	-	-	-
	Grand Total S.N. 1 to 3	-	-	44,12,488.00	47,86,680.00	-	-

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



Schedule of Receipts & Payments A/c
Schedule of Receipts for the Year Ending 31st March 2024

S. N.	Name of the Scheme	Investment Received		LIC Amount for Disbursement	
		Current Year	Previous Year	Current Year	Previous Year
		(17)		(18)	
1.	Health Scheme A/c				
	(i) Health Scheme	-	-	-	-
	Total S. N. 1	-	-	-	-
2.	Other Specific Accounts				
	(i) IPR	-	-	-	-
	(ii) Herb Garden A/c	-	-	-	-
	(iii) Pub. of Text Books A/c	-	-	-	-
	(iv) UPS A/c I	-	-	-	-
	(v) DSOP	-	-	-	-
	(vi) AIJUM A/c	-	-	-	-
	(vii) I.T. A/c	-	-	-	-
	(viii) National Conference on Unani Day	-	-	-	-
	(ix) PMJVK A/c	-	-	-	-
	(x) International Events Conference A/c	-	-	-	-
	(xi) DST A/c	-	-	-	-
	(xii) Pharmacovigilance workshop A/c	-	-	-	-
	(xiii) CRISM A/c	-	-	-	-
	(xiv) South African A/c	-	-	-	-
	Total S.N. 2	-	-	-	-
3.	(i) NPS A/c	61,84,357.00	-	-	-
	(ii) CPF/GPF A/c	-	10,10,85,099.40	-	-

Sd/- (Shakaib Hasan)
Consultant (IA)

Sd/- (Mohammad Parvez)
Administrative Officer

Sd/- (Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/- (Dr. N. Zaheer Ahmed)
Director General

Schedule of Receipts & Payments A/c
Schedule of Receipts for the Year Ending 31st March 2024

S. N.	Name of the Scheme	Investment Received		LIC Amount for Disbursement	
		Current Year	Previous Year	Current Year	Previous Year
		(17)		(18)	
	(iii) GIS A/c	-	57,47,987.00	-	2,00,000.00
	(iv) Pension Fund A/c	2,57,84,283.00	18,28,75,712.00	-	-
	Total S.N. 3	3,19,68,640.00	28,97,08,798.40	-	2,00,000.00
	Grand Total S.N. 1 to 3	3,19,68,640.00	28,97,08,798.35	-	2,00,000.00

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



Schedule of Receipts & Payments A/c
Schedule of Receipts for the Year Ending 31st March 2024

S. N.	Name of the Scheme	Pension Fund Transfer from Health Account		Govt. Contribution of Non-Pran Members		Receipts on Closing of Bank	
		Current Year	Previous Year (19)	Current Year	Previous Year (20)	Current Year	Previous Year (21)
1.	Health Scheme A/c						
	(i) Health Scheme	-	-	-	-	-	-
	Total S.N. 1	-	-	-	-	-	-
2.	Other Specific Accounts	-	-	-	-	-	-
	(i) IPR	-	-	-	-	-	-
	(ii) Herb Garden A/c	-	-	-	-	-	-
	(iii) Pub. of Text Books A/c	-	-	-	-	-	-
	(iv) UPS A/c I	-	-	-	-	-	-
	(v) DSOP	-	-	-	-	-	-
	(vi) AIUM A/c	-	-	-	-	-	-
	(vii) I.T. A/c	-	-	-	-	-	-
	(viii) National Conference on Unani Day	-	-	-	-	-	-
	(ix) PMJVK A/c	-	-	-	-	-	-
	(x) International Events Conference A/c	-	-	-	-	-	-
	(xi) DST A/c	-	-	-	-	-	-
	(xii) Pharmacovigilance workshop A/c	-	-	-	-	-	-
	(xiii) CRISM A/c	-	-	-	-	-	-

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



Schedule of Receipts & Payments A/c
Schedule of Receipts for the Year Ending 31st March 2024

S. N.	Name of the Scheme	Pension Fund Transfer from Health Account		Govt. Contribution of Non-Pran Members		Receipts on Closing of Bank	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(19)		(20)		(21)	
	(xiv) South African A/c	-	-	-	-	-	-
	Total S.N. 2	-	-	-	-	-	-
3.	(i) NPS A/c	-	-	-	-	-	-
	(ii) CPF/GPF A/c	-	-	-	-	-	-
	(iii) GIS A/c	-	-	-	-	-	-
	(iv) Pension Fund A/c	28,14,96,741.00	32,53,79,943.00	-	-	-	-
	Total S.N. 3	28,14,96,741.00	32,53,79,943.00	-	-	-	-
	Grand Total S.N. 1 to 3	28,14,96,741.00	32,53,79,943.00	-	-	-	-

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General





Schedule of Receipts & Payments A/c
Schedule of Receipts for the Year Ending 31st March 2024



S. N.	Name of the Scheme	NPS Corpus Amount		Unspent Balance (Previous Year)		Unspent Balance (Current Year)	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(22)		(23)		(24)	
1.	Health Scheme A/c						
	(i) Health Scheme	3,20,40,648.62	74,28,539.50	39,98,912.00	-	1,24,74,386.50	81,67,538.12
	Total S.N. 1	3,20,40,648.62	74,28,539.50	39,98,912.00	-	1,24,74,386.50	81,67,538.12
2.	Other Specific Accounts						
	(i) IPR	-	-	-	-	-	-
	(ii) Herb Garden A/c	-	-	-	-	-	-
	(iii) Pub. of Text Books A/c	-	-	-	-	-	-
	(iv) UPS A/c I	-	-	-	-	-	-
	(v) DSOP	-	-	-	-	-	-
	(vi) AIUM A/c	-	-	-	-	-	-
	(vii) I.T. A/c	-	-	-	-	-	-
	(viii) National Conference on Unani Day	-	-	-	-	-	-
	(ix) PMJVK A/c	-	-	-	-	-	-
	(x) International Events Conference A/c	-	-	-	-	-	-
	(xi) DST A/c	-	-	-	-	-	-
	(xii) Pharmacovigilance workshop A/c	-	-	-	-	-	-
	(xiii) CRISM A/c	-	-	-	-	-	-
	(xiv) South African A/c	-	-	-	-	-	-

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

Schedule of Receipts & Payments A/c
Schedule of Receipts for the Year Ending 31st March 2024

S. N.	Name of the Scheme	NPS Corpus Amount		Unspent Balance (Previous Year)		Unspent Balance (Current Year)	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(22)	(23)	(24)	(25)	(26)	(27)
	Total S.N. 2	-	-	-	-	-	-
3.	(i) NPS A/c	-	-	-	-	-	-
	(ii) CPF/GPF A/c	-	-	-	-	-	-
	(iii) GIS A/c	-	-	-	-	-	-
	(iv) Pension Fund A/c	-	-	-	-	-	-
	Total S.N. 3	-	-	-	-	-	-
	Grand Total S.N. 1 to 3	3,20,40,648.62	74,28,539.50	39,98,912.00	-	1,24,74,386.50	81,67,538.12

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



Schedule of Receipts & Payments A/c
Schedule of Receipts for the Year Ending 31st March 2024

S. N.	Name of the Scheme	Fund Transfer		Total Receipts	
		Current Year	Previous Year	Current Year	Previous Year
		(25)		(26)	
1.	Health Scheme A/c				
	(i) Health Scheme	-	1,97,50,400.00	1,88,37,43,192.44	1,87,59,50,933.82
	Total S.N. 1	-	1,97,50,400.00	1,88,37,43,192.44	1,87,59,50,933.82
2.	Other Specific Accounts				
	(i) IPR	-	-	5,91,896.00	13,53,079.00
	(ii) Herb Garden A/c	-	-	2,64,252.00	2,64,252.00
	(iii) Pub. of Text Books A/c	-	-	-	-
	(iv) UPS A/c I	-	-	-	-
	(v) DSOP	-	-	-	-
	(vi) AIUM A/c	-	-	-	-
	(vii) I. T. A/c	-	-	24,15,961.00	35,94,007.00
	(viii) National Conference on Unani Day	-	-	45,44,441.50	16,63,449.50
	(ix) PMJVK A/c	-	-	4,98,38,380.65	-
	(x) International Events Conference A/c	-	-	-	-
	(xi) DST A/c	-	-	-	-
	(xii) Pharmacovigilance workshop A/c	-	-	-	-
	(xiii) CRISM A/c	-	-	-	-
	(xiv) South African A/c	-	-	-	-
	Total S. N. 2	-	-	5,76,54,931.15	68,74,787.50

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



Schedule of Receipts & Payments A/c
Schedule of Receipts for the Year Ending 31st March 2024

S. N.	Name of the Scheme	Fund Transfer		Total Receipts	
		Current Year	Previous Year	Current Year	Previous Year
		(25)		(26)	
3.	(i) NPS A/c	-	-	1,42,43,150.31	78,97,056.31
	(ii) CPF/GPF A/c	-	-	8,22,40,348.29	20,53,38,579.64
	(iii) GIS A/c	-	-	47,48,448.84	1,22,77,727.84
	(iv) Pension Fund A/c	-	1,73,45,900.00	39,20,46,205.53	60,41,89,178.53
	Total S. N. 3	-	1,73,45,900.00	49,32,78,152.97	82,97,02,542.32
	Grand Total S. N. 1 to 3	-	3,70,96,300.00	2,43,46,76,576.56	2,71,25,28,263.64

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



Schedule of Payments for the Year Ending 31st March 2024

S.N.	Name of the Scheme	Establishment Expenses		Administrative Expenses		Material & Supplies Expenses	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(1)		(2)		(3)	
1.	Health Scheme						
	(i) Health scheme A/c	1,08,42,69,917.00	1,02,88,84,495.00	43,28,78,316.50	29,77,53,870.00	12,58,22,137.00	20,99,95,515.00
		-	-	3,00,96,032.00	-	-	-
		-	-	1,97,25,656.00	-	-	-
	Total(H) S.N.1	1,08,42,69,917.00	1,02,88,84,495.00	48,27,00,004.53	29,77,53,870.00	12,58,22,137.00	20,99,95,515.00
2.	Other Specific Accounts						
	(i) IPR	-	-	-	-	-	-
	(ii) Herb Garden A/c	-	-	-	-	-	-
	(iii) Pub. of Text Books A/c	-	-	-	-	-	-
	(iv) UPS A/c I	-	-	-	-	-	-
	(v) DSOP	-	-	-	-	-	-
	(vi) Allium A/c	-	-	-	-	-	-
	(vii) I.T. A/c	-	-	-	-	-	-
	(viii) National Conference on Unani Day	-	-	-	-	-	-
	(ix) PMJVK A/c	-	-	-	-	-	-
	(x) International Events Conference A/c	-	-	-	-	-	-
	(xi) DST A/c	-	-	-	-	-	-
	(xii) Pharmacovigilance workshop A/c	-	-	-	-	-	-

Sd/- (Shakaib Hasan)
Consultant (IA)

Sd/- (Mohammad Parvez)
Administrative Officer

Sd/- (Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/- (Dr. N. Zaheer Ahmed)
Director General

Schedule of Payments for the Year Ending 31st March 2024

S.N.	Name of the Scheme	Establishment Expenses		Administrative Expenses		Material & Supplies Expenses	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(1)		(2)		(3)	
	(xiii) CRISM A/c	-	-	-	-	-	-
	(xiv) South African A/c	-	-	-	-	-	-
	Total S.N. 2	-	-	-	-	-	-
3.	(i) NPS A/c	-	-	-	-	-	-
	(ii) CPF/GPF A/c	-	-	3,019.67	4,012.00	-	-
	(iii) GIS A/c	-	-	4.50	-	-	-
	(iv) Pension Fund A/c	-	-	873.00	-	-	-
	Total S.N. 3	-	-	3,897.17	4,012.00	-	-
	Grand Total S.N. 1 to 3	1,08,42,69,917.00	1,02,88,84,495.00	48,27,03,901.70	29,77,57,882.00	12,58,22,137.00	20,99,95,515.00

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



Schedule of Payments for the Year Ending 31st March 2024

S.N.	Name of the Scheme	Assets		Publications (Priced)		Advances to Government Servants	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(4)		(5)		(6)	
1.	Health Scheme	1,29,64,843.00	47,19,443.00	-	-	9,25,849.07	31,48,260.00
	(i) Health scheme A/c	25,09,000.00	-	-	-	-	-
		1,54,73,843.00	47,19,443.00	-	-	9,25,849.07	31,48,260.00
	Total (H) S. N. 1						
2.	Other Specific Accounts						
	(i) IPR	-	-	-	-	-	-
	(ii) Herb Garden A/c	-	-	-	-	-	-
	(iii) Pub. of Text Books A/c	-	-	-	-	-	-
	(iv) UPS A/c I	-	-	-	-	-	-
	(v) DSOP	-	-	-	-	-	-
	(vi) AIUM A/c	-	-	-	-	-	-
	(vii) I. T. A/c	-	-	-	-	-	-
	(viii) National Conference on Unani Day	-	-	-	-	-	-
	(ix) PMJVK A/c	-	-	-	-	-	-
	(x) International Events Conference A/c	-	-	-	-	-	-
	(xi) DST A/c	-	-	-	-	-	-
	(xii) Pharmacovigilance workshop A/c	-	-	-	-	-	-
	(xiii) CRISM A/c	-	-	-	-	-	-

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

Schedule of Payments for the Year Ending 31st March 2024

S.N.	Name of the Scheme	Assets		Publications (Priced)		Advances to Government Servants	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(4)		(5)		(6)	
	(xiv) South African A/c	-	-	-	-	-	-
	Total S.N. 2	-	-	-	-	-	-
3.	(i) NPS A/c	-	-	-	-	-	-
	(ii) CPF/GPF A/c	-	-	-	-	-	-
	(iii) GIS A/c	-	-	-	-	-	-
	(iv) Pension Fund A/c	-	-	-	-	-	-
	Total S.N. 3	-	-	-	-	-	-
	Grand Total S.N. 1 to 3	1,54,73,843.00	47,19,443.00	-	-	9,25,849.07	31,48,260.00

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General





Schedule of Payments for the Year Ending 31st March 2024



S.N.	Name of the Scheme	Outstanding Advances		Other Charges		Capital Payment	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(7)		(8)		(9)	
1.	Health Scheme A/c	1,08,42,452.00	1,88,31,811.00	3,08,78,646.00	11,07,22,370.00	5,29,89,253.00	2,28,47,512.00
		-	-	-	-	25,00,000.00	1,10,07,910.00
	Total S.N.1	1,08,42,452.00	1,88,31,811.00	3,08,78,646.00	11,07,22,370.00	5,54,89,253.00	3,38,55,422.00
2.	Other Specific Accounts						
	(i) IPR	-	-	-	10,75,094.00	-	-
	(ii) Herb Garden A/c	-	-	-	-	-	-
	(iii) Pub. of Text Books A/c	-	-	-	-	-	-
	(iv) UPS A/c I	-	-	-	-	-	-
	(v) DSOP	-	-	-	-	-	-
	(vi) AIUM A/c	-	-	-	-	-	-
	(vii) I.T. A/c	-	-	9,65,542.00	11,78,046.00	-	-
	(viii) National Conference on Unani Day	-	-	-	10,81,166.00	-	-
	(ix) PMJVK A/c	-	-	-	-	2,51,71,290.00	-
	(x) International Events Conference A/c	-	-	-	-	-	-
	(xi) DST A/c	-	-	-	-	-	-
	(xii) Pharmacovigilance workshop A/c	-	-	-	-	-	-
	(xiii) CRISM A/c	-	-	-	-	-	-
	(xiv) South African A/c	-	-	-	-	-	-
	Total S.N.2	-	-	9,65,542.00	33,34,306.00	2,51,71,290.00	-
3.	(i) NPS A/c	-	-	-	-	-	-

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

Schedule of Payments for the Year Ending 31st March 2024

S.N.	Name of the Scheme	Outstanding Advances		Other Charges		Capital Payment	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(7)		(8)		(9)	
	(ii) CPF/GPF A/c	-	-	-	-	-	-
	(iii) GIS A/c	-	-	-	-	-	-
	(iv) Pension Fund A/c	-	-	-	-	-	-
	Total S.N. 3	-	-	-	-	-	-
	Grand Total S.N. 1 to 3	1,08,42,452.00	1,88,31,811.00	3,18,44,188.00	11,40,56,676.00	8,06,60,543.00	3,38,55,422.00

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



Schedule of Payments for the Year Ending 31st March 2024

S.N.	Name of the Scheme	IPR Fund Transfer		Remittance of Recoveries		Amount Disbursed to RRIUM, Chennai	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(10)		(11)		(12)	
1.	Health Scheme	-	-	-	8,24,60,501.00	-	-
	(i) Health Scheme A/c	-	-	-	41,88,487.00	-	-
	Health Scheme A/c	-	-	-	-	-	-
	Total S.N.1	-	-	-	8,66,48,988.00	-	-
2.	Other Specific Accounts						
	(i) IPR	-	-	-	-	-	-
	(ii) Herb Garden A/c	-	-	-	-	-	-
	(iii) Pub. of Text Books A/c	-	-	-	-	-	-
	(iv) UPS A/c I	-	-	-	-	-	-
	(v) DSOP	-	-	-	-	-	-
	(vi) AIUM A/c	-	-	-	-	-	-
	(vii) I.T. A/c	-	-	-	-	-	-
	(viii) National Conference on Unani Day	-	-	-	16,598.00	-	-
	(ix) PMJV/K A/c	-	-	-	-	-	-
	(x) International Events Conference A/c	-	-	-	-	-	-
	(xi) DST A/c	-	-	-	-	-	-
	(xii) Pharmacovigilance workshop A/c	-	-	-	-	-	-

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

Schedule of Payments for the Year Ending 31st March 2024

S.N.	Name of the Scheme	IPR Fund Transfer		Remittance of Recoveries		Amount Disbursed to RRIUM, Chennai	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(10)		(11)		(12)	
	(xiii) CRISM A/c	-	-	-	-	-	-
	(xiv) South African A/c	-	-	-	-	-	-
	Total S.N. 2	-	-	-	16,598.00	-	-
3.	(i) NPS A/c	-	-	-	-	-	-
	(ii) CPF/GPF A/c	-	-	-	19,807.00	-	-
	(iii) GIS A/c	-	-	-	-	-	-
	(iv) Pension Fund A/c	-	-	1,64,87,977.00	2,40,72,252.00	-	-
	Total S.N. 3	-	-	1,64,87,977.00	2,40,92,059.00	-	-
	Grand Total S.N. 1 to 3	-	-	1,64,87,977.00	11,07,57,645.00	-	-

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



Schedule of Payments for the Year Ending 31st March 2024

S.N.	Name of the Scheme	NPS Employee Contribution Paid to Non Pran		Investments A/c		Received from LIC Disbursed	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(13)		(14)		(15)	
1.	Health Scheme						
	(i) Health Scheme A/c	-	-	-	-	-	-
	Total S. N. 1	-	-	-	-	-	-
2.	Other Specific Accounts						
	(i) IPR	-	-	-	-	-	-
	(ii) Herb Garden A/c	-	-	-	-	-	-
	(iii) Pub. of Text Books A/c	-	-	-	-	-	-
	(iv) UPS A/c I	-	-	-	-	-	-
	(v) DSOP	-	-	-	-	-	-
	(vi) AIUM A/c	-	-	-	-	-	-
	(vii) I.T. A/c	-	-	-	-	-	-
	(viii) National Conference on Unani Day	-	-	-	-	-	-
	(ix) PMJVK A/c	-	-	-	-	-	-
	(x) International Events Conference A/c	-	-	-	-	-	-
	(xi) DST A/c	-	-	-	-	-	-
	(xii) Pharmacovigilance workshop A/c	-	-	-	-	-	-
	(xiii) CRISM A/c	-	-	-	-	-	-
	(xiv) South African A/c	-	-	-	-	-	-
	Total S. N. 2	-	-	-	-	-	-

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

Schedule of Payments for the Year Ending 31st March 2024

S.N.	Name of the Scheme	NPS Employee Contribution Paid to Non Pran		Investments A/c		Received from LIC Disbursed	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(13)		(14)		(15)	
3.	(i) NPS A/c	-	-	-	-	-	-
	(ii) CPF/GPF A/c	-	-	-	10,72,21,915.40	-	-
	(iii) GIS A/c	-	-	-	60,48,090.00	-	2,00,000.00
	(iv) Pension Fund A/c	-	-	-	19,16,35,448.00	-	-
	Total S.N. 3	-	-	-	30,49,05,453.35	-	2,00,000.00
	Grand Total S.N. 1 to 3	-	-	-	30,49,05,453.35	-	2,00,000.00

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



Schedule of Payments for the Year Ending 31st March 2024

S.N.	Name of the Scheme	Amount Payable Paid/Adjusted		Other Misc. Payments/Transfer		Refund of EMD	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(16)		(17)		(18)	
1.	Health Scheme						
	(i) Health Scheme A/c	-	-	1,48,65,935.00	1,97,50,400.00	2,38,998.00	15,89,152.000
	Health Scheme A/c	-	-	669.96			
	Total S.N.1	-	-	1,48,66,604.96	1,97,50,400.00	2,38,998.00	15,89,152.00
2.	Other Specific Accounts						
	(i) IPR	-	-	-	-	-	-
	(ii) Herb Garden A/c	-	-	-	-	-	-
	(iii) Pub. of Text Books A/c	-	-	-	-	-	-
	(iv) UPS A/c I	-	-	-	-	-	-
	(v) DSOP	-	-	-	-	-	-
	(vi) AIUM A/c	-	-	-	-	-	-
	(vii) I.T. A/c	-	-	-	-	-	-
	(viii) National Conference on Unani Day	39,98,912.00	-	-	-	-	-
	(ix) PMJVK A/c	-	-	-	-	-	-
	(x) International Events Conference A/c	-	-	-	-	-	-
	(xi) DST A/c	-	-	-	-	-	-
	(xii) Pharmacovigilance workshop A/c	-	-	-	-	-	-
	(xiii) CRISM A/c	-	-	-	-	-	-
	(xiv) South African A/c	-	-	-	-	-	-

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

Schedule of Payments for the Year Ending 31st March 2024

S.N.	Name of the Scheme	Amount Payable Paid/Adjusted		Other Misc. Payments/Transfer		Refund of EMD	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(16)		(17)		(18)	
	Total S. N. 2	39,98,912.00	-	-	-	-	-
3.	(i) NPS A/c						
	(ii) CPF/GPF A/c	-	-	6,26,41,006.00	7,45,61,400.00	-	-
	(iii) GIS A/c	-	-	23,18,022.00	20,54,818.00	-	-
	(iv) Pension Fund A/c	-	-	29,24,78,405.00	28,77,49,279.00	-	-
	Total S. N. 3	-	-	35,74,37,433.00	36,43,65,497.00	-	-
	Grand Total S.N. 1 to 3	39,98,912.00	-	37,23,04,037.96	38,41,15,897.00	2,38,998.00	15,89,152.00

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General





Schedule of Payments for the Year Ending 31st March 2024



S.N.	Name of the Scheme	NPS Corpus Amount Paid		Unspent Balance Transferred to Ministry		Fund Transfer on A/c of Closer	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(19)	(20)	(21)	(22)	(23)	(24)
1.	Health Scheme						
	(i) Health scheme A/c	1,32,24,296.00	30,13,061.00	2,56,10,081.00	2,26,91,219.00	-	-
	Health scheme A/c	-	-	-	-	-	-
	Health scheme A/c	-	-	-	-	-	-
	Total S.N.1	1,32,24,296.00	30,13,061.00	2,56,10,081.00	2,26,91,219.00	-	-
2.	Other Specific Accounts						
	(i) IPR	-	-	5,65,377.00	-	-	-
	(ii) Herb Garden A/c	-	-	-	-	-	-
	(iii) Pub. of Text Books A/c	-	-	-	-	-	-
	(iv) UPS A/c I	-	-	-	-	-	-
	(v) DSOP	-	-	-	-	-	-
	(vi) AIUM A/c	-	-	-	-	-	-
	(vii) I.T. A/c	-	-	14,50,419.00	-	-	-
	(viii) National Conference on Unani Day	-	-	-	20,156.00	-	-
	(ix) PMJVK A/c	-	-	-	-	-	-
	(x) International Events Conference A/c	-	-	-	-	-	-
	(xi) DST A/c	-	-	-	-	-	-
	(xii) Pharmacovigilance workshop A/c	-	-	-	-	-	-
	(xiii) CRISM A/c	-	-	-	-	-	-
	(xiv) South African A/c	-	-	-	-	-	-
	Total S.N. 2	-	-	20,15,796.00	20,156.00	-	-

Sd/- (Shakaib Hasan) Consultant (IA) Sd/- (Mohammad Parvez) Administrative Officer Sd/- (Dr. Ram Pratap Meena) Assistant Director (Chemistry) & Incharge, Administration Sd/- (Dr. N. Zaheer Ahmed) Director General

Schedule of Payments for the Year Ending 31st March 2024

S.N.	Name of the Scheme	NPS Corpus Amount Paid		Unspent Balance Transferred to Ministry		Fund Transfer on A/c of Closer	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(19)		(20)		(21)	
3.	(i) NPS A/c	-	-	-	-	-	-
	(ii) CPF/GPF A/c	-	-	-	-	-	-
	(iii) GIS A/c	-	-	-	-	-	-
	(iv) Pension Fund A/c	-	-	-	-	-	-
	Total S.N. 3	-	-	-	-	-	-
	Grand Total S.N. 1 to 3	1,32,24,296.00	30,13,061.00	2,76,25,877.00	2,27,11,375.00	-	-

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



Schedule of Payments for the Year Ending 31st March 2024

S.N.	Name of the Scheme	Fund Transfer		Closing Balance		Total payments	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(22)		(23)		(24)	
	Health Scheme						
1.	(i) Health scheme A/c	-	-	2,34,01,411.44	3,43,46,927.82	1,88,37,43,493.00	1,87,59,50,933.82
	Health scheme A/c						
	Total S.N.1	-	-	2,34,01,411.44	3,43,46,927.82	1,88,37,43,493.00	1,87,59,50,933.82
2.	Other Specific Accounts						
	(i) IPR	-	-	26,519.00	2,77,985.00	5,91,896.00	13,53,079.00
	(ii) Herb Garden A/c	-	-	2,64,252.00	2,64,252.00	2,64,252.00	2,64,252.00
	(iii) Pub. of Text Books A/c	-	-	-	-	-	-
	(iv) UPS A/c I	-	-	-	-	-	-
	(v) DSOP	-	-	-	-	-	-
	(vi) AIUM A/c	-	-	-	-	-	-
	(vii) I.T. A/c	-	-	-	24,15,961.00	24,15,961.00	35,94,007.00
	(viii) National Conference on Unani Day	-	-	5,45,529.50	5,45,529.50	45,44,441.50	16,63,449.50
	(ix) PMJVK A/c	-	-	2,46,67,090.65	-	4,98,38,380.65	-
	(x) International Events Conference A/c	-	-	-	-	-	-
	(xi) DST A/c	-	-	-	-	-	-
	(xii) Pharmacovigilance workshop A/c	-	-	-	-	-	-
	(xiii) CRISM A/c	-	-	-	-	-	-
	(xiv) South African A/c	-	-	-	-	-	-
	Total S.N. 2	-	-	2,55,03,391.15	35,03,727.50	5,76,54,931.15	68,74,787.50

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General

Schedule of Payments for the Year Ending 31st March 2024

S.N.	Name of the Scheme	Fund Transfer		Closing Balance		Total payments	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(22)		(23)		(24)	
3.	(i) NPS A/c	-	-	1,42,43,150.31	78,97,056.31	1,42,43,150.31	78,97,056.31
	(ii) CPF/GPF A/c	-	15,000.00	1,95,96,322.62	2,35,16,445.29	8,22,40,348.29	20,53,38,579.60
	(iii) GIS A/c	-	-	24,30,422.34	39,74,819.84	47,48,448.84	1,22,77,727.84
	(iv) Pension Fund A/c	-	1,73,45,900.00	8,30,78,950.53	8,33,86,299.53	39,20,46,205.50	60,41,89,178.50
	Total S.N. 3	-	1,73,60,900.00	11,93,48,845.80	11,87,74,620.97	49,32,78,152.97	82,97,02,542.30
	Grand Total S.N. 1 to 3	-	1,73,60,900.00	16,82,53,648.39	15,66,25,276.29	2,43,46,76,577.12	2,71,25,28,263.64

Sd/-
(Shakaib Hasan)
Consultant (IA)

Sd/-
(Mohammad Parvez)
Administrative Officer

Sd/-
(Dr. Ram Pratap Meena)
Assistant Director (Chemistry) &
Incharge, Administration

Sd/-
(Dr. N. Zaheer Ahmed)
Director General



5.3. Notes on Accounts

1. Annual accounts of the Council for the year 2023–2024 have been prepared on the uniform format of account for Central Autonomous Bodies (non-profit organization).
2. The Central Council for Research in Unani Medicine is fully financed by Government of India, Ministry of Ayush through grant-in-aid. Therefore, income tax is not applicable on the organization.
3. The said accounts prepared on accrual basis.
4. Schedules are attached wherever necessary.
5. Depreciation has been charged on assets on diminishing balance method.
6. The construction works are done by the CPWD & NPCC.
7. There is no valuation of Inventories since it is not a profit earning organization but a Research Organization under the Ministry of Ayush, Government of India.
8. A schedule of Investment prepared every year and given to audit which is duly reconciled with actual documents figures mentioning there the rate of interest, duration, amount & name of Institutions, etc.
9. Retirement benefits are treated as per the Government of India Rules.
10. Depreciation has been charged under expenditure.
11. Earmarked/Endowment fund has been shown separately in the Balance Sheet with necessary Schedule.
12. The annual accounts of the Council for the year 2023-2024 have been approved by the competent authority, i.e. Standing Finance Committee, on September 04, 2024.

Sd/-
Administrative Incharge
CCRM, New Delhi



APPENDIX-I

INSTITUTIONAL NETWORK OF CCRM

1	Central Council for Research in Unani Medicine 61-65, Institutional Area, Opposite D Block, Janakpuri, New Delhi – 110 058 Phone: +91-11-28521981 Fax: +91-11-28522965 E-mail: unanimedicine@gmail.com; unani-medicine@ccrum.res.in	2	National Research Institute of Unani Medicine for Skin Disorders Opp. ESI Hospital, AG Colony Road Erragadda, Hyderabad – 500 038 Telangana Phone: +91-40-23811551, 23810246 E-mail: criumhyderabad@gmail.com
3	Central Research Institute of Unani Medicine Basaha, Kursi Road, Lucknow – 226 026 Uttar Pradesh Phone: +91-522-2361720 E-mail: ddcriumko@gmail.com	4	Hakim Ajmal Khan Institute for Literary & Historical Research in Unani Medicine Mohibbul Hasan House, Jamia Millia Islamia, Okhla New Delhi – 110 025 E-mail: Iriumnew1986@gmail.com
5	Regional Research Institute of Unani Medicine 1, West Meda Church Street, Royapuram Chennai – 600 013, Tamil Nadu Phone: +91-44-25955519 E-mail: rriumchennai@gmail.com	6	Regional Research Institute of Unani Medicine Chandbali Bypass Road, Near Rural Police Station, Bhadrak – 756 100, Odisha Phone: +91-6784-240289 E-mail: rriumbdk_unani@yahoo.co.in
7	Regional Research Institute of Unani Medicine Guzri, Patna City, Patna – 800 008, Bihar Phone: +91-612-2631106 E-mail: rriumpatna@gmail.com	8	Regional Research Institute of Unani Medicine Shahjahan Manzil, Near AMU Riding Club, Qila Road, Aligarh – 202 001, Uttar Pradesh Phone: +91-571-2704781, 2701399 E-mail: rrium_aligarh@rediffmail.com
9	Regional Research Institute of Unani Medicine Plot No. 38–39, Sector-18, Kharghar, Navi Mumbai– 410 210, Maharashtra Phone: +91-8652871023/2523 E-mail: rrium.mumbai@gmail.com, rrium.kharghar@gmail.com	10	Regional Research Institute of Unani Medicine University of Kashmir Campus, Hazrat Bal Srinagar – 190 006, Jammu & Kashmir Phone: +91-194-2421604 E-mail: rrium.srinagar@gmail.com
11	Regional Research Institute of Unani Medicine 250A/29, GT Road (North), Liluah Howrah – 711 204, West Bengal Phone: +91-33-26550108 E-mail: kolrium@gmail.com	12	Regional Research Institute of Unani Medicine D-11/1, Abul Fazal Enclave, Jamia Nagar New Delhi – 110 025 Phone: +91-11-26922759 E-mail: rridelhi@gmail.com
13	Regional Research Institute of Unani Medicine Veterinary Bazar, Ghungoor, Silchar, Assam 788014, (Cachar) Assam Phone: +91-3843-267522 E-mail: rrccsilchar@gmail.com	14	Drug Standardization Research Institute PLIM, Sector–23, Kamla Nehru Nagar, Ghaziabad – 201 002, Uttar Pradesh Phone: +91-120-2783029 E-mail: dsriccrum@gmail.com





15	Drug Standardization Research Unit 61-65, Institutional Area, Opposite D Block, Janakpuri, New Delhi – 110 058 Phone: +91-11-28521981 E-Mail: dsru.newdelhi@gmail.com	16	Regional Research Centre B-501/4, GTB Nagar, Opp. Dulhan Palace Kareli, Prayagraj – 211 016, Uttar Pradesh Phone: +91-532-2551223 E-mail: rrcallahabad@gmail.com
17	Clinical Research Unit Kurupatil Nina Memorial, Near Panchayat Office, Edathala (N) Alweye – 683 564, Kerala Phone: +91-484-2836006 E-mail: crukerala@gmail.com	18	Clinical Research Unit National Institute of Unani Medicine Kotigepaliya, Magadi Main Road Bengaluru – 560 091, Karnataka Phone: +91-80-25480863 E-mail: crubangalore2000@yahoo.com
19	Clinical Research Unit Dr. Abdul Haq Unani Medical College 40/23 Park Road, Kurnool – 518 001 Andhra Pradesh E-mail: cru.kurnool@gmail.com	20	Clinical Research Unit Cantonment General Hospital, Soti Ganj Begumpul, Meerut – 250 001, Uttar Pradesh Phone: +91-9012843253 E-mail: crumeerut@gmail.com
21	Clinical Research Unit Gandhi Medical College, Bhopal – 462 001, Madhya Pradesh Phone: +91-755-2540590 E-mail: cruu_incharge@yahoo.com	22	Clinical Research Unit SH Unani Tibbiya College, Ganpati Naka, Burhanpur – 450 331, Madhya Pradesh Phone: +91-7325-252250 E-mail: cruburhanpur@rediffmail.com
23	Clinical Research Unit RRIH Building, Opp. Tribal Colony, New Checkon Road, Imphal East – 795001 Manipur Phone: +91- 8811907160 E-mail: cruimphal1@gmail.com	24	Clinical Research Unit Old GMC Building, Ribandar, Goa – 403006 Maharashtra Mobile: +91-7817054784 E-mail: unanisc.goa@gmail.com
25	Chemical Research Unit Department of Research in Unani Medicine, Near Office of Dean, Faculty of Science, Aligarh Muslim University Aligarh – 202 001, Uttar Pradesh	26	Unani Speciality Centre (Extension Centre of RRIUM, New Delhi) Deen Dayal Upadhyay Hospital Ghantaghar, Harinagar New Delhi – 110 064 E-mail: dduhospital0786@gmail.com
27	Unani Medical Centre (Extension Centre of RRIUM, New Delhi) VMHC & Safdarjung Hospital New OPD Block, Ansari Nagar East, New Delhi – 110029 Phone: +91-11-26707121 E-mail: umcsafdarjung@gmail.com	28	Unani Medical Centre (Extension Centre of RRIUM, New Delhi) Dr. Ram Manohar Lohia Hospital New Delhi – 110 001 Phone: +91-11-23404594 E-mail: unaniopdrmlh@gmail.com
29	Unani Medical Centre (Extension Centre of RRIUM, Navi Mumbai) JJ Hospital Compound, Byculla, Mumbai – 400 008, Maharashtra Phone: +91-22-23718706 E-mail: rrium.mumbai@gmail.com	30	Ayush Wellness Centre (Unani Wing) Presidents Estate, Rashtrapati Bhawan, New Delh – 110 001 Phone: +91-9682179404 E-mail: coordinatingofficer.awcrb@gmail.com





Central Council for Research in Unani Medicine

Ministry of Ayush, Government of India

61-65, Institutional Area, Janakpuri, New Delhi – 110 058

Telephone: +91-11-28521981, 28525982

Website: <https://ccrum.res.in>

E-mail: unani-medicine@ccrum.res.in
unanimedicine@gmail.com